sofosbuvir profile

Sofosbuvir is a nucleotide analog antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It was discovered by Pharmasset, Inc. and is marketed by Gilead Sciences under the trade name Sovaldi. Sofosbuvir is a prodrug that is converted in the liver to an active metabolite, which inhibits the HCV NS5B RNA polymerase. This enzyme is essential for HCV replication, and inhibiting it prevents the virus from multiplying. Sofosbuvir is typically administered in combination with other antiviral medications, such as ribavirin and pegylated interferon, and is highly effective in treating HCV infection. It has revolutionized HCV treatment, significantly reducing the duration of treatment and improving cure rates. Sofosbuvir is studied extensively because of its high efficacy and safety profile. Research continues to explore its potential benefits for different patient populations and treatment regimens, including its use in combination with other antiviral agents and its potential for the treatment of other viral infections.'

Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

5-carboxycytosine: a 5-formylcystosine oxidation product; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-carboxycytosine : A nucleobase analogue that is cytosine in which the hydrogen at position 5 is replaced by a carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	45375808
CHEMBL ID	1259059
CHEBI ID	85083
SCHEMBL ID	2010114
MeSH ID	M0551450
PubMed CID	45375806
CHEMBL ID	1258950
SCHEMBL ID	2003999
MeSH ID	M0551450
PubMed CID	77213
CHEBI ID	76793
SCHEMBL ID	4359910
MeSH ID	M0551450

Synonym
HY-15005
gs7977
chebi:85083 ,
CHEMBL1259059
sofosbuvir
gs-7977
hepcvir
hepcinat
sovaldi
sovihep
l-alanine, n-((p(s),2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl)-, 1-methylethyl ester
unii-wj6ca3zu8b
resof
2-((5-(2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester
gs 7977
psi 7977
sofosbuvir [usan:inn]
wj6ca3zu8b ,
hsdb 8226
sofosbuvir (jan/usan)
D10366
sovaldi (tn)
isopropyl ((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-l-alaninate
AM84279
CS-0554
S2794
gi-7977
gtpl7368
propan-2-yl (2s)-2-[[[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
sofosbuvir component of epclusa
(s)-isopropyl 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate
sofosbuvir [vandf]
vosevi component sofosbuvir
sofosbuvir [inn]
sofosbuvir [orange book]
sofosbuvir component of harvoni
sofosbuvir [who-dd]
sofosbuvir [usan]
sofosbuvir [jan]
sofosbuvir component of vosevi
sofosbuvir [mi]
harvoni component sofosbuvir
epclusa component sofosbuvir
DB08934
s)-isopropyl 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate
SCHEMBL2010114
isopropyl (2s)-2-{[(s)-{[(2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate
gi 7977
psi7977
AKOS024464753
EX-A389
sofosbuvir (psi-7977, gs-7977)
SW219116-1
sofosbuvirpsi7977gs-7977
(s)-isopropyl 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate
wg6 ,
sofosbuvir(psi-7977)
Q2502747
sofosbuvir (psi-7977; gs-7977)
(s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-h
CCG-269909
sofosbuvir (gs-7977)
BS165550
DTXSID701027632
propan-2-yl (2s)-2-{[(s)-{[(2r,3r,4r,5r)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate
EN300-19897652
sofosbuvirum
isopropyl (2s)-2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
j05ap08
sovaldi access
1-methylethyl n-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)phenoxyphosphoryl)-l-alaninate
Z2235802138
propan-2-yl (2s)-2-{[(s)-{[(2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate (non-preferred name)
propan-2-yl (2s)-2-{[{[(2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate (non-preferred name)
isopropyl (2s)-2-[[[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate
psi-7851
CHEMBL1258950
psi-7977
SCHEMBL2003999
mfcd18782704
isopropyl ((((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-l-alaninate
AC-27382
AKOS025401925
gs-9851
unii-3s5s1851ov
n-((2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl)-l-alanine 1-methylethyl ester
1064684-44-1
l-alanine, n-((2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl)-, 1-methylethyl ester
3s5s1851ov ,
psi 7851
EN300-187117
propan-2-yl (2s)-2-[({[(2r,3r,4r,5r)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy}(phenoxy)phosphoryl)amino]propanoate
1221574-17-9
1190308-01-0
(2s)-isopropyl 2-(((((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
AS-19600
(s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)a
Q27257971
A898985
nsc-791959
nsc791959
CS-0164665
(2s)-isopropyl 2-(((((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate? (sofosbuvir impurity pound(c)
BB 0248369
6-amino-2-oxo-1,2-dihydro-pyrimidine-5-car boxylic acid
760cu98b9k ,
unii-760cu98b9k
einecs 222-890-1
cytosine-5-carboxylic acid
nsc 9309
nsc-9309
3650-93-9
nsc9309
AKOS005143089
AKOS006345200
SCHEMBL4359910
6-amino-2-oxo-1h-pyrimidine-5-carboxylic acid
4-amino-2-hydroxypyrimidine-5-carboxylic acid
4-amino-2-hydroxy-5-pyrimidinecarboxylic acid
1rt ,
FT-0684109
5-carboxycytosine
5-carboxylcytosine
4-amino-2-oxopyrimidine-5-carboxylic acid
CHEBI:76793
4-amino-2-oxo-1,2-dihydropyrimidine-5-carboxylic acid
5-pyrimidinecarboxylic acid, 6-amino-1,2-dihydro-2-oxo-
5-pyrimidinecarboxylic acid, 4-amino-1,2-dihydro-2-oxo-
4-amino-2-oxo-1,2-dihydro-pyrimidine-5-carboxylic acid, aldrichcpr
DTXSID70190003
mfcd00047368
4-amino-2-hydroxypyrimidine-5-carboxylic acid hydrobromide
CS-0045904
STL513101
Q27146335
A874338
D94964
SB57388
STL582075
AS-76797
EN300-7691553

Excerpt	Reference	Relevance
" However, this combination is often contraindicated and associated with severe adverse events that limit its use in clinical practice."	( Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I; Spera, AM; Zappulo, E, 2014)	0.4
"In a dose of 400 mg once daily, the drug has been safe and generally well tolerated with most adverse reactions attributable to the concurrent use of ribavirin or peginterferon plus ribavirin."	( Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Koff, RS, 2014)	0.4
" Data were extracted on virological responses including sustained virological response at post-treatment Week 12 (SVR12), relapse, treatment discontinuation due to an adverse event (AE), virological breakthrough during treatment, and AEs."	( Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. Chang, H; Han, Q; Li, N; Liu, X; Liu, Z; Lv, Y; Wang, Y; Zhang, G; Zhu, Q, 2014)	0.4
" Sofosbuvir-based combinations are safe and well tolerated without side effects directly related to the drug."	( Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Mangia, A; Piazzolla, V, 2014)	0.4
" One patient discontinued LDV-SOF because of an adverse event (AE)."	( Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S, 2015)	0.42
"This analysis suggests that 12 weeks of LDV-SOF is safe and effective for treatment-naïve patients with HCV genotype 1 and compensated cirrhosis."	( Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S, 2015)	0.42
" We analyzed treatment-emergent adverse events (AEs) and laboratory abnormalities in patients who were randomized to 8, 12, and 24 weeks of LDV/SOF with or without RBV."	( Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S, 2015)	0.42
" Daclastavir is generally safe and well tolerated, with a low barrier to resistance and low potential for drug-drug interaction."	( Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Bunchorntavakul, C; Reddy, KR, 2015)	0.42
" 1%), adverse events (AEs) requiring hospitalization (22% vs."	( Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B, 2015)	0.42
" Frequency of adverse safety outcomes were similar to matched untreated controls, suggesting that safety events reflect the natural history of cirrhosis and are not related to treatment."	( Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B, 2015)	0.42
" This drug reduces adverse events associated with IFN therapy."	( Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Fazel, Y; Golabi, P; Lam, B; Younossi, Z, 2015)	0.42
"In trials enrolling more than 3000 patients, LDV/SOF is well tolerated with a good safety and side-effect profile in diverse cohorts, including previous direct-acting antiviral (DAA) treatment failures, liver transplant recipients, decompensated cirrhosis and HIV/HCV co-infection."	( Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Fazel, Y; Golabi, P; Lam, B; Younossi, Z, 2015)	0.42
" During the eight clinical studies, adverse events were observed in 83."	( Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Ryoo, JY; Yang, HJ; Yoo, BK, 2015)	0.42
"Sofosbuvir was safe and effective in the treatment of hepatitis C virus genotype 1, 2, 3, or 4 infections."	( Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Ryoo, JY; Yang, HJ; Yoo, BK, 2015)	0.42
" Treatment was well tolerated overall with more than one-half (57%) reporting no adverse events."	( Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Barnes, M; Gautam, M; Gonzalez, S; Habib, A; Mantry, P; McAfee, J; Modi, AA; Nazario, H; Teachenor, O; Trotter, JF; Tujague, L; Weinstein, J, 2016)	0.43
" The aim of this study was to evaluate the rates of sustained virological response (SVR) and adverse events in a cohort of patients with nosocomially acquired HCV genotype-1b following 12 weeks of therapy with fixed-dose combination (FDC) ledipasvir/sofosbuvir (LDV/SOF)."	( The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM, 2016)	0.43
" The most commonly reported adverse events were gastrointestinal illness and upper respiratory viral-type illness."	( The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM, 2016)	0.43
"In this open-label, uncontrolled, pilot study enrolling patients with HCV genotype-1b and significant CVD, administration of a fixed-dose, oral combination of LDV and SOF for 12 weeks was associated with high rates of SVR and minimal adverse events."	( The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM, 2016)	0.43
" In the phase 3 ION program, the single-tablet regimen of the NS5A inhibitor ledipasvir and NS5B nucleotide polymerase inhibitor sofosbuvir was shown to be safe and highly effective in the general population."	( Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Afdhal, N; Gitlin, N; Howell, C; Jeffers, LJ; Kowdley, K; McHutchison, JG; Muir, AJ; Pang, PS; Poulos, J; Ravendhran, N; Reddy, KR; Shiffman, ML; Sulkowski, MS; Wilder, JM; Workowski, K; Yang, JC; Zhu, Y, 2016)	0.43
" The addition of ribavirin did not appear to increase SVR12 but was associated with higher rates of adverse events."	( Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Afdhal, N; Gitlin, N; Howell, C; Jeffers, LJ; Kowdley, K; McHutchison, JG; Muir, AJ; Pang, PS; Poulos, J; Ravendhran, N; Reddy, KR; Shiffman, ML; Sulkowski, MS; Wilder, JM; Workowski, K; Yang, JC; Zhu, Y, 2016)	0.43
" The tolerance to anti-HCV therapy was excellent and no adverse event was observed."	( Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. Alric, L; Barange, K; Cointault, O; Del Bello, A; Esposito, L; Izopet, J; Kamar, N; Lavayssière, L; Marion, O; Métivier, S; Ribes, D; Rostaing, L, 2016)	0.43
" To better understand the mechanism for adverse events, clinically relevant HCV NI were characterized in biochemical and cellular assays, including assays of decreased viability in multiple cell lines and primary cells, interaction with human DNA and RNA polymerases, and inhibition of mitochondrial protein synthesis and respiration."	( Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. Ahmadyar, S; Babusis, D; Barauskas, O; Feng, JY; McCutcheon, K; Park, Y; Perron, M; Perry, JK; Ray, AS; Sakowicz, R; Schultz, BE; Stepan, G; Xu, Y; Yu, H, 2016)	0.43
" Sustained virological response at 12 weeks, treatment-emergent adverse events (AEs), and graded laboratory abnormalities were analyzed according to age group."	( Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y, 2016)	0.43
" This study aimed to compare severe adverse events (SAEs) amongst therapeutic combinations for HCV in a community clinic setting."	( Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ, 2016)	0.43
" Adverse events were recorded from baseline to 12 or 24 weeks of treatment."	( Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ, 2016)	0.43
" Conversely, sofosbuvir plus simeprevir reached similar SVR rates at week 12 post-treatment compared to all ribavirin-containing regimens, but with significantly fewer adverse events (P = 0."	( Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ, 2016)	0.43
"The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions."	( Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ, 2015)	0.42
" Only five patients (20%) experienced minor adverse events, including grade 1 fatigue and headache."	( Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ, 2015)	0.42
"In a real clinical practice, sofosbuvir-based therapy for CHC patients in Korea achieved optimal antiviral efficacy with insignificant adverse events."	( Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ, 2015)	0.42
"To review adverse events (AEs) uniquely associated with DAA therapy across a broad spectrum of patient populations."	( Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Banerjee, D; Reddy, KR, 2016)	0.43
"Full dose sofosbuvir/simeprevir or sofosbuvir/ledipasvir therapy for HCV-infected patients with end stage renal disease was well tolerated with no discontinuation owing to side effects and no significant adverse events."	( Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Alkhouri, N; Anthony, S; Guirguis, J; Hanouneh, IA; Rivas, J; Singh, T, 2016)	0.43
" However, these patients had higher rates of anaemia, worsening renal dysfunction and serious adverse events regardless of use of RBV."	( Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Chung, RT; Fried, MW; Koraishy, FM; Liapakis, A; Lim, JK; Nelson, DR; Saxena, V; Schmidt, M; Sise, ME; Terrault, NA, 2016)	0.43
" In this pharmacokinetic study, sofosbuvir full dose (400mg once daily) administered every day with another direct antiviral agent did not accumulate in hemodialysis patients and was safe and effective."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
" Cases were patients who experienced hepatic decompensation and/or serious adverse events (SAE) during or within one month of completing treatment."	( Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R, 2016)	0.43
" In orthotopic liver transplantation (OLT) recipients, the interferon-free treatment of HCV re-infection with novel direct-acting antivirals has been demonstrated to be safe and effective in clinical trials, but real-world data are missing."	( Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H, 2016)	0.43
" Hepatic decompensation and other serious adverse events were investigated in an observational cohort study of 511 patients treated with regimens containing sofosbuvir, December 2013-June 2014."	( High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens. Bichoupan, K; Branch, AD; Chang, C; Dieterich, DT; Grewal, P; Harty, A; Khaitova, V; Ku, L; Liu, L; Motamed, D; Patel, N; Perumalswami, PV; Schiano, TD; Woodward, M; Yalamanchili, R, 2016)	0.43
" No discontinuations were attributed to treatment-related adverse events."	( 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Ackerman, P; Bhore, R; Luetkemeyer, AF; McDonald, C; Noviello, S; Ramgopal, M, 2016)	0.43
" Patients with GT3 HCV were analyzed to assess predictors of treatment response and adverse events using descriptive statistics and multivariable logistic regression."	( Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Akushevich, L; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Kuo, A; Maan, R; Mailliard, M; Manns, MP; Nelson, DR; Schmidt, M; Sherman, K; Sterling, R; Vainorius, M; Zeuzem, S, 2016)	0.43
" Adverse events were reported in 11 patients (46%) and were managed clinically without discontinuation of therapy."	( Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME, 2016)	0.43
" Common adverse events (AEs) included fatigue, anaemia, nausea, headache, insomnia, rash and flu-like symptoms."	( Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S, 2017)	0.46
"In this clinical practice setting, SOF and RBV was safe and effective for treatment of patients with HCV GT2 infection."	( Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S, 2017)	0.46
" We postulate that this adverse drug reaction may have been secondary to the known interaction between ledipasvir and TDF, which results in increased TDF exposure."	( Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. Bunnell, KL; Gallagher, MA; Glowacki, RC; Huhn, G; Osei, AM; Vibhakar, S, 2016)	0.43
" Demographic, clinical and virological data as well as adverse outcomes were collected."	( Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. El-Amin, H; El-Khayat, HR; Fouad, YM; Maher, M; Muhammed, H, 2017)	0.46
" The combination of elbasvir/grazoprevir also demonstrated a superior safety and tolerability profile based on fewer serious adverse events, no serious drug-related adverse events, and no treatment discontinuations."	( Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. Asante-Appiah, E; Barr, E; Flisiak, R; Gerstoft, J; Halota, W; Horvath, G; Jancoriene, L; Kazenaite, E; Kileng, H; Koklu, S; Leiva, R; Nguyen, BY; Patel, S; Platt, HL; Prinzing, R; Qiu, J; Ruiz-Tapiador, JA; Sperl, J; Streinu-Cercel, A; Urbanek, P; Wahl, J; Werling, K, 2016)	0.43
" Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low."	( Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y, 2016)	0.43
"28), and serious adverse events (4% vs 3%; P = ."	( Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y, 2016)	0.43
" The primary outcome measures were the sustained virological response weeks 12 (SVR12) post-treatment and adverse events (AEs)."	( Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. He, QF; Zhang, DZ; Zhang, QF, 2016)	0.43
"Excellent SVR12 rates and the favorable side-effect profile of DAA-combination therapy can be well translated into "real-world"."	( Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR, 2016)	0.43
" Fatal adverse events occurred in 23/6211 cases (0."	( Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Abdel Rehim, S; Abdo, M; Doss, W; El Kassas, M; El Raziky, M; El Serafy, M; El-Sayed, MH; Elakel, W; Elbaz, T; Eletreby, R; ElShazly, Y; Esmat, G; Fouad, R; Gamal Eldeen, H; Korany, M; Said, M; Seif, S; Waked, I; Yosry, A; Zaky, S, 2017)	0.46
"" Sustained virologic response at 12 weeks after the end of treatment (SVR12) rate, incidence of serious adverse events (SAEs) and/or adverse events, discontinuation rate with 95% confidence intervals (CI) were pooled with random-effects model."	( Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients. Guo, Y; Li, T; Qu, Y; Sun, C; Wang, L; Yang, B; Ye, Q, 2017)	0.46
" The most common adverse event (AE) in elderly patients was a grade 2 anaemia (35."	( Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P, 2017)	0.46
"Sofosbuvir/simeprevir plus a daily flat dose of RBV 800 mg for 12 weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis."	( Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P, 2017)	0.46
" The most common adverse effect was anemia (hemoglobin <10 g/dL), especially for patients aged ≥ 65 with the inosine triphosphate pyrophosphatase CC genotype at rs1127354 (26."	( Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K, 2016)	0.43
" Secondary end-points of the study include SVR 4, virological relapse and appearance of adverse events."	( Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R, 2016)	0.43
"9 %) patients reported adverse events during the course of sofosbuvir-based treatment."	( Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R, 2016)	0.43
"Sofosbuvir-based treatment is safe and efficacious in clinical practice in Indian patients with HCV genotype-1 and genotype-3 infection."	( Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R, 2016)	0.43
"There is no known reason to suspect an adverse drug interaction between dolutegravir-based antiretroviral therapy and sofosbuvir, simeprevir, or ledipasvir."	( Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy. Bhattarai, S; Fallon, JP; Galang, H; Habeeb, R; Johnson, TM; Shukla, PP; Sison, R; Slim, J, 2016)	0.43
" No patients ended therapy secondary to adverse events."	( Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy. Bhattarai, S; Fallon, JP; Galang, H; Habeeb, R; Johnson, TM; Shukla, PP; Sison, R; Slim, J, 2016)	0.43
" The most common adverse events were fatigue (one [17%] of six patients receiving sofosbuvir, ledipasvir, and asunaprevir; one [17%] of six patients receiving sofosbuvir, daclatasvir, and simeprevir; and two [33%] of six patients receiving sofosbuvir, daclatasvir, and asunaprevir) and headache (one [17%] patient in each group)."	( Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V, 2016)	0.43
" By shortening the duration of therapy from the currently recommended 12 weeks to 3 weeks, we could drastically reduce the cost of therapy and the rate of adverse events."	( Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V, 2016)	0.43
" We included in the analysis demographic, clinical, and virologic data and details of serious adverse events (SAEs), including mortality rate 6 months after treatment."	( Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Castells, L; Fernandez Vazquez, I; Herrero, JI; Londoño, M; Narvaez Rodriguez, I; Otero, A; Pascasio, JM; Prieto, M; Sanchez Antolin, G; Testillano, M, 2016)	0.43
"3%) had serious adverse events, including three deaths (1."	( Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. Alonso, S; Ampuero, J; Badia, E; Baliellas, C; Buti, M; Carrión, JA; Castro, Á; Devesa, MJ; Esteban, R; Fernandez, I; Fernandez-Carrillo, C; Fernández-Rodríguez, CM; Gea, F; Gómez, A; Granados, R; Lens, S; Llerena, S; Montero, JL; Olveira, A; Pascasio, JM; Planas, JM; Polo, B; Real, Y; Rincón, D; Riveiro-Barciela, M; Rubín, A; Salmeron, J; Turnes, J, 2017)	0.46
" The three most commonly reported adverse events were headache (27% of patients), diarrhea (14%), and fatigue (13%)."	( The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Balistreri, WF; Bansal, S; Brainard, DM; German, P; Gonzalez-Peralta, RP; Jonas, MM; Kanwar, B; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, K; Svarovskaia, E; Wen, J; Zhu, Y, 2017)	0.46
" LDV- SOF plus RBV therapy had significantly higher rate of the overall adverse events (RR=0."	( Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Chen, Y; Jiang, X; Song, Y; Tao, T, 2017)	0.46
"This meta-analysis suggests that LDV-SOF based therapy is a safe and effective treatment for patients with GT 1 HCV."	( Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Chen, Y; Jiang, X; Song, Y; Tao, T, 2017)	0.46
" The safety data available for LDV/SOF±RBV and OBV/PTV/r±DSV±RBV show that discontinuation due to adverse events was necessary in no more than 3% of patients and the frequency of serious adverse events was between 0 and 11%, in particular in real-world studies."	( Hepatitis C: efficacy and safety in real life. Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J, 2017)	0.46
" The most common adverse events (AEs) were rash and/or pruritus (23."	( Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A, 2017)	0.46
" Details of serious adverse events (SAEs) were recorded."	( Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017)	0.46
" After a median follow-up period of 26 months (interquartile range, 20-30 mo), no patients had a serious adverse event or relapse of vasculitis."	( Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. Alric, L; Bouyer, AS; Cacoub, P; Comarmond, C; de Saint Martin, L; Ferfar, Y; Hezode, C; Musset, L; Pol, S; Poynard, T; Resche Rigon, M; Saadoun, D; Si Ahmed, SN, 2017)	0.46
" The therapy was found to be reasonably safe with no major adverse effects noted with the use of sofosbuvir, ledipasvir or daclatasvir."	( Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R, 2018)	0.48
" Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis."	( Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G, 2017)	0.46
" Adverse events were mild with all-oral therapy."	( Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience. Aung, ST; Bwa, AH; Hlaing, NKT; Kyaw, AMM; Mitrani, RA; Phyo, WW; Reddy, KR; Serper, M; Win, KM, 2017)	0.46
" Although the most frequent adverse event was anemia, no patients discontinued the use of either ribavirin or sofosbuvir."	( Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A, 2017)	0.46
"Treatment with sofosbuvir/ribavirin for genotype 2-infected CHC was effective and safe even for elderly patients, although the incidence of adverse events including ribavirin-related anemia was relatively high."	( Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A, 2017)	0.46
" Adverse events were generally mild and transient."	( Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M, 2017)	0.46
"Treatment with LDV/SOF±RBV is an effective and safe option for patients with HCV, including those with advanced liver disease or a history of non-response to PEG-IFN-based therapy."	( Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M, 2017)	0.46
" The primary efficacy endpoint was sustained virologic response 12, whereas the primary safety endpoint was drug discontinuation or occurrence of grade 3/4 adverse events."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
" Adverse events occurred in 32% of patients (grade 1 and 2), but none discontinued treatment."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
"SMV/SOF or DCV/SOF combinations are safe and highly effective in HCV-GT4 treatment."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
" In our study, we will report the real-life experience of serious adverse events (SAEs) that were reported by the National Committee for Control of Viral Hepatitis (NCCVH, Cairo, Egypt) program while treating chronic HCV using the triple therapy, sofosbuvir combined with pegylated interferon and ribavirin (PEG/RIBA/SOF), which led to premature discontinuation of treatment."	( Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A, 2017)	0.46
"The use of IFN-free regimens is safe and effective in the treatment of most HCV-related rheumatologic EHM."	( Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection. Amer, SA; Said, M; Shahin, AA; Zayed, HS, 2018)	0.48
" No serious adverse events (AEs) were observed."	( Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX, 2017)	0.46
"In our cohort of cirrhotic HCV/HIV-coinfected patients, DAAs were highly safe and efficacious."	( Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH, 2017)	0.46
" Tolerance was satisfactory, with mainly grade 1 or 2 adverse events."	( Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). Allegre, T; Alric, L; Amri, I; Aumaitre, H; Bailly, F; Bellissant, E; Billaud, E; Bourlière, M; Carrieri, MP; Chas, J; Chevaliez, S; Cotte, L; De Truchis, P; Dominguez, S; Dupon, M; Fougerou-Leurent, C; Garraffo, R; Girard, PM; Jeantils, V; Lacombe, K; Leroy, V; Marcellin, F; Metivier, S; Molina, JM; Morlat, P; Naqvi, A; Neau, D; Pabic, EL; Pageaux, GP; Pailhé, A; Perré, P; Piroth, L; Poizot-Martin, I; Pol, S; Raffi, F; Renault, A; Reynes, J; Rosenthal, E; Salmon-Ceron, D; Teicher, E; Tual, C; Valantin, MA; Yazdanpanah, Y; Zucman, D, 2018)	0.48
" Adverse events were reported in 63."	( Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. Beumont, M; Corregidor, AM; Feld, JJ; Felizarta, F; Gamil, M; Ghalib, R; Kakuda, TN; Khalid, O; Lawitz, E; Luo, D; Ouwerkerk-Mahadevan, S; Smith, WB; Sulkowski, MS; Van Eygen, V; Van Remoortere, P; Vijgen, L, 2018)	0.48
" Demographic, clinical, adverse event, and virologic data were collected every 12 weeks during treatment and during the follow-up period."	( Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S, 2018)	0.48
" Headache was the most common side effect in all patients (20%)."	( The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Attia, D; Ayoub, H; El Sheemy, RY; El-Khayat, HR; El-Sayed, MH; El-Shabrawi, M; Fouad, YM; Kamal, EM; Maher, M; RizK, A, 2018)	0.48
" The main endpoints were assessment of sustained virological response and serious adverse events rates."	( Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study. Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C, 2018)	0.48
"To determine frequency and pattern of adverse events reporting in a subset of Pakistani population being treated for chronic hepatitis C with sofosbuvir combination therapy."	( Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population. Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH, 2018)	0.48
" Patients were screened for subjective as well as objective evidence of adverse events at regular intervals."	( Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population. Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH, 2018)	0.48
"Sofosbuvir showed less severe adverse effects in terms of symptomatology and less frequent neutropenia and thrombocytopenia as compared to previous regimens."	( Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population. Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH, 2018)	0.48
" One patient showed an increase in ALT of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 severity that returned to the normal range following treatment of his HCV infection with ledipasvir 90 mg/sofosbuvir 400 mg."	( Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. Khattak, MA; Kothapalli, A, 2018)	0.48
" Patients were closely monitored for treatment-related adverse effects and the potential need for adjustment in their immunosuppression."	( The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P, 2018)	0.48
"The combination of LED/SOF with RBV for 12 weeks or LED/SOF for 24 weeks is very effective and safe in treating OLT recipients with RHC."	( The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P, 2018)	0.48
"Low-dose Sofosbuvir and full-dose Daclatasvir are safe and effective in treating CHC in patients with CKD with eGFR less than 30 mL/min/1."	( Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. Chawla, Y; De, A; Dhiman, RK; Duseja, A; Gupta, KL; Kohli, HS; Kumar, V; Mehta, M; Ramachandran, R; Taneja, S, 2018)	0.48
" Treatment was well tolerated with 37% reporting no adverse events."	( Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir. Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE, 2018)	0.48
" We assessed the rate of sustained virological response at 12 weeks post-treatment (SVR12), incidence of adverse events, and serum markers of hepatocellular carcinoma (HCC)."	( Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. Akahane, T; Hasebe, C; Itakura, J; Izumi, N; Joko, K; Kimura, H; Kobashi, H; Kojima, Y; Kondou, M; Kurosaki, M; Kusakabe, A; Mitsuda, A; Mori, N; Nakata, R; Narita, R; Ogawa, C; Sohda, T; Takaki, S; Takezawa, J; Tamada, T; Tsuji, K; Uchida, Y; Yagisawa, H, 2018)	0.48
" Adverse events were rare and not associated with age."	( Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. Akahane, T; Hasebe, C; Itakura, J; Izumi, N; Joko, K; Kimura, H; Kobashi, H; Kojima, Y; Kondou, M; Kurosaki, M; Kusakabe, A; Mitsuda, A; Mori, N; Nakata, R; Narita, R; Ogawa, C; Sohda, T; Takaki, S; Takezawa, J; Tamada, T; Tsuji, K; Uchida, Y; Yagisawa, H, 2018)	0.48
"LDV/SOF therapy is highly effective and safe in elderly Japanese patients with HCV GT1, even in the presence of cirrhosis or NS5A RASs."	( Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. Akahane, T; Hasebe, C; Itakura, J; Izumi, N; Joko, K; Kimura, H; Kobashi, H; Kojima, Y; Kondou, M; Kurosaki, M; Kusakabe, A; Mitsuda, A; Mori, N; Nakata, R; Narita, R; Ogawa, C; Sohda, T; Takaki, S; Takezawa, J; Tamada, T; Tsuji, K; Uchida, Y; Yagisawa, H, 2018)	0.48
"Treatment of severe psoriasis in HCV positive patients is challenging, because several psoriasis medications have a toxic effect on the liver, and interferon alpha, used to treat hepatitis, can induce worsening of psoriatic lesions."	( Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis. Di Cesare, A; Lazzeri, L; Pescitelli, L; Prignano, F; Ricceri, F; Tripo, L, 2018)	0.48
" The most common adverse events recorded were fatigue, headache, nausea, asthenia, and gastrointestinal troubles."	( Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Abdel-Gabaar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI, 2018)	0.48
"DAA in adult dosage are safe and effective for treatment of chronic hepatitis C (genotype 3) in pediatric β-thalassemic major population."	( Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children. Garg, K; Gupta, GK; Maharshi, S; Nijhawan, S; Padhi, S, 2018)	0.48
" Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16."	( Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ, 2018)	0.48
" The endpoints were sustained virological response 12- and 24-weeks after the cessation of therapy (SVR12 and SVR24), the adverse events (AEs) and the severe adverse events (SAEs)."	( Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials. Fan, H; Feng, Y; Huang, P; Tian, T; Wang, J; Wu, J; Xia, X; Yu, R; Yue, M; Zhang, Y, 2018)	0.48
" Adverse events leading to treatment discontinuations were not observed."	( Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study. Aghemo, A; Brancaccio, G; D'Offizi, G; Gaeta, GB; Giorgini, A; Hasson, H; Menzaghi, B; Palma, M; Termini, R, 2018)	0.48
" However, information about the rate of adverse events (AEs) across different DAA regimens is limited."	( Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study. Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N, 2018)	0.48
" One patient had three serious adverse events, which were considered to be not related to study treatment: tooth abscess, abdominal pain, and gastroenteritis."	( Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Arnon, R; Balistreri, WF; Bansal, S; Brainard, DM; Evans, HM; Garrison, KL; Gillis, LA; Gonzalez-Peralta, RP; Jonas, MM; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Narkewicz, MR; Parhy, B; Rosenthal, P; Schwarz, K; Shao, J; Wen, J; Whitworth, S, 2018)	0.48
"DAAs appear to be safe and effective for HCV treatment in patients with a history of liver and/or kidney transplantation."	( Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation. Hill, L; Kerr, J; Mansour, M, 2018)	0.48
" As advanced age is associated with increasing risk of development of cirrhosis and hepatocellular carcinoma, elderly patients are in special need of safe and effective antiviral therapies."	( Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM, 2019)	0.51
" Most adverse events (AEs) were consistent with clinical sequelae of advanced liver disease or known toxicities of ribavirin."	( Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G, 2019)	0.51
" No serious adverse effects like anemia and decompensation were reported."	( Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Satsangi, S; Taneja, S, 2019)	0.51
" For the 182 treated with the 8-week LDV/SOF treatment, there were no serious adverse events requiring hospitalization or signs of liver failure requiring transplantation."	( Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL. Aziz, A; Durazo, F; Hanna, RM; Latt, N; Mikhail, MM; Mitry, A; Saab, S; Sahota, A; Yanny, B, 2018)	0.48
" Adverse events were recorded for safety analysis."	( Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC, 2019)	0.51
" SOF/DCV/ribavirin regimen resulted in more adverse events, significantly higher bilirubin levels, and decline of hemoglobin during treatment than SOF/DCV regimen."	( Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC, 2019)	0.51
"SOF/DCV with or without ribavirin is highly effective and safe for patients with genotype 2 HCV infection in real-world experience in Taiwan."	( Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC, 2019)	0.51
"No adverse cardiovascular events were observed in this group of HCV infected children and adolescents treated with sofosbuvir/ledipasvir."	( Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus? Abdullatif, H; El-Karaksy, H; Ghobrial, C; Mogahed, E; Sobhy, R, 2019)	0.51
" Combined SOF/DCV was found to be effective and safe for treating HCV Genotype 4-infected children, 8 years of age and above."	( Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. Abdel Gawad, M; Abdel Ghaffar, A; Abdel Ghaffar, TY; El Naghi, S; Helmy, S; Moafy, M; Yousef, M, 2019)	0.51
" SOF-based therapy was well-tolerated, and no serious adverse events were reported."	( Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB, 2019)	0.51
" Adverse events were monitored during the treatment period."	( The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC, 2018)	0.48
" The most common adverse events were anemia, dyspepsia, and insomnia."	( The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC, 2018)	0.48
" Patients' outcome and Adverse effects (AE) were evaluated."	( Efﬁcacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience. Abdelaziz, A; Abdelmoniem, R; Doss, W; El-Serafy, M; Elakel, W; Esmat, G; Gamal Eldeen, H; Kaddah, M; Medhat, E; Mehrez, M; Yosry, A; Zayed, N, 2019)	0.51
" The treatment discontinuation rate due to adverse events (AEs) and serious AE rate were assessed for safety."	( Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC, 2018)	0.48
"Interferon-alpha (IFN-α)-based therapy is associated with several hematological adverse events in hepatitis C virus (HCV)-infected patients with advanced fibrosis."	( Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients. Abushouk, AI; Al-Husseini, M; El-Raey, F; Johar, D; Mohammed, EG; Montasser, MF; Salaheldin, M; Zaky, S, 2019)	0.51
" The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" No patient treatment withdrawal secondary to severe adverse events was observed."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" The regimen was safe and well tolerated."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" Sustained virological response (SVR12/24) rate and serious adverse event (SAE) rate with 95% confidence intervals were aggregated."	( Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q, 2019)	0.51
" Clinical, adverse events, and virological data were collected throughout treatment and post-treatment follow-up."	( Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. Abergel, A; Alric, L; Bourliere, M; Bronowicki, JP; Cales, P; Carrat, F; Causse, X; Chazouilleres, O; Diallo, A; Dorival, C; Fontaine, H; Ganne-Carrie, N; Geist, C; Guyader, D; Haour, G; Hezode, C; Larrey, D; Laurain, A; Loustaud-Ratti, V; Luzivika-Nzinga, C; Marcellin, P; Mathurin, P; Metivier, S; Petrov-Sanchez, V; Pol, S; Riachi, G; Samuel, D; Thabut, D; Tran, A; Zarski, JP; Zoulim, F, 2019)	0.51
" Data on treatment outcomes and adverse events (AE) were analysed in patients with available sustained virologic response 12 weeks after cessation of treatment (SVR12) information overall and by subgroups."	( Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Atanasov, PK; Buggisch, P; Lee, J; Petersen, J; Stoehr, A; Supiot, R; Ting, J; Wursthorn, K, 2019)	0.51
" Efficacy was defined as HCV RNA below the lower limit of detection 12 weeks after the end of treatment (SVR12), while safety endpoints included the incidence of grade 3 and 4 adverse events (AEs) following treatment, and the proportion of patients who stopped treatment prematurely due to AEs."	( A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E, 2019)	0.51
"Retreatment with 12 weeks of SOF/VEL/VOX was safe and effective in patients with relapsed HCV following initial combination DAA-based treatment."	( A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E, 2019)	0.51
"Twelve weeks of the combination of direct-acting antivirals (SOF/VEL/VOX) was safe and effective in patients with relapsed hepatitis C virus infection who had previously received combination therapy with direct-acting antivirals."	( A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E, 2019)	0.51
" Adverse effects were mild and non-specific."	( Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J, 2019)	0.51
"Real-world data show that SOF/VEL/VOX is an effective, safe rescue therapy for patients with prior DAA treatment failure despite the presence of resistance-associated substitutions."	( Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J, 2019)	0.51
" Treatment with SOF/VEL/VOX is an effective and safe rescue therapy due to its high efficacy and very good safety profile."	( Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J, 2019)	0.51
" We collected data on on-treatment adverse events (AEs), severe AEs, and laboratory abnormalities."	( Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. Aoufi-Rabih, S; Dixit, V; Fabrizi, F; Garcia-Agudo, R; Mendizabal, M; Ridruejo, E; Silva, M, )	0.13
" Most frequent adverse events included fatigue (6%), hyperbilirubinemia (6%) and anemia (4%)."	( Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Aghemo, A; Alberti, A; Bonfanti, P; Carolo, G; Carriero, C; Centenaro, R; Degasperi, E; Fabris, P; Faggiano, G; Fagiuoli, S; Gatti, F; Giorgini, A; Grossi, G; Lampertico, P; Landonio, S; Lombardi, A; Lomonaco, L; Maggiolo, F; Noventa, F; Paolucci, S; Paon, V; Pasin, F; Pasulo, L; Pozzoni, P; Puoti, M; Romano, A; Rossi, MC; Rovere, P; Russo, FP; Soffredini, R; Soria, A; Spinetti, A; Vario, A; Vinci, M; Zoncada, A, 2019)	0.51
"SOF/VEL/VOX is an effective and safe retreatment for patients with HCV who have failed on a previous DAA course in a real-life setting."	( Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Aghemo, A; Alberti, A; Bonfanti, P; Carolo, G; Carriero, C; Centenaro, R; Degasperi, E; Fabris, P; Faggiano, G; Fagiuoli, S; Gatti, F; Giorgini, A; Grossi, G; Lampertico, P; Landonio, S; Lombardi, A; Lomonaco, L; Maggiolo, F; Noventa, F; Paolucci, S; Paon, V; Pasin, F; Pasulo, L; Pozzoni, P; Puoti, M; Romano, A; Rossi, MC; Rovere, P; Russo, FP; Soffredini, R; Soria, A; Spinetti, A; Vario, A; Vinci, M; Zoncada, A, 2019)	0.51
" Demographics, HCV viral load, lipid and sugar profiles, and adverse events were recorded and reviewed."	( Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan. Chen, JJ; Cheng, PN; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD, 2020)	0.56
" Serious adverse events (SAEs) were reported in 2 patients and were not related to coblopasvir and sofosbuvir."	( Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. Guan, Y; Guo, X; Jia, J; Jiang, X; Li, C; Li, G; Mao, Q; Ning, J; Pan, H; Qin, H; Rao, H; Song, G; Wang, C; Wei, L; Wu, X; Yang, Y; Zhang, Y, 2020)	0.56
" Direct-acting antiviral therapy is efficacious and safe even in patients with advanced liver disease and/ or previous virological failure; Model-for-End-Liver-Disease <10 and alanine aminotransferase reduction during therapy were found to be reliable predicting markers of sustained-virological-response."	( Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases. Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V, 2019)	0.51
"Sofosbuvir-based regimens are effective and safe for treating patients with chronic HCV and moderate to severe CKD, and in those with associated hepatic decompensation."	( Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Abdel Haleem, H; Abdel-Razek, W; Anees, M; El-Sayed, MH; El-Serafy, M; El-Shazly, Y; Eletreby, R; Elkhouly, R; Elshenawy, M; Esmat, G; Hamdy, M; Hassany, M; Kamal, E; Kasem, G; Salama, M; Salama, R; Shafeek, A, 2020)	0.56
" Incidence rates of liver adverse events (LAE) were calculated; Poisson regression model was used to identify factors associated with LAE."	( Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C, 2020)	0.56
" Nevertheless, there are many reports in which these patients have been treated with sofosbuvir-containing regiments without important adverse events."	( The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH, 2020)	0.56
" No adverse events leading to discontinuation of medicine was observed."	( The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH, 2020)	0.56
"The combination of sofosbuvir and daclatasvir is an effective and safe treatment for patients infected with all genotypes of hepatitis C who have severe renal impairment, including patients on hemodialysis."	( The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH, 2020)	0.56
" Adverse events were observed in 191 patients (41."	( Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ, 2020)	0.56
"A shortened 8-week regimen of LED/SOF (45/200 mg) is safe and effective with 100% SVR12 in treatment-naïve children with cirrhosis aged 4-10 years with chronic HCV infection genotype 4."	( Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. Ayoub, BA; Basiouny, HM; Behairy, BE; El-Araby, HA; El-Guindi, MA; Fouad, OA; Marei, AM; Sira, MM, 2020)	0.56
"This work aims to evaluate the therapeutic survey of adverse events during antiviral treatment of hepatitis in the three major University Hospitals in Abidjan."	( Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals . Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG, 2020)	0.56
"A retrospective cross-sectional descriptive study of 203 patients from August 1, 2015, to July 31, 2018, enumerated adverse events during antiviral treatments, drugs used for their management, and their clinical or biological impact."	( Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals . Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG, 2020)	0.56
"Correction of the adverse events was made either using causal treatment or using symptomatic drugs."	( Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals . Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG, 2020)	0.56
" Plasma pharmacokinetic parameters were estimated by using noncompartmental models, and safety was assessed through clinical evaluation and monitoring of adverse events."	( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects. Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020)	0.56
" Only four patients discontinued treatment before week 4 due to non-hepatic adverse events."	( Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. Bunchorntavakul, C; Charatcharoenwitthaya, P; Chonprasertsuk, S; Komolmit, P; Piratvisuth, T; Sanpajit, T; Sethasine, S; Siripipattanamongkol, C; Sobhonslidsuk, A; Sukeepaisarnjaroen, W; Sutthivana, C; Tangkijvanich, P; Tanwandee, T; Wongpaitoon, V, 2020)	0.56
" We concluded that sofosbuvir while looking toxic and pro-oxidant in lower concentrations, acts as protective and antioxidant in higher concentrations."	( Contrasting Role of Dose Increase in Modulating Sofosbuvir-Induced Hepatocyte Toxicity. Nabavi, N; Pourahmad, J; Yousefsani, BS, 2020)	0.56
" Safety was determined by adverse events and ribavirin, when combined, was administered in escalating doses to all patients with GFR <60 mL/min."	( HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Amaral, ACC; Carvalho-Filho, RJ; Ferraz, MLG; Michels, FBL; Souza, ALDS; Vieira, GA, )	0.13
" The treatment was well tolerated and there were no major clinically relevant adverse events, with the most prevalent being asthenia (57."	( HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Amaral, ACC; Carvalho-Filho, RJ; Ferraz, MLG; Michels, FBL; Souza, ALDS; Vieira, GA, )	0.13
"The direct-acting antivirals were safe and efficacious in CKD patients treated with SOF-containing regimens, with the observation of high SVR rates, good tolerability and few severe adverse events."	( HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Amaral, ACC; Carvalho-Filho, RJ; Ferraz, MLG; Michels, FBL; Souza, ALDS; Vieira, GA, )	0.13
" The safety variable was withdrawal secondary to severe adverse events (SAEs)."	( Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P, 2020)	0.56
"SOF/VEL±RBV or GLE/PIB are safe and effective for treating G3-HCV-infections, with a lower effectiveness in patients with advanced fibrosis F3-4."	( Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P, 2020)	0.56
" These findings provide reassurance that the combination of TAF, boosted PIs and ledipasvir/sofosbuvir is safe in HIV/HCV-coinfected populations."	( Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH, 2020)	0.56
" The most frequent adverse event was fatigue with a pooled prevalence of 16% (95% CI 5-29%), followed by anemia 15% (95% CI 3-31%), and nausea or vomiting 14% (95% CI 4-27%)."	( Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Byrd, K; D'Agata, EMC; Kalligeros, M; Martin, P; Mylonakis, E; Shehadeh, F; Shemin, D, 2020)	0.56
"As patients with chronic hepatitis C virus (HCV) tend to be older and/or have advanced liver disease in Japan, real-world data are needed to evaluate safe and effective treatment options."	( Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. Fujiyama, N; Hedskog, C; Littman, M; Liu, LJ; Mizokami, M; Ng, LJ; Sekiya, T; Yuan, J, 2021)	0.62
" Secondary outcome was frequency of adverse events (AE)."	( Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A, 2021)	0.62
" Demographic data, adverse events, renal function and metabolic profiles were recorded."	( Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH, 2021)	0.62
" Neither drug-related severe adverse events nor discontinuation due to drug-related adverse event were reported."	( Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH, 2021)	0.62
"Twelve weeks of LDV/SOF treatment provided an excellent and safe regimen for GT2 CHC infection, particularly in non-cirrhotic patients."	( Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH, 2021)	0.62
" Serious adverse events were reported in 16/349 (4."	( Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study. Baicus, C; Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iacob, S; Iliescu, L; Istratescu, D; Manuc, M; Meianu, C; Pop, CS; Preda, C; Stanciu, C; Tieranu, C; Trifan, A; Tugui, L; Voiosu, T, 2020)	0.56
"Sofosbuvir plus Velpatasvir fixed-dose combination is safe and effective in treating CHC in patients with ESRD on MHD."	( Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. De, A; Dhiman, RK; Duseja, A; Kohli, HS; Kumar, V; Mehta, M; Premkumar, M; Ramachandran, R; Ratho, RK; Singh, MP; Singh, V; Taneja, S; Verma, N, 2021)	0.62
" There were no adverse events related to the use of Sof-Vel, with no major fluctuations in cyclosporine levels."	( Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation. Bhakuni, P; Chakrabarti, S; Gupta, M; Jaiswal, SR; Soni, M; Thatai, A, 2021)	0.62
" Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15."	( Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L, 2021)	0.62
"SOF-based pangenotypic DAAs including SOF plus DCV and SOF plus VEL, were effective and safe for CHC patients without GT determination in this study."	( Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study. Chen, EQ; Chen, XB; Jiang, W; Li, J; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Xiao, GB, 2020)	0.56
"Treatment was safe and well-tolerated and there were no drug discontinuations due to DAA-related adverse events."	( Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders. Ahmed-Belkacem, A; Chevaliez, S; Demontant, V; Donati, F; Fourati, S; François, M; N'Debi, M; Pawlotsky, JM; Poiteau, L; Rodriguez, C; Ruiz, I; Scoazec, G; Soulier, A, 2021)	0.62
" The secondary outcome measures were SVR12 stratified by the presence of decompensated cirrhosis, prior treatment, HCC, and HIV/hepatitis C virus coinfection and the occurrence rate of serious adverse events requiring treatment cessation or hospitalization."	( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021)	0.62
" Apart from one patient who developed myositis, no other serious adverse events were observed."	( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021)	0.62
"The SOF/VEL ± RBV is a safe and efficacious treatment option for GT3 HCV patients in a real-world setting."	( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021)	0.62
" Adverse effects were not observed."	( Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis. Farooq, MO; Malik, K; Mengal, FUA; Salim, A, 2020)	0.56
" No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE."	( Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. Ahn, SH; Amarsanaa, J; Baatarkhuu, O; Badamsuren, D; Batbayar, P; Choijamts, N; Enkhtuya, D; Gantuul, C; Gegeebadrakh, B; Han, KH; Kim, DY; Lee, JS; Naranzul, N; Otgonbayar, R; Otgonbold, J; Saruul, BU; Tuvshinbayar, N; Ulzmaa, G, 2021)	0.62
" We conclude that sofosbuvir-based DAA therapy is safe and highly effective in HCV-HIV patients with decompensated liver disease and post-LT, with post-LT survival rates comparable to other indications."	( Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. Amara, D; Blumberg, E; Dove, L; Durand, CM; Emond, J; Fishbein, T; Florman, S; Grab, J; Haydel, B; Huprikar, S; Husson, J; Kottilil, S; Luetkemeyer, AF; Masur, H; Olthoff, K; Peters, MG; Rogers, R; Smith, C; Stock, PG; Sulkowski, MS; Terrault, N, 2021)	0.62
" No adverse effects leading to drug discontinuation occurred."	( Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Ahmadinejad, Z; Dehghan Manshadi, SA; Emadi Kouchak, H; Jafari, S; Kebriaeezadeh, A; Khalili, H; Nourian, A; Rasolinejad, M, 2020)	0.56
" No significant adverse event was detected."	( Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Ahmadinejad, Z; Dehghan Manshadi, SA; Emadi Kouchak, H; Jafari, S; Kebriaeezadeh, A; Khalili, H; Nourian, A; Rasolinejad, M, 2020)	0.56
" The most common adverse events were fatigue (12."	( Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience. Akarca, US; Akarsu, M; Akbulut, S; Akın, M; Aladağ, M; Albayrak, B; Alkım, H; Atalay, R; Balkan, A; Balkan, Y; Çoban, M; Coşar, AM; Danış, N; Değertekin, B; Demir, M; Demircan, M; Dinçer, D; Doğanay, L; Dursun, H; Erarslan, E; Göktürk, HS; Gündüz, F; Güneş, Ş; Gürel, S; Güzelbulut, F; Harputluoğlu, M; İnci, İ; Irak, K; Kaçar, S; Kani, HT; Kartal, A; Kefeli, A; Koklu, H; Mert, A; Nuriyev, K; Özakyol, A; Özdoğan, O; Öztaşkın, S; Sen, İ; Şimşek, H; Soylu, A; Sümer, H; Temel, T; Üçbilek, E; Uğurlu, ÇB; Uyanıkoğlu, A; Vatansever, S; Yalçın, K; Yaras, S; Yıldırım, E, 2020)	0.56
" The most common treatment-emergent adverse events were pyrexia (35 [12%]), cough (26 [9%]), upper respiratory tract infection (23 [8%]), and headache (20 [7%])."	( Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Andrieux-Meyer, I; Avihingsanon, A; Bompart, F; Chan, WK; Cressey, TR; Goyal, V; Hassan, MRA; Khemnark, S; Kumar, S; Menétrey, C; Murad, S; Ngo-Giang-Huong, N; Omar, H; Pécoul, B; Said, HRHM; Salvadori, N; Simon, F; Siva, S; Swanson, A; Tan, SS; Tee, HP; Thanprasertsuk, S; Thetket, K; Thongsawat, S; Yerly, S, 2021)	0.62
" Exploratory studies to identify potential rare adverse drug events associated with DAAs to optimize their use are scarce."	( Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. Burden, AM; Burkard, T; Hayes, KN; Tadrous, M; Weiler, S, 2021)	0.62
"We aimed to describe the most common serious DAA-associated adverse drug reaction (ADR) reports overall and by DAA regimen."	( Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. Burden, AM; Burkard, T; Hayes, KN; Tadrous, M; Weiler, S, 2021)	0.62
" Adverse events were evaluated in all patients who started their assigned treatment."	( Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. Afsharian, M; Bozorgomid, A; Janbakhsh, A; Khodarahmi, R; Khosravi Shadmani, F; Mansouri, F; Miladi, R; Mohseni Afshar, Z; Najafi, F; Rahimi, Z; Salimi, M; Sayad, B; Shirvani, M; Vaziri, S; Zamanian, MH, 2021)	0.62
" Adverse events (A/Es) were reported in 59."	( Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study. Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT, 2021)	0.62
" The secondary endpoint was virologic response rate at end-of-treatment and adverse event outcome."	( Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y, 2021)	0.62
"LDV/SOF is a safe and relatively effective treatment for hepatitis C in drug users."	( Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Pang, L; Tang, H; Tang, Y; Xu, D; Xu, P; Yang, X; Zhang, G, 2021)	0.62
"DCV 30 mg OD was predicted to achieve effective and safe exposures in children 14 to <35 kg, perhaps down to 10 kg."	( Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations. Abbassi, M; Al-Nahari, M; Cressey, TR; Easterbrook, P; El-Sayed, MH; Farid, S; Indolfi, G; Lallemant, M; Penazzato, M, 2021)	0.62
" Subjective adverse events were reported by 42."	( Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Su, PS; Wang, YJ; Wu, SH, 2022)	0.72
"HCV-infected patients can be treated well with an interferon-free SOF/DAC regimen, tolerated with generally mild adverse effects with a higher SVR."	( Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients. Alsrhani, A; Alzahrani, B; Ejaz, H; Gohar, UF; Junaid, K; Mukhtar, H; Qamar, MU; Younas, S, 2021)	0.62
"A 12 week course of sofosbuvir-velpatasvir-voxilaprevir is safe and efficacious for the re-treatment of individuals infected with HCV genotype 4 non-a/d subtypes with frequent baseline NS5A resistance-associated substitutions, following failure of previous direct-acting antiviral treatment."	( Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F, 2022)	0.72
"A 12-week regimen of sofosbuvir-velpatasvir is safe and efficacious in treating chronic HCV genotype 4 infection in patients in Rwanda."	( Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. Camus, G; Grant, PM; Gupta, N; Kabakambira, JD; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Murangwa, A; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F; Sylvain, H, 2022)	0.72
" Therefore, there is a need for effective and safe antiviral."	( Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. Adinolfi, LE; De Lucia Sposito, P; Fusco, R; Gaglione, P; Izzi, A; Lumino, P; Maggi, P; Marrone, A; Messina, V; Nevola, R; Rega, R; Rinaldi, L; Sasso, FC; Simeone, F, 2022)	0.72
" Demographic information, HCV viral load (VL), profiles of lipid and sugar, and adverse events were recorded and reviewed."	( Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD, 2022)	0.72
"Included studies were randomized trials comparing the same SOF-based medication regimens with and without RBV in HCV patients and measuring serious adverse events (SAEs) and/or sustained virologic response at 12 weeks post-treatment (SVR-12)."	( Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis. Ebell, M; Elshafie, S; Trivedi-Kapoor, R, 2022)	0.72
" No mortality or serious adverse events were recorded."	( Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. Abd Elghafar, MS; Abd-Elsalam, S; Abdelghaffar, H; Abdelghaffar, K; Al Shafie, A; Badr, M; El-Kassas, M; Esmael, HE; Ezz Eldin, AM; Ezzat, S; Hassany, SM; Kamal, DT; Karam-Allah, H; Medhat, MA; Moaz, I; Moustafa, E; Ossimi, A; Salama, M; Sayed, H; Shamseldeen, A, 2022)	0.72
" These drugs represent a safe and affordable treatment for COVID-19."	( Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. Abd Elghafar, MS; Abd-Elsalam, S; Abdelghaffar, H; Abdelghaffar, K; Al Shafie, A; Badr, M; El-Kassas, M; Esmael, HE; Ezz Eldin, AM; Ezzat, S; Hassany, SM; Kamal, DT; Karam-Allah, H; Medhat, MA; Moaz, I; Moustafa, E; Ossimi, A; Salama, M; Sayed, H; Shamseldeen, A, 2022)	0.72
"Ledipasvir/sofosbuvir fixed-dose combination is a safe and highly effective therapeutic option in Egyptian children aged ≥ 12 years, with chronic HCV infection, genotype 4, either without or with comorbidities."	( Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities. AbouBakr, O; El Sayed Zaki, M; Ezz El Regal, M; Noaman, A; Sarhan, AA, 2022)	0.72
" Methods Adults receiving 24-week SOF+RBV treatment for HCV GT3-6 infection were prospectively enrolled and observed through 24 weeks post-treatment for treatment-emergent adverse events (AEs) considered related to SOF and/or RBV by treating physicians and for a sustained virologic response at 12 and 24 weeks post-treatment (SVR12, SVR24)."	( Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan. Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D, 2023)	0.91
"Gastrointestinal adverse drug reactions (GADRs) of direct-acting antiviral agents (DAAs) in patients with chronic hepatitis C are underestimated."	( Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System. Li, J; Wang, L; Xie, W; Zhou, Y; Zhu, X, 2023)	0.91
"The US FDA Adverse Event Reporting System database was searched for GADR cases reported from 01 to 2012 to 30 September 2021."	( Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System. Li, J; Wang, L; Xie, W; Zhou, Y; Zhu, X, 2023)	0.91
" Serious adverse events (SAE) were registered."	( Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy. Diculescu, MM; Gheorghe, L; Iacob, SM; Iliescu, L; Istratescu, D; Manuc, M; Manuc, T; Popescu, CP; Preda, C; Stanciu, C; Stroie, TG; Tieranu, CG; Trifan, A, 2022)	0.72
" Serious adverse events related to therapy were reported in 1/143(0."	( Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy. Diculescu, MM; Gheorghe, L; Iacob, SM; Iliescu, L; Istratescu, D; Manuc, M; Manuc, T; Popescu, CP; Preda, C; Stanciu, C; Stroie, TG; Tieranu, CG; Trifan, A, 2022)	0.72
" Researchers assessed treatment-emergent adverse events (TEAEs) and laboratory abnormalities in patients randomized to SOF/VEL or placebo for 12 weeks in ASTRAL-1 and SOF/VEL for 12 weeks in ASTRAL-2 and ASTRAL-3."	( The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis. Bourgeois, S; Foster, GR; Gerken, G; Hernandez, C; Jacobson, IM; Mathurin, P; Osinusi, A; Ryder, SD; Scherbakovsky, S; Tedesco, D; Thuluvath, P; Vanstraelen, K, 2023)	0.91
" However, a comprehensive review of the adverse event (AE) profile of the DAAs is lacking."	( Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study. El-Marakby, MG; Sabri, NA; Solayman, MH, 2023)	0.91
" No grade III/IV adverse events were reported, and there was no worsening of blood counts, liver or renal function test parameters."	( Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy. Bhagat, N; Charak, S; De, A; Duseja, A; Goel, K; Premkumar, M; Rathi, S; Sharma, A; Singh, V; Taneja, S; Verma, N, 2023)	0.91
" The average incidence of adverse reactions during treatment was approximately 10%."	( Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis. Hsin, YH; Huang, CW; Ko, CY; Tsai, QZ; Tsai, YC; Yu, ML, 2023)	0.91
" Thirty-three reported adverse events (AEs) were considered related to the administration of SOF/VEL, all of them were mild or moderate."	( Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study. Aniszewska, M; Dobrzeniecka, A; Indolfi, G; Marczyńska, M; Pluta, M; Pokorska-Śpiewak, M; Talarek, E, 2023)	0.91
" Overall, sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir were safe and well tolerated."	( Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study. Ahn, SH; Byun, KS; Cho, JY; Heo, J; Jang, BK; Jang, JW; Jeong, SH; Jung, YJ; Kim, HJ; Kim, IH; Kim, JH; Kim, YJ; Kwon, JH; Kwon, KM; Lee, BS; Lee, SW; Lee, YJ; Lim, YS; Paik, SW; Park, NH; Suri, V; Tak, WY; Wu, P; Yang, SH; Yoon, KT, 2023)	0.91
"Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients."	( Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study. Ahn, SH; Byun, KS; Cho, JY; Heo, J; Jang, BK; Jang, JW; Jeong, SH; Jung, YJ; Kim, HJ; Kim, IH; Kim, JH; Kim, YJ; Kwon, JH; Kwon, KM; Lee, BS; Lee, SW; Lee, YJ; Lim, YS; Paik, SW; Park, NH; Suri, V; Tak, WY; Wu, P; Yang, SH; Yoon, KT, 2023)	0.91
"Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant use of opioids and DAAs."	( Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021. Collins, M; Conway, B; Dylla, DE; Khan, T; Marcinak, J; Martinez, A; Saget, B, 2023)	0.91

Excerpt	Reference	Relevance
" In this review we provide an overview of the clinical pharmacokinetic characteristics of these agents by describing their absorption, distribution, metabolism and excretion."	( Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M, 2014)	0.4
" This was a 112-day, open-label, fixed-sequence pharmacokinetic (PK) study in healthy female subjects that included a lead-in cycle (OC only; N = 21), cycle 1 (OC only; N = 15), cycle 2 (OC + sofosbuvir; N = 15), and cycle 3 (OC + ledipasvir; N = 15)."	( Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. German, P; Mathias, A; Moorehead, L; Pang, P; Vimal, M, 2014)	0.4
" The method was successfully applied to a pharmacokinetic study of ledipasvir, sofosbuvir and GS-331007 in rats."	( Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. Chen, W; Chen, Y; Jin, L; Lin, W; Pan, C; Pan, Z; Zheng, Y; Zhou, G, 2016)	0.43
" In one patient receiving the once daily regimen, sofosbuvir-007 half-life was slightly higher (38h) than for patients with normal renal function receiving a full dose."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
" In this pharmacokinetic study, sofosbuvir full dose (400mg once daily) administered every day with another direct antiviral agent did not accumulate in hemodialysis patients and was safe and effective."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
" This novelty allows us to measure serum concentrations of the drug for a longer time postdose and provides more opportunity for pharmacokinetic studies of sofosbuvir."	( Quantification of sofosbuvir in human serum by liquid chromatography with negative ionization mass spectrometry using the parent peak and its source-induced fragment: Application to a bioequivalence study. Babaei, A; Bahrami, G; Bahrami, MT; Ghaheri, M; Miraghaei, S; Mohammadi, B, 2016)	0.43
" Areas covered: This article reviews the pharmacokinetic and pharmacodynamic properties of the SOF/LDV fixed dose combination for the treatment of HCV."	( Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. Cuenca-Lopez, F; Rivero, A; Rivero-Juárez, A, 2017)	0.46
" Following approval in 2016, new pharmacokinetic and pharmacodynamic data were reported, which led to important clinical applications."	( Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. Brieva, T; Rivero, A; Rivero-Juarez, A, 2017)	0.46
" Pharmacokinetics and safety assessments were performed, and pharmacokinetic parameters were calculated using non-compartmental methods and summarized using descriptive statistics and compared statistically by geometric least-squares mean ratios and 90% confidence intervals."	( Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R, 2018)	0.48
" Expert opinion: This combination, taken orally with or without food, has an excellent pharmacokinetic and pharmacodynamic profile."	( Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Brieva, T; Frias, M; Rivero, A; Rivero-Juarez, A, 2018)	0.48
"The purpose of this study was to investigate the safety, tolerability, and pharmacokinetic profile of sofosbuvir and its metabolites after a single dose of sofosbuvir 400mg and once daily dosing of sofosbuvir 400mg for 7days in healthy Chinese subjects."	( Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects. Brainard, DM; Chen, G; Chen, H; Ding, Y; Li, X; Massetto, B; Niu, J; Shen, G; Zhang, H; Zhu, X, 2018)	0.48
" The pharmacokinetic properties of sofosbuvir, GS-556500, and GS-311007 were found to be broadly similar in healthy Chinese subjects compared with non-Chinese subjects in previous sofosbuvir studies."	( Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects. Brainard, DM; Chen, G; Chen, H; Ding, Y; Li, X; Massetto, B; Niu, J; Shen, G; Zhang, H; Zhu, X, 2018)	0.48
"Limited data exist on the pharmacokinetic profile of novel direct-acting antivirals in kidney transplant recipients."	( Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. Algharably, E; Budde, K; Duerr, M; Glander, P; Halleck, F; Hoffmann, F; Jaeger, C; Kreutz, R; Lisec, J; Schrezenmeier, E; Schrezenmeier, J, 2019)	0.51
" This study provides the rationale for future studies investigating the pharmacokinetic profile of sofosbuvir-based HCV treatment in kidney transplant recipients with an eGFR <30 mL/min."	( Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. Algharably, E; Budde, K; Duerr, M; Glander, P; Halleck, F; Hoffmann, F; Jaeger, C; Kreutz, R; Lisec, J; Schrezenmeier, E; Schrezenmeier, J, 2019)	0.51
"A series of deuterated sofosbuvir analogs were designed and prepared with the aim of improving their pharmacokinetic properties."	( Synthesis and biological evaluation of deuterated sofosbuvir analogs as HCV NS5B inhibitors with enhanced pharmacokinetic properties. Ao, W; Lin, Y; Ma, X; Song, W; Wang, Q; Wang, X; Xu, H; Zhang, X; Zhang, Y, 2019)	0.51
" Pharmacokinetic study was successfully applied and proved the possibility of co-administration of SOF with PAR and MET."	( Determination of sofosbuvir with two co-administered drugs; paracetamol and DL-methionine by two chromatographic methods. Application to a pharmacokinetic study. Abdel-Rahman, HM; Abdelrahman, MM; Abdelwahab, NS; Fares, MY, 2019)	0.51
" Pharmacokinetic data on both calcineurin inhibitors and direct-acting antiviral exposure in liver transplant recipients remain sparse."	( Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM, 2019)	0.51
" Although both have been approved in China, there are currently no data on their pharmacokinetic profiles in Chinese individuals."	( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects. Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020)	0.56
" Plasma pharmacokinetic parameters were estimated by using noncompartmental models, and safety was assessed through clinical evaluation and monitoring of adverse events."	( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects. Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020)	0.56
" The pharmacokinetic parameters for sofosbuvir, GS-566500, GS-331007, and ledipasvir or velpatasvir were similar to historical values in non-Chinese subjects."	( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects. Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020)	0.56
"Overall, ledipasvir/sofosbuvir and sofosbuvir/velpatasvir exhibited pharmacokinetic and safety profiles in healthy Chinese subjects similar to those in non-Chinese subjects in historical studies, supporting their use in the Chinese population with HCV infection."	( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects. Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020)	0.56
" This study was to evaluate the pharmacokinetic characteristics and effectiveness of daclatasvir/sofosbuvir (DAC/SOF) and ledipasvir/SOF (LDV/SOF) in HD patients."	( Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease. Feng, Z; Gao, H; Huang, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Wang, X; Xu, L; Zhang, L, 2020)	0.56
" Pharmacokinetic sampling, urine biomarker collection [urine protein (UPCR), retinol binding protein (RBP) and β2 microglobulin (β2M) normalized to creatinine] and safety assessments occurred at the end of each phase."	( Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH, 2020)	0.56
" Physiological changes in pregnancy alter the pharmacokinetics of some medications; thus, our aim was to compare the pharmacokinetic parameters of ledipasvir 90 mg plus sofosbuvir 400 mg during pregnancy with non-pregnant women."	( Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. Bogen, DL; Bunge, KE; Chappell, CA; Gaggar, A; Hillier, SL; Kirby, BJ; Krans, EE; Macio, IS; Meyn, LA; Scarsi, KK; Suri, V, 2020)	0.56
" A reference group of women who had participated in pharmacokinetic studies of ledipasvir-sofosbuvir during phase 2 and 3 trials was used."	( Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. Bogen, DL; Bunge, KE; Chappell, CA; Gaggar, A; Hillier, SL; Kirby, BJ; Krans, EE; Macio, IS; Meyn, LA; Scarsi, KK; Suri, V, 2020)	0.56
" This study aimed to evaluate the pharmacokinetic interaction of atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir "FDCSL" with rationalization to the underlying mechanism."	( Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers. Abdelaziz, AE; Abdelkawy, KS; Ali, AA; Belal, F; Elbarbry, F; Elmekawy, HA, 2021)	0.62
" This calls for a deep investigation of CMD effects on the pharmacokinetic parameters of these drugs to ensure their safety and efficacy."	( In-depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS. Abdine, HH; Aboras, SI; El-Yazbi, AF; Korany, MA; Ragab, MAA, 2022)	0.72
" For this reason, inhibitors, or inducers of intestinal P-gp may alter the plasma concentration of sofosbuvir and increase or decrease its efficacy causing a significant change in its pharmacokinetic parameters."	( Effects of aged garlic and ginkgo biloba extracts on the pharmacokinetics of sofosbuvir in rats. El-Demerdash, E; Saeed, NM; Wahdan, SA; Wasef, AK, 2022)	0.72
"This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity."	( Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. Batista, R; Blanchet, B; Cabanes, L; Chouchana, L; Goldwasser, F; Huillard, O; Khoudour, N; Monribot, A; Pallet, N; Préta, LH; Sogni, P; Thomas-Schoemann, A, 2023)	0.91

Excerpt	Reference	Relevance
" We randomly allocated all eligible patients with HCV genotype 1 (cohort A) to receive sofosbuvir 200 mg, sofosbuvir 400 mg, or placebo (2:2:1) for 12 weeks in combination with peginterferon (180 μg per week) and ribavirin (1000-1200 mg daily), after which they continued peginterferon and ribavirin for an additional 12 weeks or 36 weeks (depending on viral response)."	( Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT, 2013)	0.39
"The objectives were to (1) compare the frequency of contraindicated drug-drug interactions (XDDI) when simeprevir (SIM)- and sofosbuvir (SOF)-containing regimens are theoretically added to a patient's medication profile; (2) identify which hepatitis C (HCV) regimen is associated with the lowest frequency of XDDIs within different types of antiretroviral treatment (ART) regimens; and (3) determine the risk factors for XDDIs with each regimen."	( Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection. Amin, R; Koroglu, A; McGuey, L; McNutt, LA; Miller, C; Nasiri, M; Patel, N; Roman, M, 2015)	0.42
" The efficacy, tolerability, and absence of drug-drug interactions of ledipasvir-sofosbuvir suggest that it could be an important option for treatment of genotype 1 hepatitis C virus in Japanese patients."	( Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O, 2015)	0.42
" This phase 1, drug-drug interaction, open-label, multiple-dose study enrolled 32 healthy subjects to receive the 3D or 2D regimen in combination with sofosbuvir."	( Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir. Awni, WM; Cohen, D; Ding, B; Dutta, S; King, JR; Menon, RM; Podsadecki, TJ, 2016)	0.43
"Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or simeprevir (SMV) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection."	( Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O, 2016)	0.43
" health agencies issued warning letters in response to 9 reported clinical cases of severe bradycardia/bradyarrhythmia in hepatitis C virus (HCV)-infected patients treated with sofosbuvir (SOF) in combination with other direct acting antivirals (DAAs) and the antiarrhythmic drug, amiodarone (AMIO)."	( Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys. DeGeorge, JJ; Fitzgerald, K; Gerenser, P; Gruver, S; Morissette, P; Regan, CP; Regan, HK; Sannajust, FJ; Travis, JJ; Wen, J, 2016)	0.43
" Here, we evaluated the ability of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) to recapitulate the interaction between sofosbuvir and amiodarone in vitro, and more generally assessed the feasibility of hiPSC-CMs as a model system for drug-drug interactions."	( Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes. Anson, BD; Aoyama, N; Becker, N; Carlson, CB; Fertig, N; Goetze, TA; January, CT; Juhasz, K; Millard, DC; Ross, JD; Stoelzle-Feix, S; Strock, CJ, 2016)	0.43
"To evaluate the plasma trough concentrations ( C trough ) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis."	( Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. Ariaudo, A; Bonora, S; Castagna, A; D'Avolio, A; Galli, L; Hasson, H; Lazzarin, A; Marinaro, L; Merli, M; Messina, E; Uberti-Foppa, C, 2017)	0.46
"Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated."	( Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. Bourgeois, S; de Galocsy, C; Degré, D; Delwaide, J; Geerts, A; Gustot, T; Laleman, W; Langlet, P; Lasser, L; Lepida, A; Moreno, C; Negrin Dastis, S; Orlent, H; Reynaert, H; Sersté, T; Starkel, P; Van Steenkiste, C; Vanwolleghem, T, 2017)	0.46
" MBL-HCV1, a neutralizing human monoclonal antibody (mAb) targeting the HCV envelope, was combined with a licensed oral direct-acting antiviral (DAA) to prevent HCV recurrence post-transplant in an open-label exploratory efficacy trial."	( Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study. Boucher, E; Chapman, W; Cheslock, P; Chung, RT; Curry, MP; Mantry, P; Molrine, DC; Schiano, TD; Smith, HL; Wang, Y, 2017)	0.46
" We aimed to determine the efficacy and safety of SOF in combination with either SMV or DCV in GT4-infected patients."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
" In our study, we will report the real-life experience of serious adverse events (SAEs) that were reported by the National Committee for Control of Viral Hepatitis (NCCVH, Cairo, Egypt) program while treating chronic HCV using the triple therapy, sofosbuvir combined with pegylated interferon and ribavirin (PEG/RIBA/SOF), which led to premature discontinuation of treatment."	( Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A, 2017)	0.46
" No clinically relevant differences in the pharmacokinetics (PK) of SOF, SOF metabolite GS-331007, or VEL were observed other than an approximate 50% decrease in VEL exposure when administered with EFV/FTC/TDF."	( Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Brainard, DM; Ling, KHJ; Mathias, A; Mogalian, E; Osinusi, A; Shen, G; Stamm, LM, 2018)	0.48
"While direct-acting antivirals have been approved for treating hepatitis C, the guidelines highlight the importance of considering potential drug-drug interactions between DAAs and concomitant medications."	( Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Brooks-Rooney, C; Chen, CY; Chen, JJ; Cheng, PN; Hsieh, TY; Huang, YH; Kao, JH; Lin, CL; Liu, CH; Lo, CC; Ma, Q; Peng, CY; Su, WW; Yu, ML, 2018)	0.48
"To assess comorbidity prevalence, concomitant medication use and potential drug-drug interactions between DAAs and concomitant medications for hepatitis C patients in Taiwan."	( Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Brooks-Rooney, C; Chen, CY; Chen, JJ; Cheng, PN; Hsieh, TY; Huang, YH; Kao, JH; Lin, CL; Liu, CH; Lo, CC; Ma, Q; Peng, CY; Su, WW; Yu, ML, 2018)	0.48
" The potential drug-drug interactions between these concomitant medications and DAA regimens differed, with the fewest potential interactions with sofosbuvir-based regimens."	( Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Brooks-Rooney, C; Chen, CY; Chen, JJ; Cheng, PN; Hsieh, TY; Huang, YH; Kao, JH; Lin, CL; Liu, CH; Lo, CC; Ma, Q; Peng, CY; Su, WW; Yu, ML, 2018)	0.48
" The aim of this study was to report on possible drug-drug interactions between ledipasvir/sofosbuvir and other medications received by children and adolescents with hepatitis C virus, in addition to suggested management for these drug-drug interactions."	( Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R, 2019)	0.51
" Medications were reviewed by the Kasr Alainy Drug Information Center to identify possible drug-drug interactions with prescribed ledipasvir/sofosbuvir and their management."	( Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R, 2019)	0.51
"Early identification and prompt response to drug-drug interactions with the aid of pharmacists optimize the pharmacotherapeutic outcome and eliminate possible morbidities when using direct-acting antivirals in children and adolescents with hepatitis C virus."	( Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R, 2019)	0.51
" The last wave of DAAs is also characterized by a lesser tendency to generate or being victim of drug-drug interactions."	( Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy. Cariti, G; Di Perri, G, 2019)	0.51
" Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population."	( Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Chang, JM; Chen, SC; Chiu, YW; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JC; Huang, JF; Hwang, SJ; Jang, TY; Lee, JJ; Liang, PC; Lin, YH; Lin, ZY; Niu, SW; Wei, YJ; Yeh, ML; Yu, ML, 2021)	0.62
"The increasing number of direct-acting antiviral (DAA) regimens along with limited number of subjects and co-medications involved in clinical trials results in drug-drug interactions (DDIs) with DAAs is to be determined."	( Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study. Au, CL; Chan, HL; Hui, VW; Lai, JC; Lam, ASM; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2022)	0.72
"This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity."	( Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. Batista, R; Blanchet, B; Cabanes, L; Chouchana, L; Goldwasser, F; Huillard, O; Khoudour, N; Monribot, A; Pallet, N; Préta, LH; Sogni, P; Thomas-Schoemann, A, 2023)	0.91

Excerpt	Reference	Relevance
"The present study describes synthesis of amino-decorated mesoporous silica nanoparticles (MSNs) for sustained delivery and enhanced bioavailability of sofosbuvir."	( Amino-decorated mesoporous silica nanoparticles for controlled sofosbuvir delivery. Asghar, S; Asif, M; Hussain, T; Khalid, I; Khalid, SH; Khan, IU; Khan, RU; Mehmood, Y; Shah, SU; Shahzad, Y; Yousaf, AM, 2020)	0.56
" A high-fat meal appeared to promote the bioavailability of sofosbuvir and the metabolite GS-566500."	( Evaluation of the pharmacokinetics and food intake effect of generic sofosbuvir in healthy Chinese subjects . Li, X; Li, Y; Liu, L; Liu, Y; Wang, Y; Xu, B; Zhang, P, 2020)	0.56
" The increase in sofosbuvir bioavailability was more pronounced after atorvastatin intake."	( Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein. Abdelaziz, A; Abdelgaied, MY; Abdelkawy, KS; Belal, F; El-Khodary, NM; Elmekawy, HA, 2022)	0.72
" This formulation would be a good alternate for the management of viral diseases with better dissolution profile, stability and improved bioavailability for the patients."	( Formulation and evaluation of antiviral drug sofosbuvir fast dissolving tablets using natural super disintegrants. Aamir, MN; Akbar Sheikh, F; Khalid, N; Khurram Syed, S; Madni, A; Munir, F; Shirazi, JH, 2022)	0.72

Excerpt	Relevance	Reference
" Among HCV protease inhibitors, the safety, potency, and convenient dosing of simeprevir, asunaprevir, faldaprevir, and ABT-450/r were particularly highlighted."	( Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. Barreiro, P; Fernández-Montero, JV; Poveda, E; Soriano, V; Vispo, E, 2013)	0.39
" In addition, after oral dosing of several phosphoramidate derivatives of compound 21 to rats, substantial hepatic levels of the active triphosphate metabolite were found."	( Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase. Berke, JM; Fanning, G; Hu, L; Jonckers, TH; Lachau-Durand, S; Leclercq, L; Lin, TI; Nilsson, M; Raboisson, P; Rosenquist, Å; Samuelsson, B; Simmen, K; Stoops, B; Tahri, A; Van Hoof, S; Vandekerckhove, L; Vandyck, K; Vijgen, L, 2014)	0.4
"Treatment with GS-9669, a novel nonnucleoside inhibitor (site II) of hepatitis C virus (HCV) nonstructural 5B (NS5B) polymerase, resulted in significant antiviral activity in HCV genotype (GT) 1 patients dosed at 50 and 500 mg once daily (QD) and at 50, 100, and 500 mg twice daily (BID) for 3 days."	( Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C, 2014)	0.4
" A therapeutic range was identified for RBV-MP in persons with HCV GT1 disease receiving 24 weeks of sofosbuvir plus ribavirin, suggesting a potential pharmacological basis for individualized ribavirin dosing in IFN-free regimens."	( Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. Bushman, LR; Jimmerson, LC; Kiser, JJ; Kottilil, S; McHutchison, JG; Meissner, EG; Osinusi, A; Petersen, T; Rower, JE; Sims, Z; Wolfe, P, 2015)	0.42
" Harvoni(®), a combination tablet of sofosbuvir and ledipasvir, dosed once daily is recommended for 24 weeks for treatment-experienced genotype 1 patients with cirrhosis, but 12 weeks of therapy is sufficient for all other populations."	( Changing the face of hepatitis C management - the design and development of sofosbuvir. Besur, SV; deLemos, AS; Noell, BC, 2015)	0.42
" When surveying the DAA regimens available, efficacy, safety and tolerability of LDV/SOF is comparable or better, and LDV/SOF provides an option with convenient single-tablet, once daily, ribavirin-free dosing with relatively few significant drug-drug interactions."	( Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Fazel, Y; Golabi, P; Lam, B; Younossi, Z, 2015)	0.42
"Simeprevir and sofasbuvir have advantages in response rates and convenient dosage forms and frequency compared with other HCV treatments; however, they are more expensive than previous HCV therapies."	( Simeprevir and sofosbuvir for treatment of hepatitis C infection. Chopp, S; Hult, A; Klepser, M; Vanderwall, R, 2015)	0.42
" Our findings suggest that in interferon-free ribavirin-containing regimens, concerns over ribavirin dosing to achieve previously determined target plasma concentrations are unnecessary."	( The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin. Alavi, M; Day, R; Dore, GJ; Martinello, M; Matthews, GV; Schteinman, A; Williams, K, 2016)	0.43
"A once-daily dosage of ledipasvir/sofosbuvir was similarly effective in black and non-black patients with genotype 1 HCV infection."	( Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Afdhal, N; Gitlin, N; Howell, C; Jeffers, LJ; Kowdley, K; McHutchison, JG; Muir, AJ; Pang, PS; Poulos, J; Ravendhran, N; Reddy, KR; Shiffman, ML; Sulkowski, MS; Wilder, JM; Workowski, K; Yang, JC; Zhu, Y, 2016)	0.43
" Strategies for the management of expected and observed drug interactions consequent to the addition of simeprevir to preexisting complex medication regimens included modifications of HIV antiretroviral regimens (n = 4) and tacrolimus dosing (n = 4) and frequent monitoring of tacrolimus trough levels."	( Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. Abecassis, MM; Brooks, H; Grant, JL; Hawkins, C; Koppe, SW; Palella, FJ; Stosor, V, 2016)	0.43
" The open-label ALLY-1 study assessed the safety and efficacy of a 60-mg once-daily dosage of daclatasvir (pan-genotypic NS5A inhibitor) in combination with sofosbuvir at 400 mg once daily (NS5B inhibitor) and ribavirin at 600 mg/day for 12 weeks with a 24-week follow-up in two cohorts of patients with chronic HCV infection of any genotype and either compensated/decompensated cirrhosis or posttransplantation recurrence."	( Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R, 2016)	0.43
" We aimed to describe the pharmacokinetics, safety and efficacy of sofosbuvir in 2 dosing regimens and associated antiviral agents in HCV-infected patients requiring hemodialysis."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
" No clinically relevant drug-drug interactions were noted, but 52% of patients required a change to the dosage of immunosuppressive drugs."	( Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. Abergel, A; Anty, R; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; de Ledinghen, V; Debette-Gratien, M; Di Martino, V; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rohel, A; Roque-Afonso, AM; Rossignol, E; Samuel, D; Silvain, C, 2016)	0.43
" The efficacy of selected DAAs was determined in dose-response assays, in which the number of HCV-infected cells was measured after incubation with different concentrations of the specific DAA."	( Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. Bukh, J; Gottwein, JM; Mikkelsen, LS; Ramirez, S, 2016)	0.43
" Tacrolimus dosing required adjustment during and after ledipasvir-sofosbuvir therapy but antiretroviral regimens did not."	( Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients. Blumberg, EA; Doyle, AM; Lee, DH; Sawinski, D, 2017)	0.46
"To describe international normalized ratio (INR) trends and warfarin dosage adjustments required for four veterans who were receiving warfarin therapy and started treatment for hepatitis C virus (HCV) with ledipasvir/sofosbuvir with or without ribavirin."	( Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. Britnell, SR; Britt, RB; Vanderman, AJ; Willets, AE; Woodard, CL, 2016)	0.43
" SOF 400 mg/day and R (median dosage 800 mg/day) were given for a median of 35 days before LT."	( Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R, 2017)	0.46
" Simple, sensitive, and rapid spectrophotometric methods are presented for the determination of sofosbuvir and ledipasvir in their combined dosage form."	( Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products. Abo-Talib, NF; El-Ghobashy, MR; Tammam, MH, 2017)	0.46
" The patient continued with this warfarin dosage until 18 weeks after completion of his HCV regimen."	( Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin. Peterson, D; Van Ermen, A, 2017)	0.46
"Our data shows that successful treatment of CHC patients with and without prior RG-101 dosing results in reduction of broad immune activation, and normalisation of miR-122 levels (EudraCT: 2014-002808-25)."	( Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Barnes, E; Brown, A; de Vree, JML; Klenerman, P; Kootstra, NA; Reesink, HW; Sinnige, MJ; Stelma, F; Swadling, L; van der Ree, MH; van der Valk, M; van Nuenen, AC; Willemse, SB, 2017)	0.46
" Furthermore this method was successfully applied to the analysis of ledipasvir in pharmaceutical dosage form without interference from sofosbuvir and other additives and the results were statistically compared to a reported method and found no significant difference."	( Spectroflurimetric estimation of the new antiviral agent ledipasvir in presence of sofosbuvir. Abolmagd, E; Abouserie, AA; Attia, KA; El-Olemy, A; Salama, FM, 2018)	0.48
" Pharmaceutical dosage form was quantified by developed methods and the results were compared with the High Performance Liquid Chromatography (HPLC) reference method."	( Chemometric simultaneous determination of Sofosbuvir and Ledipasvir in pharmaceutical dosage form. Khalili, M; Mirzabeygi, V; Sohrabi, MR; Torabi Ziaratgahi, N, 2018)	0.48
" Geometric least squares means ratios (coadministration:alone) and 90% confidence intervals were constructed for area under the plasma concentration-time curve over the dosing interval, maximum concentration, and trough, for all analytes."	( Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Brainard, DM; Ling, KHJ; Mathias, A; Mogalian, E; Osinusi, A; Shen, G; Stamm, LM, 2018)	0.48
" RBV was dosed by physician discretion between 600-1200 mg daily."	( Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM, 2018)	0.48
"DAA in adult dosage are safe and effective for treatment of chronic hepatitis C (genotype 3) in pediatric β-thalassemic major population."	( Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children. Garg, K; Gupta, GK; Maharshi, S; Nijhawan, S; Padhi, S, 2018)	0.48
"The purpose of this study was to investigate the safety, tolerability, and pharmacokinetic profile of sofosbuvir and its metabolites after a single dose of sofosbuvir 400mg and once daily dosing of sofosbuvir 400mg for 7days in healthy Chinese subjects."	( Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects. Brainard, DM; Chen, G; Chen, H; Ding, Y; Li, X; Massetto, B; Niu, J; Shen, G; Zhang, H; Zhu, X, 2018)	0.48
" Steady state of the major metabolite GS-331007 was achieved after 4days of consecutive dosing with sofosbuvir 400mg once daily."	( Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects. Brainard, DM; Chen, G; Chen, H; Ding, Y; Li, X; Massetto, B; Niu, J; Shen, G; Zhang, H; Zhu, X, 2018)	0.48
" We evaluated non-adherence (<90% adherent) as measured by electronic blister-pack assessed using logistic regression and generalised estimating equations (continuous) with detailed analyses of dosing dynamics."	( Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. Amin, J; Applegate, TL; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Dunlop, AJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Litwin, AH; Marks, P; Matthews, GV; Norton, B; Powis, J; Quiene, S; Read, P; Shaw, D; Siriragavan, S; Thurnheer, MC; Weltman, M, 2018)	0.48
"5%, both at 12 and 24 weeks) whose average ribavirin dosage was 937."	( Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting? Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH, 2019)	0.51
" Age ≥70 years, with liver cirrhosis, and female gender were associated with ribavirin dosage reduction."	( Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting? Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH, 2019)	0.51
" Treatment was a combination of sofosbuvir 400 mg/day + daclatasvir 60 mg/day, with or without a weight-adjusted dosing of ribavirin for 12 or 24 weeks."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" The PK parameters of sofosbuvir and its metabolite (GS-331007) in both blood and urine samples were analyzed after dosing by the established liquid chromatography tandem mass spectrometry analytical method."	( Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects. Chen, G; Chen, H; Ding, Y; Li, X; Niu, J; Shen, Z; Zhang, H; Zhu, X, 2019)	0.51
"Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not licensed for this indication, and there is an absence of dosing recommendations in this population."	( Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. Agarwal, K; Ampuero, J; Ben-Ari, Z; Borgia, SM; Brown, A; Bruck, R; Calleja, JL; Cooper, C; Cramp, ME; Dearden, J; Dvory-Sobol, H; Esteban, R; Fox, R; Foxton, M; Gane, EJ; Haider, S; Hyland, R; Kirby, BJ; Lu, S; Lurie, Y; Markova, S; Meng, A; Osinusi, AO; Rodriguez, CF; Ryder, SD; Shafran, SD; Shaw, D; Willems, B; Yoshida, EM, 2019)	0.51
" Despite the lack of dosing recommendations, sofosbuvir-containing regimens (including sofosbuvir/velpatasvir) are frequently used for HCV-infected patients undergoing dialysis."	( Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. Agarwal, K; Ampuero, J; Ben-Ari, Z; Borgia, SM; Brown, A; Bruck, R; Calleja, JL; Cooper, C; Cramp, ME; Dearden, J; Dvory-Sobol, H; Esteban, R; Fox, R; Foxton, M; Gane, EJ; Haider, S; Hyland, R; Kirby, BJ; Lu, S; Lurie, Y; Markova, S; Meng, A; Osinusi, AO; Rodriguez, CF; Ryder, SD; Shafran, SD; Shaw, D; Willems, B; Yoshida, EM, 2019)	0.51
" For all patients, ribavirin dosing was determined by baseline weight (up to 1,400 mg/day, two divided doses)."	( Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. Balistreri, WF; Bansal, S; Brainard, DM; Davison, S; Feiterna-Sperling, C; Gillis, LA; Gonzalez-Peralta, RP; Hsueh, CH; Indolfi, G; Jonas, MM; Kelly, DA; Lin, CH; Massetto, B; Murray, KF; Nightingale, S; Parhy, B; Rosenthal, P; Schwarz, KB; Shao, J; Sokal, EM; Wirth, S, 2020)	0.56
" The method was validated according to International Conference on Harmonization guidelines, and it was successively applied for the determination of the studied drugs in their different pharmaceutical dosage forms and gave excellent percent of recovery."	( Silver Nanoparticles Synthesis for Sensitive Spectrophotometric Determination of Sofosbuvir, Lamivudine, and Ritonavir in Pure Forms and Pharmaceutical Dosage Forms. Elhenawee, M; Saleh, H; Saraya, RE, 2020)	0.56
" Patients from 46 centers were dosed for 12 or 24 weeks with or without ribavirin, in line with existing guidelines."	( SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Merat, S, 2020)	0.56
"Hepatitis C direct-acting antiviraltherapy may decrease calcineurin inhibitor levels, but this was not associated with clinically different dosing requirements or rejection rates."	( Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients. Berg, C; Byrns, J; Harris, M; Laub, M; Sanoff, S, 2021)	0.62
"4%) received DCV at a dosage of 60 mg, 52 (16."	( Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C, 2020)	0.56
"DCV use resulted in high SVR rate regardless of dosage and correctness of prescription."	( Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C, 2020)	0.56
" Although 1 had a favorable in vitro activity profile in HCV replicons, oral dosing in dog resulted in low levels of the active 5'-triphosphate (TP) in liver."	( Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors. Bow, DAJ; Carr, RA; Chen, HJ; Chris Krueger, A; DeGoey, DA; Dekhtyar, T; Heyman, HR; Irvin, M; Krishnan, P; Li, T; Peterkin, V; Randolph, JT; Stolarik, D; Van Handel, C; Wagner, R, 2020)	0.56
" Repeated dosing did not result in drug accumulation in the blood."	( Evaluation of the pharmacokinetics and food intake effect of generic sofosbuvir in healthy Chinese subjects . Li, X; Li, Y; Liu, L; Liu, Y; Wang, Y; Xu, B; Zhang, P, 2020)	0.56
" We developed a long-acting DAA system (LA-DAAS) capable of prolonged dosing and explored its cost-effectiveness."	( Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M, 2020)	0.56
" The validated HPLC method was successfully used to analyze the abovementioned drugs in their pure and dosage forms without interference from common excipients present in commercial formulations."	( Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms. Abo-Talib, NF; Almehizia, AA; Amr, AEE; Asiri, YA; Ezzeldin, E; Tammam, MH, 2020)	0.56
"Two chemometric assisted spectrophotometric models were applied for the quantitative analysis of velpatasvir and sofosbuvir in their newly FDA approved pharmaceutical dosage form."	( Simultaneous spectrophotometric quantitative analysis of velpatasvir and sofosbuvir in recently approved FDA pharmaceutical preparation using artificial neural networks and genetic algorithm artificial neural networks. Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Olemy, A; Goda, AI; Shahin, M; Zeid, AM, 2021)	0.62
"Four chemometric assisted spectrophotometric models were developed for the quantitative analysis of velpatasvir and sofosbuvir, in their newly FDA approved pharmaceutical dosage form."	( Application of different chemometric assisted models for spectrophotometric quantitative analysis of velpatasvir and sofosbuvir. Abdelazim, AH; Abu-Khadra, AS; Shahin, M, 2021)	0.62
" The suggested methodology has been effectively employed for the determination of the mentioned drugs in their pure forms and their pharmaceutical dosage forms as well as human plasma without significant interference of the pharmaceutical excipients or plasma components."	( Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma. Derayea, SM; Hamad, AE; Mohammed, BS, 2021)	0.62
" In the 194 subjects treated with sofosbuvir/ribavirin, median initial ribavirin dosage was 13."	( Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C, 2021)	0.62
" This valor is even more important in the case of the combined dosage form (Darvoni® tablets) to the pharmaceutical market."	( HPLC-UV and TLC-Densitometry Methods for Simultaneous Determination of Sofosbuvir and Daclatasvir: Application to Darvoni® Tablet. Eissa, MS; Fayed, AS; Hegazy, MA; Kamel, EB, 2022)	0.72
" This work critically reviews the recent advances in chromatographic methods for the analysis of sofosbuvir and/or its metabolites in pure samples, pharmaceutical dosage forms, and in the presence of other co-administered drugs to highlight the current status and future perspectives to enhance its determination in different matrixes."	( Recent advances in the chromatographic determination of the most commonly used anti-hepatitis C drug sofosbuvir and its co-administered drugs in human plasma. Abd El-Moghny, MG; Abdel-Tawab, MA; El Nashar, RM, 2022)	0.72
" For this purpose, simple, sensitive, rapid, and smart spectrophotometric methods were developed and validated for the determination of these drugs in their combined dosage form."	( Three Smart and Original Spectrophotometric Data Processing Ratio Techniques for Resolving the Partial Overlapped Spectra of the Binary Antiviral Mixture Daclatasvir/Sofosbuvir: Application to Combined Dosage Form Darvoni® Tablets. Eissa, MS; Fayed, AS; Hegazy, MA; Kamel, EB, 2022)	0.72
"Development of smart, sensitive, low-cost spectrophotometric methods for the determination of DCV and SFV in their combined dosage form."	( Three Smart and Original Spectrophotometric Data Processing Ratio Techniques for Resolving the Partial Overlapped Spectra of the Binary Antiviral Mixture Daclatasvir/Sofosbuvir: Application to Combined Dosage Form Darvoni® Tablets. Eissa, MS; Fayed, AS; Hegazy, MA; Kamel, EB, 2022)	0.72
" They were tested on their tablet dosage form, and a good recovery was obtained."	( Three Smart and Original Spectrophotometric Data Processing Ratio Techniques for Resolving the Partial Overlapped Spectra of the Binary Antiviral Mixture Daclatasvir/Sofosbuvir: Application to Combined Dosage Form Darvoni® Tablets. Eissa, MS; Fayed, AS; Hegazy, MA; Kamel, EB, 2022)	0.72
" This benefit is even more important in the case of the combined dosage form (Darvoni® tablets) for the pharmaceutical market."	( Three Smart and Original Spectrophotometric Data Processing Ratio Techniques for Resolving the Partial Overlapped Spectra of the Binary Antiviral Mixture Daclatasvir/Sofosbuvir: Application to Combined Dosage Form Darvoni® Tablets. Eissa, MS; Fayed, AS; Hegazy, MA; Kamel, EB, 2022)	0.72
" Using in vitro short-term dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy."	( Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Ansari, MA; Barnes, E; Bowden, R; Bukh, J; Chaturvedi, N; Fellay, J; Fernandez-Antunez, C; Foster, GR; Irving, WL; Magri, A; McLauchlan, J; Pedergnana, V; Ramirez, S; Simmonds, P; Smith, DA, 2021)	0.62
"Sofosbuvir-based direct-acting antiviral agents have no protective effects against the development of severe illness in patients with COVID-19 with the current dosing regimen."	( Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Hasan, SS; Javed, A; Kow, CS; Ramachandram, D, 2022)	0.72
" Recent studies showed sofosbuvir (SOF) can inhibit HEV replication in vitro and has add-on effect when combined with RBV, but the clinical effect of SOF against HEV infection remains controversial and the dosage of SOF warrants further exploration."	( High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection. Dai, L; He, Q; Liang, Z; Lu, F; Shu, J; Wang, L; Zhang, F, 2022)	0.72
"A smooth, exceptionally sensitive, correct, and extra reproducible RP-HPLC technique was developed and demonstrated to estimate Sofosbuvir (SOF) in pharmaceutical dosage formulations."	( RP-HPLC Method Development, Validation, and Drug Repurposing of Sofosbuvir Pharmaceutical Dosage Form: A Multidimensional Study. Chanihoon, GQ; Jafar, TH; Khalid, Z; Maneengam, A; Mangrio, GR; Nassani, R; Unar, A, 2022)	0.72

Role	Description
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
hepatitis C protease inhibitor	An inhibitor of hepatitis C protease, an enzyme required for production of proteins needed for viral assembly.
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
L-alanyl ester	Any alpha-amino acid ester that results from the formal condensation of the carboxylic acid group of L-alanine with an alcohol.
phosphoramidate ester	A phosphoric ester (phosphate) that has an NR2 instead of an OH group.
nucleotide conjugate
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
isopropyl ester	Any carboxylic ester resulting from the formal condensation of a carboxylic acid with the hydroxy group of propan-2-ol.
aminopyrimidine	A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
nucleobase analogue	A molecule that can substitute for a normal nucleobase in nucleic acids.
pyrimidone	A pyrimidine carrying one or more oxo substituents.
aromatic carboxylic acid	Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Gene expression (Transcription)	902	49
Epigenetic regulation of gene expression	117	17
Oxidative demethylation of DNA	4	9

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cereblon isoform 4	Magnetospirillum gryphiswaldense	Ki	24.5000	0.6420	3.9428	9.6000	AID1685002; AID1685006
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	1.7740	10.0000	AID1449550
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	8.4000	0.0001	1.7536	10.0000	AID1449548
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	2.0151	10.0000	AID1449551
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	60.0000	0.0000	2.8005	10.0000	AID1449549
Protein cereblon	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.2860	1.7066	3.0000	AID1685005
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NS5	Zika virus	EC50 (µMol)	15.5100	0.0087	0.5475	1.3000	AID1558369; AID1558370
Cytochrome P450 2C9	Homo sapiens (human)	EC50 (µMol)	0.2300	0.0008	0.4170	2.3000	AID1666939
RNA-directed RNA polymerase		EC50 (µMol)	0.1454	0.0018	0.2348	2.8000	AID1392412; AID1445766; AID1576087; AID1614291; AID1614292; AID1614293; AID1614294; AID1614296; AID1614301; AID1614302; AID1666938; AID1666939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RNA-directed RNA polymerase		EC90 (µMol)	0.8343	0.1300	1.9675	9.9000	AID1614291; AID1614292; AID1614293; AID1614294; AID1614296; AID1614301; AID1614302
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
protein ubiquitination	Protein cereblon	Homo sapiens (human)
positive regulation of Wnt signaling pathway	Protein cereblon	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Protein cereblon	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Protein cereblon	Homo sapiens (human)
negative regulation of monoatomic ion transmembrane transport	Protein cereblon	Homo sapiens (human)
locomotory exploration behavior	Protein cereblon	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Protein cereblon	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
protein binding	Protein cereblon	Homo sapiens (human)
transmembrane transporter binding	Protein cereblon	Homo sapiens (human)
metal ion binding	Protein cereblon	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
nucleus	Protein cereblon	Homo sapiens (human)
cytoplasm	Protein cereblon	Homo sapiens (human)
cytosol	Protein cereblon	Homo sapiens (human)
membrane	Protein cereblon	Homo sapiens (human)
perinuclear region of cytoplasm	Protein cereblon	Homo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complex	Protein cereblon	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1783408	Effect on formation of DENV replication complex in human Huh-7 cells assessed as reduction in expression of NS5 at 100 uM measured after 8 to 24 hrs by DAPI staining based confocal microscopy analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1614308	Selectivity ratio of EC50 for HCV genotype 1b NS5B polymerase S282T mutant to EC50 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614323	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1449506	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1401643	Antiviral activity against Hepatitis C virus JFH-1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by quantitative real-time RT-PCR analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis and biological evaluation of a novel β-D-2'-deoxy-2'-α-fluoro-2'-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection.
AID1650027	Stability in human plasma assessed as parent compound remaining after 4 hrs	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1614377	Selectivity ratio of EC90 for HCV genotype 1a NS5B polymerase to EC90 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614298	Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1449508	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 96 hrs by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1071249	Ratio of EC90 for Hepatitis C virus harboring NS5B polymerase S282T mutant gene to EC90 for Hepatitis C virus harboring wild type NS5B polymerase	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.
AID1614363	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level at 12.5 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1649893	Half life in human	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Hepatitis C - New drugs and treatment prospects.
AID517723	Antiviral activity against HCV infected in human clone A cells	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1467745	Drug recovery in human urine at 100 to 800 mg	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID517747	Cytotoxicity against human CEM cells assessed as inhibition of ribosomal DNA up to 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1666941	Intrinsic clearance in human hepatocytes	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID1366663	Cytotoxicity against human CEM cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.
AID1328887	Cytotoxicity against human Huh7.5.1 cells after 48 hrs by luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of 2'-α-C-Methyl-2'-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus.
AID1819072	Antiviral activity against HCVcc infected in human Huh7.5 cells assessed as inhibition of viral replication	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1697211	Cytotoxicity against human HuH-7-Luc/Neo-ET cells	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Synthesis and biological evaluation of 5'-C-methyl nucleotide prodrugs for treating HCV infections.
AID1666942	Prodrug conversion in human hepatocytes assessed as nucleotide triphosphate level at 100 uM after 4 hrs	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID1650025	Aqueous solubility of compound in pH 7.4 phosphate buffer	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1614369	Mitochondrial toxicity in human HepG2 cells assessed as lactic acid production at 12.5 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1401642	Cytotoxicity against human HuH7 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis and biological evaluation of a novel β-D-2'-deoxy-2'-α-fluoro-2'-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection.
AID1783355	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1650030	Intrinsic clearance in dog hepatocytes	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1449523	Selectivity ratio of EC90 for HCV genotype 1b harboring NS5B S282T mutant to EC90 for HCV genotype 1b harboring wild type NS5B	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1783345	Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1650021	Prodrug conversion in human primary hepatocytes assessed as nucleotide triphosphate level at 100 uM incubated for 4 hrs followed by compound wash-out for 20 hrs and measured following 4 hrs incubation period by LC-MS/MS analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1449548	Inhibition of human CYP3A4 using ketoconazole as substrate	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1614307	Selectivity ratio of EC50 for HCV genotype 1b/5a chimeric replicon NS5B polymerase to EC50 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614299	Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1366660	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 5 days by RT-PCR method	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.
AID1576087	Inhibition of HCV genotype 1b NS5B RNA dependent RNA polymerase	2019	MedChemComm, Jun-01, Volume: 10, Issue:6	Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of
AID1650012	Antiviral activity against HCV genotype 4a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1614530	Cytotoxicity against human HuH7 cells infected with HCV genotype 1b replicon after 72 hrs by CellTiter-Fluor reagent based fluorescence assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents.
AID1449551	Inhibition of human CYP2D6 using quinidine as substrate	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1449510	Antiviral activity against HCV genotype 2b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 96 hrs by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1449521	Antiviral activity against HCV genotype 1b harboring NS5B S282T mutant infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by luciferase reporter gene assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1449522	Selectivity ratio of EC50 for HCV genotype 1b harboring NS5B S282T mutant to EC50 for HCV genotype 1b harboring wild type NS5B	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1614301	Inhibition of NS5B polymerase in HCV genotype 1b/5a chimeric replicon infected in human HuH7 replicon cells after 5 days by RT-PCR analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1654878	Antiviral activity against wild type HCV by qRT-PCR analysis based by Reed-Muench method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1449525	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels at 50 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1819075	Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1783356	Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1650009	Antiviral activity against HCV genotype 2a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1449529	Mitochondrial toxicity in human HepG2 cells assessed as cytochrome c oxidase subunit 2 DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1614328	Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1366662	Cytotoxicity against human PBMC assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.
AID517759	Antiviral activity against HCV expressing NS5B polymerase S282T mutation infected in clone A cells	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1614302	Inhibition of NS5B polymerase S282T mutant in HCV genotype 1b infected in human Huh7 replicon cells after 5 days by RT-PCR assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614389	Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method	2019	Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4	Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.
AID1507860	Antiviral activity against CSFV infected in SK6 cells assessed as reduction of pseudo-plaque formation after 2 days by immunoperoxidase monolayer assay	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1666938	Inhibition of NS5B polymerase in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID517748	Cytotoxicity against human CEM cells assessed as inhibition of mitochondrial DNA up to 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1614364	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level at 12.5 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1783350	Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1449504	Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1654848	Selectivity index, ratio of CC50 for cytotoxicity in human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay to EC50 for antiviral activity against HCV J6/JFH/JC1 infected in human Huh7.5 cells incubated for 72 hrs by	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1819070	Selectivity index, ratio of CC50 for cytotoxicity against human Huh7.5.1 cells to EC50 for antiviral activity against HCV infected in human Huh7.5.1 cells	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1614300	Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1558370	Inhibition of RNA-dependent RNA polymerase in Zika virus infected in human NPC assessed as antiviral activity by DAPI-staining based assay	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Drugs for the Treatment of Zika Virus Infection.
AID1614321	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level at 50 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1463884	Dose normalized AUC (0 to 24 hrs) in mouse plasma assessed as 2'-C-MeU level at 10 mg/kg, po administered as single dose	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1783346	Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1328886	Antiviral activity against HCV JFH-1 infected in human HuH7.5.1 cells after 48 hrs by luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of 2'-α-C-Methyl-2'-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus.
AID1599418	Antiviral activity against DENV2 infected in human Huh7 cells assessed as reduction in virus yield by qRT-PCR analysis	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Recent update on anti-dengue drug discovery.
AID1449505	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1650007	Antiviral activity against HCV genotype 1b Con1 expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1467742	Fraction absorbed in po dosed portal vein cannulated dog	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1507864	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability after 72 hrs by MTT method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1328888	Antiviral activity against HCV infected in human Huh7 cells assessed as reduction in viral RNA replication after 4 days	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of 2'-α-C-Methyl-2'-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus.
AID1614291	Inhibition of NS5B polymerase in HCV genotype 1b/3a chimeric replicon infected in human HuH7 replicon cells after 5 days by RT-PCR analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1650003	Antiviral activity against HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID517760	Selectivity, ratio of EC90 for HCV expressing NS5B polymerase S282T mutation to EC90 for HCV expressing wild type NS5B polymerase	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1445770	Half life in human liver S9 fraction at 10 uM by LC/MS/MS analysis	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID1497245	Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase.
AID1167620	Selectivity index, ratio of CC50 for human ORL8 cells to EC50 for Hepatitis C virus infected in African green monkey OR6 cells	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID1783406	Effect on formation of DENV replication complex in human Huh-7 cells assessed as reduction in expression of NS3 at 100 uM measured after 8 to 24 hrs by DAPI staining based confocal microscopy analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1449507	Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as inhibition of viral RNA replication after 96 hrs by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1614306	Selectivity ratio of EC50 for HCV genotype 1b/4a chimeric replicon NS5B polymerase to EC50 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614303	Selectivity ratio of EC50 for HCV genotype 1a NS5B polymerase to EC50 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1445769	Half life in human plasma at 200 uM by LC/MS/MS analysis	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID1463883	Selectivity index, ratio of CC50 for human Huh-7 cells to EC50 for HCV genotype 1b Con1 expressing NS3 protease	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1449511	Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as inhibition of viral RNA replication after 96 hrs by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1449550	Inhibition of human CYP1A2 using alpha-naphthoflavone as substrate	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1449502	Antiviral activity against HCV genotype 1b harboring wild type NS5B infected in human HuH7 cells assessed as inhibition of viral RNA replication after 5 days by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1666939	Inhibition of NS5B polymerase in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID1614330	Cardiotoxicity against human embryonic stem cell-induced ventricular cardiomyocytes administered on day 7 and measured on day 10 after 30 mins incubation by CellTiter Glo assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID517761	Antiviral activity against HCV infected in human ET-lunet cells	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1655774	Selectivity index, ratio of CC50 for human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay to EC50 for Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human H	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.
AID1650029	Unbound drug level in human plasma	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1783359	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based direct yield reduction a	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1650026	Stability in dog plasma assessed as parent compound remaining after 4 hrs	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1312842	Antiviral activity against HCV genotype 3a infected in homozygous cDNA-uPA chimeric SCID mouse bearing humanized hepatocytes assessed as reduction in HCV RNA level in serum administered through oral gavage twice daily daily for 7 days by RT-PCR method	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosp
AID1714220	Antiviral activity against wild-type HCV J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1167619	Cytotoxicity against human ORL8 cells after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID1650028	Unbound drug level in dog plasma	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1654847	Antiviral activity against HCV J6/JFH/JC1 infected in human Huh7.5 cells incubated for 72 hrs by In-Cell Western assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1650005	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1463866	Antiviral activity against HCV genotype 1b Con1 expressing NS3 protease infected in human Huh-7 cells assessed as reduction in viral RNA replication after 72 hrs by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1445764	Inhibition of wild type NS5B in HCV genotype 1b replicon expressed in human HuH7 cells after 72 hrs by bright Glo-luciferase reporter gene assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID1507880	Antiviral activity against HCV infected in human Huh7-J17 cells assessed as inhibition of viral RNA replication after 72 hrs by bright-glo luciferase reporter assay	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1614527	Antiviral activity against HCV genotype 1b replicon infected in human HuH7 cells at 20 uM after 72 hrs by bright-glo luciferase reporter gene assay relative to control	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents.
AID1614317	Drug metabolism in human primary hepatocytes assessed as Tmax for NTP formation at 10 uM after 2 to 48 hrs by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1467727	Protein binding in human plasma	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1449530	Mitochondrial toxicity in human HepG2 cells assessed as cytochrome c oxidase subunit 2 DNA levels at 50 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID517763	Selectivity, ratio of EC90 for HCV expressing NS5B polymerase S282T mutation to EC90 for HCV expressing wild type NS5B polymerase in ET-Lunet cells	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1783343	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1312838	Antiviral activity against HCV genotype 3a infected in homozygous cDNA-uPA chimeric SCID mouse bearing humanized hepatocytes assessed as change in HCV RNA level in serum at 100 mg/kg, po qd administered through gavage for 7 days by RT-PCR method	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosp
AID1714217	Antiviral activity against HCV J6/JFH/JC1 harboring S282T mutant infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1650023	Antiviral activity against HCV genotype 1b Con1 over expressing CES1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1614293	Inhibition of NS5B polymerase in HCV genotype 2a infected in human HuH7 replicon cells after 5 days by RT-PCR analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614388	Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels after 5 days by RT-PCR analysis	2019	Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4	Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.
AID1449528	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1599373	Antiviral activity against DENV2 New Guinea C/PUO-218 by qRT-PCR analysis	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Recent update on anti-dengue drug discovery.
AID1449526	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels at 50 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1366664	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.
AID1819089	Selectivity index, ratio of CC50 for cytotoxicity against human Huh7.5 cells infected with HCVcc to EC50 for antiviral activity against HCVcc infected in human Huh7.5 cells	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1650004	Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1614319	Half life in human HuH7 cells at 10 uM pretreated for 24 hrs followed by change of media by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1463892	AUC (0 to t) in human hepatocytes assessed as ((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate level per 10'6 cells at 10 uM after 48 to 96 hrs	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1614379	Selectivity ratio of EC90 for HCV genotype 1b/3a chimeric replicon NS5B polymerase to EC90 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1312841	Antiviral activity against HCV genotype 3a infected in homozygous cDNA-uPA chimeric SCID mouse bearing humanized hepatocytes assessed as reduction in HCV RNA level in serum administered through oral gavage once daily for 7 days by RT-PCR method	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosp
AID1783357	Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1463888	Drug metabolism assessed as CES1 (unknown origin)-mediated monophosphate formation after 21 hrs relative to control	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1685006	Binding affinity to Magnetospirillum gryphiswaldense cereblon isoform 4 by measuring baseline corrected normalized fluorescence by MST based assay	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID1538367	Antiviral activity against HCV JFH-1 harboring K78E/E2-G451R/NS3-M260K/NS5A-T462I mutant infected in human Huh7.5.1 cells after 2 days by renilla luciferase reporter gene assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors.
AID1650006	Antiviral activity against HCV genotype 1b Con1 expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1666956	Lipophilicity, log D of compound	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID1467741	Oral bioavailability in portal vein cannulated dog	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1655772	Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.
AID1650010	Antiviral activity against HCV genotype 3a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1614381	Selectivity ratio of EC90 for HCV genotype 1b/5a chimeric replicon NS5B polymerase to EC90 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1449524	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1497239	Antiviral activity against Dengue virus 2 infected in human PBMC after 2 days post infection by plaque assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase.
AID1614297	Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614292	Inhibition of NS5B polymerase in HCV genotype 1b/4a chimeric replicon infected in human HuH7 replicon cells after 5 days by RT-PCR analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1783358	Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1697212	Therapeutic index, ratio of TC50 for human HuH-7-Luc/Neo-ET cells to EC50 for HCV infected in human HuH7-Luc/Neo-ET cells	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Synthesis and biological evaluation of 5'-C-methyl nucleotide prodrugs for treating HCV infections.
AID1366661	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.
AID1649894	Oral bioavailability in human	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Hepatitis C - New drugs and treatment prospects.
AID517732	Antiviral activity against HCV infected in human clone A cells assessed as inhibition of cellular rRNA replication at 50 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1783352	Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1614305	Selectivity ratio of EC50 for HCV genotype 1b/3a chimeric replicon NS5B polymerase to EC50 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614526	Antiviral activity against HCV genotype 1b replicon infected in human HuH7 cells after 72 hrs by bright-glo luciferase reporter gene assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents.
AID1463873	AUC (0 to t) in human cardiomyocytes assessed as ((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate level per 10'6 cells at 10 uM after 24 to 168 hrs	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1614329	Nephrotoxicity in human HK2 cells after 72 hrs by Hoechst 33342/HCS live/dead green dye-based assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1449509	Antiviral activity against HCV genotype 2a/k infected in human HuH7 cells assessed as inhibition of viral RNA replication after 96 hrs by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1467743	Fraction absorbed in human	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1650011	Antiviral activity against HCV genotype 3a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1558283	Cytotoxicity against African green monkey Vero cells	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Drugs for the Treatment of Zika Virus Infection.
AID1614320	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level at 50 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1819073	Antiviral activity against HCV infected in human Huh7.5 cells carrying HCV subgenomic replicons assessed as inhibition of viral replication	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1449549	Inhibition of human CYP2C9 using sulfaphenazole as substrate	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1467726	Protein binding in plasma of patient with end stage renal disease	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1614391	Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometric method	2019	Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4	Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.
AID1614362	Half life in human hepatocytes cells at 10 uM pretreated for 12 hrs followed by change of media by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614294	Inhibition of NS5B polymerase in HCV genotype 1a infected in human HuH7 replicon cells after 5 days by RT-PCR analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614380	Selectivity ratio of EC90 for HCV genotype 1b/4a chimeric replicon NS5B polymerase to EC90 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1449512	Antiviral activity against HCV genotype 4 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 96 hrs by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1614296	Inhibition of NS5B polymerase in wild type HCV genotype 1b infected in human Huh7 replicon cells after 5 days by RT-PCR assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1685005	Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence by MST based assay	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID1392412	Inhibition of Hepatitis C virus genotype 1b NS5B RNA-dependent-RNA polymerase assessed as reduction in viral replication after 72 hrs by indirect immunofluorescence assay	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
AID1449552	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels at 25 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1654843	Antiviral activity against HCV J6/JFH/JC1 infected in human Huh7.5 cells assessed as reduction in viral RNA levels incubated for 72 hrs by qRT-PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1654849	Selectivity index, ratio of CC50 for cytotoxicity in human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay to EC50 antiviral activity against HCV J6/JFH/JC1 infected in human Huh7.5 cells assessed as reduction in vir	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1507862	Selectivity index, ratio of CC50 for SK6 cells to IC50 for CSFV	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1071250	Antiviral activity against Hepatitis C virus harboring NS5B polymerase S282T mutant gene	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.
AID1467720	Prodrug activation in human urine assessed as 2'-deoxy-2'-fluoro-2'-C-methyluridine formation at 100 to 800 mg	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1463889	Drug metabolism assessed as CatA (unknown origin)-mediated monophosphate formation after 18 hrs relative to control	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1445766	Inhibition of NS5B S282T mutant in HCV genotype 1b replicon expressed in human HuH7 cells after 72 hrs by bright Glo-luciferase reporter gene assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID1783349	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID517762	Antiviral activity against HCV expressing NS5B polymerase S282T mutation infected in human ET-lunet cells	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1614382	Selectivity ratio of EC90 for HCV genotype 1b NS5B polymerase S282T mutant to EC90 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1463891	AUC (0 to t) in human Huh-7 cells assessed as ((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate level per 10'6 cells at 10 uM after 24 to 72 hrs	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1666957	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID1666943	Prodrug conversion in human hepatocytes assessed as nucleotide triphosphate level at 100 uM incubated for 4 hrs followed by compound washout and further incubated in fresh media for 24 hrs	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID1614290	Mitochondrial toxicity in human HepG2 cells assessed as lactic acid production at 50 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1685002	Binding affinity to Magnetospirillum gryphiswaldense cereblon isoform by FRET assay	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID1614322	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1614304	Selectivity ratio of EC50 for HCV genotype 2a NS5B polymerase to EC50 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1783353	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1819069	Antiviral activity against HCV infected in human Huh7.5 cells incubated for 72 hrs by in-cell western assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1614327	Cytotoxicity in human HepaRG cells assessed as reduction in cell viability incubated for 14 days by CellTiter-Glo assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1697210	Antiviral activity against HCV subtype 1b infected in human HuH-7-Luc/Neo-ET cells by luciferase replicon-reporter gene assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Synthesis and biological evaluation of 5'-C-methyl nucleotide prodrugs for treating HCV infections.
AID1449554	Mitochondrial toxicity in human HepG2 cells assessed as cytochrome c oxidase subunit 2 DNA levels at 25 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1666940	Aqueous solubility of compound at pH 7.4	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID517765	Cytotoxicity against human HepG2 cells assessed as inhibition of ribosomal DNA	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1783351	Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1449527	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1445765	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability up to 100 uM after 72 hrs by Cell Titer-Fluor Cell assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID1507865	Selectivity index, ratio of CC50 for Huh7.5 cells to IC50 for HCV Jc1/JFH	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1650013	Antiviral activity against HCV genotype 6a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1655773	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.
AID1819080	Binding affinity to HCV E1 protein at 12.5 to 200 uM by SPR analysis	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1650022	Prodrug conversion in human primary hepatocytes assessed as nucleotide triphosphate level at 100 uM incubated for 4 hrs and followed by compound washout for 20 hrs and measured following 24 hrs incubation period by LC-MS/MS analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1614378	Selectivity ratio of EC90 for HCV genotype 2a NS5B polymerase to EC90 for wild type HCV genotype 1b NS5B polymerase	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1783348	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction ass	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1449553	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels at 25 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1463886	Antiviral activity against HCV genotype 1b Con1 infected in human Huh-7 cells over-expressing CES1	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1463887	Drug metabolism assessed as CES1 (unknown origin)-mediated monophosphate formation after 3 hrs relative to control	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1650008	Antiviral activity against HCV genotype 2a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1783347	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1650024	Distribution coefficient, logD of compound by HT-LCMS analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1783344	Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1649892	Inhibition of HCV NS3/4a protease	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Hepatitis C - New drugs and treatment prospects.
AID1312834	Antiviral activity against HCV genotype 1a infected in homozygous cDNA-uPA chimeric SCID mouse bearing humanized hepatocytes assessed as change in HCV RNA level in serum at 100 mg/kg, po qd administered through gavage for 7 days by RT-PCR method	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosp
AID1071252	Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.
AID1783354	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1558369	Inhibition of RNA-dependent RNA polymerase in Zika virus infected in African green monkey Vero cells assessed as antiviral activity by DAPI-staining based assay	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Drugs for the Treatment of Zika Virus Infection.
AID517764	Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial DNA	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1650031	Intrinsic clearance in human hepatocytes	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
AID1463885	Dose normalized AUC (0 to 24 hrs) in mouse liver assessed as 2'-C-MeUTP level at 10 mg/kg, po administered as single dose	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1666937	Half life in human hepatocytes	2020	Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
AID1167618	Antiviral activity against Hepatitis C virus infected in African green monkey OR6 cells after 72 hrs by luciferase reporter gene assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID1614387	Antiviral activity against HCV genotype 1b subgenomic replicon infected in human HuH7 clone B cells assessed as inhibition of viral RNA replication after 5 days by RT-PCR method	2019	Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4	Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.
AID1714214	Resistance ratio of EC50 for antiviral activity against HCV J6/JFH/JC1 harboring S282T mutant infected in human Huh7.5 cells to EC50 for antiviral activity against wild-type HCV J6/JFH/JC1 infected in human Huh7.5 cells	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1819090	Antiviral activity against HCV infected in human Huh7.5 cells assessed as reduction in HCV core protein expression at 6.4 nM incubated for 72 hrs by in-cell western assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1654881	Antiviral activity against HCV expressing NS5B S282T mutant by qRT-PCR analysis based by Reed-Muench method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1467746	Renal clearance in human at 100 to 800 mg	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1783410	Effect on formation of DENV replication complex in human Huh-7 cells assessed as reduction in NS5 translocation into nucleus at 100 uM measured after 16 to 24 hrs by DAPI staining based confocal microscopy analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1449516	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1445767	Ratio of EC50 for HCV genotype 1b replicon NS5B S282T mutant to EC50 for wild type HCV genotype 1b replicon NS5B	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID1783411	Effect on formation of DENV replication complex in human Huh-7 cells assessed as reduction NS3 translocation into cytoplasm at 100 uM measured after 16 to 24 hrs by DAPI staining based confocal microscopy analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1507863	Antiviral activity against HCV Jc1/JFH infected in human Huh7.5 cells assessed as reduction of pseudo-plaque formation after 72 hrs by immunoperoxidase monolayer assay	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1507881	Cytotoxicity against human Huh7-J17 cells assessed as decrease in cell viability after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1819074	Cytotoxicity against human Huh7.5 cells infected with HCVcc assessed as reduction in cell viability incubated for 96 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1654845	Cytotoxicity in human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1879226	Antiviral activity against HCV by replicon assay	2022	Bioorganic & medicinal chemistry letters, 04-01, Volume: 61	Design, chemical synthesis and antiviral evaluation of 2'-deoxy-2'-fluoro-2'-C-methyl-4'-thionucleosides.
AID1558371	Cytotoxicity against human Neural progenitor cells	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Drugs for the Treatment of Zika Virus Infection.
AID1449503	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1467744	Tmax in po dosed human	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1507861	Cytotoxicity against SK6 cells assessed as reduction in cell viability after 2 days by MTS method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus.
AID1783360	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1819068	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.
AID1614390	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method	2019	Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4	Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1402276	Antiviral activity against HCV infected in human GS4.3 cells assessed as inhibition of viral core protein levels at 0.8 uM treated with fresh media containing compound every 2 days measured after 6 days by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
AID517741	AUC (0 to infinity) in cynomolgus monkey plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547055	Antiviral activity against West Nile virus New York by neutral red assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517726	Cmax in rat liver assessed as 2'-F-2'-C-Methyluridine-5''-TP level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517734	Tmax in dog plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547296	Antiviral activity against Hepatitis C virus assessed as clearance of HCV from replicon cells at 2 uM	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547285	Antiviral activity against Hepatitis C virus harboring wild-type NS5B infected in human lunet cells by luciferase-based replicon assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547048	Antiviral activity against Hepatitis C virus Con1 infected in human lunet cells assessed as inhibition of viral RNA replication after 4 days by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547076	Cytotoxicity against human CEM cells assessed as effect on ribosome RNA gene level at up to 100 uM after 14 days by quantitative real-time PCR assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547290	Antiviral activity against Hepatitis C virus assessed as log reduction in viral RNA at 1 uM after 3 weeks	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517731	Half life in simulated gastric fluid at pH 1.2 at 50 ug/mL	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1595513	Cytotoxicity against human HuH7 cells infected with HCV con1 subgenomic replicon assessed as reduction in cell viability measured after 3 days by CellTiter-blue cell viability assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID517740	Tmax in cynomolgus monkey plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517737	AUC (0 to t) in dog plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1402257	Antiviral activity against HCV J6/JFH/JC-1 infected in human Huh7.5 cells assessed as inhibition of NS3/4A S282T mutant levels at 0.01 to 1 uM treated with fresh media containing compound every 2 days by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
AID1402293	Antiviral activity against 22.5 to 90 IU/cell of HCV J6/JFH/JC-1 infected in human Huh7.5 cells assessed as inhibition of viral core protein levels at 0.05 uM treated with fresh media containing compound every 2 days by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
AID1535562	Cytotoxicity against human Huh7.5 cells after 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus.
AID547081	Cytotoxicity against human erythroid progenitor cells after 14 to 16 days by colony formation assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517753	Cytotoxicity against human myeloid progenitor cells after 14 to 16 hrs	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517729	Half life in simulated intestinal fluid of pH 7.5 at 50 ug/mL	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547052	Antiviral activity against Hepatitis C virus H77 harboring Htat protein assessed as viral RNA level by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517746	Cytotoxicity against HuH7 cells at 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1402260	Antiviral activity against HCV J6/JFH/JC-1 infected in human Huh7.5 cells harboring NS3/4A S282T mutant assessed as inhibition of viral core protein levels at 0.01 to 1 uM treated with fresh media containing compound every 2 days by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
AID547054	Antiviral activity against Hepatitis C virus H77	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547063	Cytotoxicity against human HepG2 cells assessed as effect on cellular GAPDH RNA level after 8 days by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547091	Antiviral activity against Hepatitis C virus harboring NS5B polymerase S96T/N142T mutant gene infected in human lunet cells by luciferase-based replicon assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517723	Antiviral activity against HCV infected in human clone A cells	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517735	AUC (0 to infinity) in dog plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547051	Antiviral activity against Hepatitis C virus genotype 1b harboring Ntat protein assessed as viral RNA level by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID1535561	Antiviral activity against HCV genotype 2a JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA replication after 72 hrs by qRT-PCR analysis	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus.
AID547293	Antiviral activity against Hepatitis C virus assessed as inhibition of viral rebound at 2 uM after 3 weeks in presence of G418	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547050	Antiviral activity against Hepatitis C virus isolate Con1 harboring Btat protein assessed as viral RNA level by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547283	Antiviral activity against Hepatitis C virus harboring NS5B polymerase S282T mutant gene infected in human HuH7 cells by luciferase-based replicon assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547060	Antiviral activity against Hepatitis B virus infected in human HepAD38 cells by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547282	Antiviral activity against Hepatitis C virus harboring wild-type NS5B infected in human HuH7 cells by luciferase-based replicon assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547080	Cytotoxicity against human CEM cells assessed as inhibition of mitochondrial DNA synthesis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547291	Antiviral activity against Hepatitis C virus assessed as log reduction in viral RNA at 2 uM after 3 weeks	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547068	Cytotoxicity against human HeLaP4 cells	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547077	Cytotoxicity against human HepG2 cells	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547284	Selectivity ratio of EC90 for Hepatitis C virus harboring NS5B polymerase S282T mutant gene to EC90 for Hepatitis C virus harboring wild-type NS5B polymerase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID1402275	Antiviral activity against HCV infected in human GS4.3 cells assessed as inhibition of NS3/4A levels at 0.8 uM treated with fresh media containing compound every 2 days measured after 6 days by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
AID517751	Cytotoxicity against human CEM cells at 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1535563	Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for antiviral activity against HCV genotype 2a JFH/JC1 infected in human Huh7.5 cells	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus.
AID517754	Toxicity in rat assessed as mortality at 50 to 1800 mg/kg, po after 14 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547065	Cytotoxicity against human CEM cells assessed as effect on cellular GAPDH RNA level after 8 days by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517738	Metabolic stability in dog liver assessed as 2'-F-2'-C-Methyluridine-5''-triphosphate level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1595512	Antiviral activity against HCV con1 subgenomic replicon infected in human HuH7 cells assessed as reduction in viral RNA replication by qRT-PCR analysis	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID547062	Cytotoxicity against human HuH7 cells assessed as effect on cellular GAPDH RNA level after 8 days by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547053	Antiviral activity against Hepatitis C virus JFH1 assessed as viral RNA level by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547082	Cytotoxicity against human myeloid progenitor cells after 14 to 16 days by colony formation assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547064	Cytotoxicity against human BxPC3 cells assessed as effect on cellular GAPDH RNA level after 8 days by quantitative real-time PCR	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547056	Antiviral activity against Yellow fever virus 17D by neutral red assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517727	Tmax in rat liver assessed as 2'-F-2'-C-Methyluridine-5''-TP level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517725	AUC (0 to t) in rat liver assessed as 2'-F-2'-C-Methyluridine-5''-TP level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547066	Cytotoxicity against HFF	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517742	AUC (0 to t) in cynomolgus monkey plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517755	Toxicity in rat assessed as change in body weight at 50 to 1800 mg/kg, po after 14 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547286	Antiviral activity against Hepatitis C virus harboring NS5B polymerase S96T mutant gene infected in human lunet cells by luciferase-based replicon assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547049	Antiviral activity against Hepatitis C virus isolate Con1 infected in human HuH-7 cells assessed as inhibition of viral RNA replication after 4 days by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517733	Cmax in dog plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517743	Metabolic stability in cynomolgus monkey liver assessed as prodrug level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517745	Permeability by PAMPA assay	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547289	Antiviral activity against Hepatitis C virus assessed as log reduction in viral RNA at 0.1 uM after 3 weeks	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547292	Antiviral activity against Hepatitis C virus assessed as inhibition of viral rebound at 1 uM after 3 weeks in presence of G418	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517752	Cytotoxicity against human erythroid progenitor cells after 14 to 16 hrs	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547057	Antiviral activity against Influenza A virus (A/Brisbane/59/2007 (H1N1)) infected in HFF by neutral red assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517724	AUC (0 to infinity) in rat liver assessed as 2'-F-2'-C-Methyluridine-5''-TP level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547079	Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial DNA synthesis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547078	Cytotoxicity against human CEM cells	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517757	Toxicity in rat assessed as change in kidney weight at 50 to 1800 mg/kg, po after 14 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517750	Cytotoxicity against human BxPC3 cells at 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517728	Half life in human liver S9 fraction at 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517730	Half life in human plasma at 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517744	Metabolic stability in cynomolgus monkey liver assessed as 2'-F-2'-C-Methyluridine-5''-triphosphate level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID517758	Toxicity in rat assessed as change in macroscopic pathology at 50 to 1800 mg/kg, po after 14 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547295	Antiviral activity against Hepatitis C virus assessed as clearance of HCV from replicon cells at 1 uM	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517732	Antiviral activity against HCV infected in human clone A cells assessed as inhibition of cellular rRNA replication at 50 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547089	Inhibition of human RNA polymerase at 2 uM	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547061	Antiviral activity against HIV infected in human HeLaP4 cells by beta-galactosidase-based reporter gene assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID1294756	Antiviral activity against HCV subtype 1b by replicon assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors.
AID517736	Metabolic stability in dog liver assessed as prodrug level at 50 mg/kg, po	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547073	Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 gene level up to 100 uM after 14 days by real-time PCR assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517739	Cmax in cynomolgus monkey plasma at 50 mg/kg, po qd for 4 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547075	Cytotoxicity against human HepG2 cells assessed as effect on ribosome RNA gene level at up to 100 uM after 14 days by quantitative real-time PCR assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID1402292	Antiviral activity against 22.5 to 90 IU/cell of HCV J6/JFH/JC-1 infected in human Huh7.5 cells assessed as inhibition of NS3/4A levels at 0.05 uM treated with fresh media containing compound every 2 days by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
AID547058	Antiviral activity against Influenza A virus (A/Viet Nam/1203/2004(H5N1)) infected in HFF by neutral red assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517756	Toxicity in rat assessed as change in liver weight at 50 to 1800 mg/kg, po after 14 days	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547059	Antiviral activity against Influenza A virus (A/Brisbane/10/2007(H3N2)) infected in HFF by neutral red assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547074	Mitochondrial toxicity in human CEM cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 gene level up to 100 uM after 14 days by quantitative real-time PCR assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID547287	Selectivity ratio of EC90 for Hepatitis C virus harboring NS5B polymerase S96T mutant gene to EC90 for HCV harboring wild type NS5B polymerase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
AID517749	Cytotoxicity against human HepG2 cells at 100 uM	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID547067	Cytotoxicity against human HepAD38 cells	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1615 (73.88)	24.3611
2020's	571 (26.12)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	318 (14.70%)	5.53%
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	243 (11.23%)	6.00%
Reviews	0 (0.00%)	6.00%
Reviews	16 (13.68%)	6.00%
Case Studies	239 (11.04%)	4.05%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	146 (6.75%)	0.25%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	1,218 (56.28%)	84.16%
Other	6 (100.00%)	84.16%
Other	101 (86.32%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (322)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Lung Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients: A Pilot Study [NCT03112044]	Early Phase 1	26 participants (Actual)	Interventional	2017-09-19	Active, not recruiting
The Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4 [NCT03743727]	Phase 4	25 participants (Anticipated)	Interventional	2018-08-01	Recruiting
A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study [NCT03236506]	Phase 2	129 participants (Actual)	Interventional	2018-01-19	Completed
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania (CUTTS HepC): a Non-randomised, Quasiexperimental, Prospective Comparative Trial [NCT06159504]	Early Phase 1	3,040 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV [NCT03057847]	Phase 4	32 participants (Actual)	Interventional	2018-01-30	Completed
Pharmacokinetics of Low-dose Sofosbuvir in Dialysis-dependent Patients With Hepatitis C Virus Infection [NCT03883698]	Phase 3	30 participants (Actual)	Interventional	2019-03-15	Completed
Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection [NCT03646396]		40 participants (Anticipated)	Interventional	2018-08-01	Recruiting
Role of Pegylated Interferon in Combination With Direct Acting Antivirals (DAAs) to Cure Hepatitis C As Soon As Possible (ASAP) - Hepatitis C [ASAP-C] [NCT03480932]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2018-02-02	Completed
Evaluation of the Natural History and Vertical Transmission of Chronic Hepatitis C Virus Infection in Pregnancy With Targeted Elimination by Postpartum Treatment [NCT03570112]		150 participants (Anticipated)	Observational	2018-06-08	Recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects With Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed [NCT02822794]	Phase 3	117 participants (Actual)	Interventional	2016-07-25	Completed
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Stud [NCT03512210]	Phase 4	400 participants (Actual)	Interventional	2018-10-22	Completed
A Phase 3 Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection and Compensated Cirrhosis [NCT04112303]	Phase 3	37 participants (Actual)	Interventional	2019-10-16	Completed
The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia [NCT03169348]		50 participants (Anticipated)	Interventional	2017-11-01	Recruiting
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis [NCT02994056]	Phase 2	32 participants (Actual)	Interventional	2017-01-23	Completed
A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 [NCT02371408]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2015-01-31	Active, not recruiting
A Randomized Study of a Rapid HCV Treatment Initiation Strategy (HCV Seek, Test and Rapid Treatment) Compared to Standard Care in Young People Who Inject Drugs [NCT03627546]	Phase 4	39 participants (Actual)	Interventional	2018-09-18	Completed
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease [NCT03036852]	Phase 2	59 participants (Actual)	Interventional	2017-03-22	Completed
A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease [NCT02858180]	Phase 4	15 participants (Actual)	Interventional	2016-12-31	Completed
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection [NCT03074331]	Phase 3	130 participants (Actual)	Interventional	2017-03-23	Completed
Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic [NCT03235154]	Phase 4	11 participants (Actual)	Interventional	2017-10-11	Completed
Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin Versus Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin in the Management of Hepatitis C Patients Fauilre to Prior Sofosbuvir/ Daclatasvir (An Open-labeled Randomized Trial) [NCT03549832]		40 participants (Actual)	Interventional	2018-01-01	Completed
Demonstration Project on Assessment of Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar [NCT03579576]		803 participants (Actual)	Observational	2017-12-20	Completed
An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection [NCT02156570]	Phase 4	20 participants (Anticipated)	Interventional	2014-10-31	Completed
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study [NCT03818308]	Phase 2	20 participants (Actual)	Interventional	2019-05-28	Completed
Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital [NCT03965286]		80 participants (Anticipated)	Observational	2019-06-01	Not yet recruiting
Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic G [NCT02483156]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2015-07-31	Completed
Outcome of New Direct Acting Agents For Hepatitis C [NCT02485262]		340 participants (Anticipated)	Observational [Patient Registry]	2013-11-30	Recruiting
A Randomized, Open-Label, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2) [NCT02723084]	Phase 3	136 participants (Actual)	Interventional	2016-04-08	Completed
Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney [NCT03296930]	Phase 4	100 participants (Anticipated)	Interventional	2017-10-01	Not yet recruiting
Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus [NCT03250910]	Phase 4	228 participants (Actual)	Interventional	2016-08-01	Completed
The Relationship Between Direct Acting Antiviral Treatment Effect and Myeloid-Derived Suppressor Cells and NK Cells Activity in Chronic Hepatitis C [NCT03188276]	Early Phase 1	52 participants (Actual)	Interventional	2016-02-01	Completed
A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of an 8-Week and 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection With and Witho [NCT02253550]	Phase 2	30 participants (Anticipated)	Interventional	2014-10-31	Completed
Evaluation of Vitamin D and Iron Status in Chronic Hepatitis C Virus Patients Before and After Treatment [NCT03166280]		87 participants (Anticipated)	Observational	2017-06-30	Not yet recruiting
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease [NCT03036839]	Phase 2	95 participants (Actual)	Interventional	2017-06-27	Completed
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection [NCT03022981]	Phase 2	216 participants (Actual)	Interventional	2017-01-26	Completed
A Multicenter, Single-arm, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection [NCT03487107]	Phase 3	362 participants (Actual)	Interventional	2018-04-17	Completed
Does Directly Acting Antivirals Usage Affect HCV Related Hepatocellular Carcinoma Recurrence After Percutaneous Ablation: A Randomized Controlled Trial [NCT04653818]	Phase 4	84 participants (Actual)	Interventional	2020-10-05	Completed
Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet [NCT03389061]	Phase 4	0 participants (Actual)	Interventional	2018-04-01	Withdrawn(stopped due to Lack of patients who are eligible for inclusion: less patients on treatment and not using epclusa.)
Efficacy of a Fixed-Dose Combination Pill of Sofosbuvir and Daclatasvir in Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus [NCT03369327]	Phase 3	232 participants (Actual)	Interventional	2017-01-01	Completed
A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C [NCT02097966]		0 participants	Expanded Access		No longer available
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection [NCT02125500]	Phase 2	68 participants (Actual)	Interventional	2014-08-31	Completed
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV [NCT03549312]	Phase 4	25 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Monitoring of Hepatitis C Therapy Using Telemedicine in a Simplified Protocol With Pangenotypic Regimen in Non-cirrhotic Patients - a Single Group Clinical Trial in the National Public Health System in Brazil [NCT04039698]		144 participants (Actual)	Interventional	2019-08-23	Active, not recruiting
A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis [NCT02781558]	Phase 2	204 participants (Actual)	Interventional	2016-07-29	Completed
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infect [NCT02639338]	Phase 3	220 participants (Actual)	Interventional	2015-12-23	Completed
An Open Label, Pilot Study to Investigate the Safety and Efficacy of 12 Weeks of Simeprevir and Sofosbuvir, for HIV-infected, HCV Genotype 1 Patients With Advanced Fibrosis [NCT02206932]	Phase 4	0 participants (Actual)	Interventional	2014-08-31	Withdrawn(stopped due to never opened)
The ATOMIC Study: A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin [NCT01329978]	Phase 2	332 participants (Actual)	Interventional	2011-03-31	Completed
QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepa [NCT01435044]	Phase 2	239 participants (Actual)	Interventional	2011-09-30	Completed
Effect of Direct-acting Antiviral Drugs on Erectile Function Among Hepatitis c Patients [NCT03444272]	Phase 3	105 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Demonstration Project on Assessment of Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine [NCT04038320]		868 participants (Actual)	Observational	2018-03-26	Completed
Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Strategic Therapeutic Intervention to Enhance Linkage to Care in People Who Inject Drugs [NCT03981211]		60 participants (Anticipated)	Interventional	2021-02-12	Recruiting
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study [NCT02220868]	Phase 4	10 participants (Actual)	Interventional	2014-07-31	Completed
Same-visit Hepatitis C Testing and Treatment to Accelerate Cure Among People Who Inject Drugs: a Cluster Randomised Control Trial (The QuickStart Study) [NCT05016609]	Phase 4	1,800 participants (Anticipated)	Interventional	2022-03-09	Recruiting
Open Label Study to Evaluate the Safety and Pharmacokinetics of Elpida® in Healthy Subjects and Patients With Hepatic Impairment, as Well as to Assess the Impact of Food Intake and Drug-Drug Interactions in Case of Co-administration With Other Antiviral D [NCT03706898]	Phase 1	36 participants (Actual)	Interventional	2018-10-01	Completed
Measuring Inflammation Cells (CD163 and CD206) With the Purpose of Examining Reduction of Fibrosis in the Liver of Chronic Hepatitis C Patients Following Treatment With the Medication Sofosbuvir [NCT02528461]		71 participants (Actual)	Observational	2015-01-31	Completed
Evaluation of Efficacy and Safety of KW-136 Capsule Combined With Sofosbuvir Tablet for Treatment of Adult Chronic Hepatitis C: an Open-label, Multi-center, Phase 3 Study [NCT03995485]	Phase 3	371 participants (Actual)	Interventional	2017-06-07	Completed
Insulin Resistance and Resistin In Non-Diabetic Patients With Chronic Hepatitis C Before and After Direct-Acting Antiviral Drugs. [NCT04457050]	Phase 4	160 participants (Actual)	Interventional	2017-10-30	Completed
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver [NCT03619837]	Phase 4	122 participants (Actual)	Interventional	2018-07-15	Completed
Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial [NCT04498936]	Phase 4	240 participants (Actual)	Interventional	2020-07-15	Completed
Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents [NCT03343444]	Phase 3	80 participants (Anticipated)	Interventional	2017-04-15	Enrolling by invitation
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination Therapy in Treatment of Chronic Hepatitis C Infection in Egyptian Children With Gaucher Disease [NCT03721627]	Phase 4	10 participants (Anticipated)	Interventional	2018-04-03	Recruiting
An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative Recipient [NCT03801707]	Phase 2/Phase 3	54 participants (Actual)	Interventional	2019-03-22	Completed
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland) [NCT02491450]	Phase 1	24 participants (Actual)	Interventional	2015-02-28	Completed
Efficacy and Safety of Neutrino Therapy for Chronic HCV Genotype 1b Treatment-experienced Patients [NCT02480686]	Phase 4	32 participants (Actual)	Interventional	2015-01-31	Completed
Effect of Triple Direct Acting Antiviral Agents (DAAs) for Non-cirrhotic Subjects With Chronic HCV G1b Infection [NCT02470858]	Phase 2	18 participants (Actual)	Interventional	2015-01-31	Completed
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers [NCT03313414]	Phase 4	0 participants (Actual)	Interventional	2019-08-13	Withdrawn(stopped due to No participant enrollment, funding withdrawn.)
Expanding the Pool in Lung Transplantation: The Use of Hepatitis C Positive Donor Lungs in Hepatitis C Negative Recipients [NCT03377478]	Phase 1	10 participants (Actual)	Interventional	2019-07-30	Completed
Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection [NCT02683005]	Phase 1	9 participants (Actual)	Interventional	2016-09-30	Completed
Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy [NCT02638233]	Phase 4	40 participants (Anticipated)	Interventional	2015-09-30	Recruiting
A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-Cirrhotic Subjects Infected With Chronic HCV Genotype 3 [NCT02551861]	Phase 2	0 participants (Actual)	Interventional	2015-12-31	Withdrawn
A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas [NCT02836925]	Phase 2	40 participants (Actual)	Interventional	2016-03-31	Completed
A Prospective, Non-Interventional Cohort Study of Approved Sofosbuvir-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice [NCT02783976]		25 participants (Actual)	Observational	2016-10-28	Completed
A Phase IV Open-label Multicentre International Pilot Study of 4-week Treatment With Sofosbuvir (400 mg) Plus Glecaprevir/Pibrentasvir (300mg/120mg) in Chronic HCV Treatment naïve Patients With Early Liver Disease [NCT03855917]	Phase 4	30 participants (Anticipated)	Interventional	2020-02-11	Recruiting
A Phase 2 Open-Label Study in Patients With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant to Explore the Safety And Efficacy of Simeprevir and Sofosbuvir With and Without Ribavirin [NCT02165189]	Phase 2	46 participants (Actual)	Interventional	2014-08-31	Completed
TAC (Treatment Africa Hepatitis C) : Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus- [NCT02405013]	Phase 2	120 participants (Actual)	Interventional	2015-10-31	Completed
The Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Naïve Children [NCT05091008]	Phase 2	50 participants (Actual)	Interventional	2018-03-01	Completed
Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection [NCT02482077]	Phase 4	112 participants (Actual)	Interventional	2015-01-31	Completed
Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children From 3 to Less Than 18 Years of Age With GT-1 to -6 Chronic Hepatitis C (CHC) Infection [NCT03487848]	Phase 2	5 participants (Actual)	Interventional	2018-06-25	Terminated(stopped due to Business objectives have changed)
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection [NCT02472886]	Phase 3	153 participants (Actual)	Interventional	2015-06-17	Completed
A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting [NCT02064049]	Phase 4	3,692 participants (Actual)	Interventional	2014-10-31	Completed
Use of Direct-acting Antiviral Therapy to Prevent Spread of HCV Infection for Patients Receiving a HCV Positive Kidney Transplant as a HCV Negative Recipient [NCT03093740]	Phase 4	0 participants (Actual)	Interventional	2018-10-01	Withdrawn(stopped due to Withdrew IRB application, never approved and no subjects enrolled)
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China : a Mutil-center,Prospective,Single-arm,Open-label [NCT04997564]	Phase 4	120 participants (Anticipated)	Interventional	2021-08-31	Recruiting
Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort. [NCT02057003]		1,000 participants (Anticipated)	Observational	2012-01-31	Recruiting
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subje [NCT02607800]	Phase 3	943 participants (Actual)	Interventional	2015-11-16	Completed
Parallel, Open-Label, Randomized Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PSI-7977 in Combination With BMS-790052 With or Without Ribavirin in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotypes 1, [NCT01359644]	Phase 2	350 participants (Actual)	Interventional	2011-06-30	Completed
Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents [NCT03547895]		80 participants (Actual)	Interventional	2015-06-01	Completed
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Subjects With Chronic Hepatitis C and Decompensated Cirrhosis or Post-Liver Transplant Subjects With Chronic Hepatitis C Recurrence [NCT02161939]		0 participants	Expanded Access		No longer available
Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan [NCT05248919]		318 participants (Anticipated)	Interventional	2023-06-01	Enrolling by invitation
Transplantation of Livers of Hepatitis C (HCV) Seropositive Donors to HCV Seronegative Recipients With Subsequent Therapy With Sofosbuvir/Velpatasvir (Epclusa®) [NCT03819322]	Phase 2	73 participants (Actual)	Interventional	2019-08-15	Active, not recruiting
The Treatment And Prevention (TAP) Study: Treating People Who Inject Drugs (PWID) in Community-based Settings Using a Social Network Approach [NCT02363517]	Phase 3	420 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4 [NCT02772744]		250 participants (Anticipated)	Observational	2017-11-01	Not yet recruiting
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy [NCT03903185]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2019-03-01	Completed
Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin [NCT02705534]	Phase 3	50 participants (Actual)	Interventional	2016-09-30	Completed
Metabolic Changes in Chronic Hepatitis C Virus Patients Receiving Direct Acting Antivirals [NCT04211844]		100 participants (Anticipated)	Observational [Patient Registry]	2019-10-01	Recruiting
Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods [NCT02657694]		10,000 participants (Anticipated)	Observational [Patient Registry]	2015-07-01	Enrolling by invitation
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir [NCT02647632]	Phase 2	26 participants (Actual)	Interventional	2016-01-31	Completed
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC [NCT02771405]	Phase 3	150 participants (Anticipated)	Interventional	2016-03-31	Recruiting
Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 3 Infection [NCT02576314]	Phase 3	48 participants (Actual)	Interventional	2015-05-31	Completed
A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk o [NCT04561063]	Phase 2	1,950 participants (Actual)	Interventional	2020-12-08	Completed
A Prospective Multicenter Cohort Study: the Efficacy of Vosevi in Treating Direct Antiviral Agent Therapy Failure Patients [NCT06180590]		200 participants (Anticipated)	Observational	2023-02-28	Recruiting
A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India [NCT02592057]		532 participants (Actual)	Observational	2015-11-30	Completed
Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT-1 Study) [NCT02624063]	Phase 4	121 participants (Actual)	Interventional	2015-12-31	Completed
A Phase IIa, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 2,3,6 Hepatitis C Virus Infection [NCT04111367]	Phase 2	36 participants (Anticipated)	Interventional	2019-04-03	Recruiting
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGE [NCT02939989]	Phase 3	33 participants (Actual)	Interventional	2016-11-21	Completed
Pharmacokinetics of Sofosbuvir and Ledipasvir in Hepatitis C Virus - Infected Adolescent Patients With Haematological Disorders [NCT04353986]	Phase 3	24 participants (Anticipated)	Interventional	2018-06-11	Recruiting
Clinical Pharmacokinetics, Safety and Efficacy Study of Daclatasvir/Sofosbuvir in Adolescents Aged 12 to 18 Years Old With Hepatitis C Virus: A Preliminary Study [NCT03540212]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2017-12-10	Recruiting
Direct Antiviral Agents for the Treatment of Chronic HCV/HBV Co-infection Patients [NCT02555943]	Phase 2/Phase 3	23 participants (Actual)	Interventional	2015-02-28	Completed
Comparative Open-label,Randomized, Fasting, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Scien [NCT02953535]	Phase 1	36 participants (Actual)	Interventional	2016-05-31	Completed
Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon (Hepatitis Eradication Accuracy Trial of Sofosbuvir): An Observational Non-interventional Real Life Trial [NCT02804386]	Phase 4	573 participants (Actual)	Interventional	2016-06-30	Completed
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience [NCT02745535]	Phase 2	77 participants (Actual)	Interventional	2016-05-31	Completed
Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus During Pregnancy (STORC) [NCT05140941]	Phase 4	100 participants (Anticipated)	Interventional	2022-04-04	Recruiting
Transplantation of Kidneys of Hepatitis C (HCV) Seropositive Donors to HCV Seronegative Recipients With Subsequent Therapy With Sofosbuvir/Velpatasvir (Epclusa) [NCT03809533]	Phase 2	30 participants (Actual)	Interventional	2019-05-29	Active, not recruiting
A Phase Ib/IIa, Single Center, Randomized, Open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability， Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects [NCT04202952]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2020-07-06	Completed
Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria. JAILFREE-C [NCT02768961]	Phase 4	64 participants (Actual)	Interventional	2016-05-10	Completed
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 1 Hepatitis C Virus Infection. [NCT04001608]	Phase 3	206 participants (Actual)	Interventional	2018-10-17	Active, not recruiting
Evolution of Estimated Glomerular Filtration Rate in Chronic Hepatitis C Patients Receiving Sofosbuvir-based or Sofosbuvir-free Direct Acting Antivirals [NCT04047680]		441 participants (Actual)	Observational	2015-02-28	Completed
Efficacy and Safety of Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly Cirrhotic Patients: a Real Life Study [NCT02702739]	Phase 4	270 participants (Actual)	Interventional	2015-01-31	Completed
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) [NCT02556086]	Phase 2	0 participants (Actual)	Interventional	2015-12-31	Withdrawn
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication [NCT03823911]	Phase 4	87 participants (Actual)	Interventional	2018-11-18	Completed
Evaluation of Liver Fibrosis by Serum Hyalornic Acid Measurement in β-Thalassemic Children Infected With Hepatitis C Virus Before and After Direct-Acting Antiviral Therapy [NCT03961828]	Phase 4	50 participants (Actual)	Interventional	2017-10-01	Completed
Open Label Phase II/III, Multicenter, Trial to Assess the Efficacy, Safety, Tolerance, and Pharmacokinetics of Sofosbuvir Plus Ravidasvir in HCV (+/- HIV) Chronically Infected Adults With no or Compensated Cirrhosis in Thailand and Malaysia [NCT02961426]	Phase 2/Phase 3	603 participants (Actual)	Interventional	2016-09-30	Active, not recruiting
Evaluation of Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Adults Chronically Infected With Genotype 2 Hepatitis C Virus: an Open-label, Multicenter Confirmatory Study [NCT03453346]		136 participants (Actual)	Interventional	2016-08-05	Completed
Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C [NCT03118674]	Phase 2	23 participants (Actual)	Interventional	2017-09-06	Completed
A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection [NCT02759861]	Phase 4	16 participants (Actual)	Interventional	2016-08-01	Completed
A Phase 2a, Partly Randomized, Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Subjects With Chronic Genotype 4 Hepatitis C Infect [NCT02278419]	Phase 2	63 participants (Actual)	Interventional	2014-12-31	Completed
Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment [NCT04530422]	Phase 3	250 participants (Actual)	Interventional	2020-04-15	Completed
Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 [NCT04532931]	Phase 2	192 participants (Actual)	Interventional	2020-09-03	Completed
Expanding the Pool in Orthotopic Heart Transplantation: The Use of Hepatitis C Positive Donor Hearts in Hepatitis C Negative Recipients [NCT03222531]	Phase 2	20 participants (Anticipated)	Interventional	2017-08-01	Active, not recruiting
The Effects of Anti-Viral Therapy on the Clinical Status, Quality of Life, and Survival of Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection [NCT02597166]	Phase 3	14 participants (Actual)	Interventional	2016-01-31	Completed
Management of Hepatitis C Virus Infection Among People Who Inject Drugs in a Low-threshold Setting: Efficacy of Direct-acting Antiviral Treatment and the Risk of Reinfection [NCT04063839]		300 participants (Anticipated)	Observational	2015-01-31	Recruiting
Hepatitis C Virus Infection Induced Insulin Resistance: Different Contribution From Liver and Extrahepatic Sites as Inferred by Treating Chronic Hepatitis C Patients With an Interferon-free Antiviral Combination [NCT02760355]		17 participants (Actual)	Interventional	2016-03-31	Completed
A Multi-center, Open-Labeled Exploratory Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 400 mg and Ribavirin for 12 Weeks With and Without Pegylated Interferon in Treatment-Na [NCT01260350]	Phase 2	292 participants (Actual)	Interventional	2010-12-31	Completed
The Renal Safety and Rates of Acute Kidney Injury (AKI) in Patients With Chronic HCV Undergoing Sofosbuvir Containing Direct Acting Antiviral Therapy [NCT04169464]	Phase 4	200 participants (Anticipated)	Interventional	2019-04-01	Enrolling by invitation
Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection [NCT04159246]		30 participants (Anticipated)	Observational	2019-02-10	Active, not recruiting
Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium [NCT02799355]		1,203 participants (Actual)	Observational	2016-05-31	Completed
Transplanting Organs From Hepatitis C Positive Donors to Hepatitis C Uninfected Recipients [NCT03086044]	Phase 4	148 participants (Anticipated)	Interventional	2017-03-01	Recruiting
Efficacy and Safety of Interferon Based Therapy and Interferon-free Direct-acting Antivirals in Cirrhotic Patients With Hepatitis C. Impact of Antiviral Therapy on Gastroesophageal Varices. [NCT02758509]		237 participants (Actual)	Observational	2010-01-01	Completed
Comparative Open-label,Randomized, Fasting, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (G [NCT02605798]	Phase 1	24 participants (Actual)	Interventional	2015-08-31	Completed
Pharmacokinetics, Safety, Efficacy and Acceptability Study of Daclatasvir/Sofosbuvir in Children Weighing 14-35 Kilograms With Chronic Hepatitis C Virus Infection [NCT05854511]	Phase 3	30 participants (Anticipated)	Interventional	2022-06-05	Recruiting
New Drugs And New Concerns: Gaining Insight Through Pharmacovigilance Of Direct Acting Anti-Viral's In Chronic HCV Patients [NCT04664894]		511 participants (Actual)	Observational	2018-05-15	Completed
Impact of Serum Alpha-fetoprotein Levels on the Response to Direct Antiviral Therapy in Egyptian Patients With Chronic Hepatitis C [NCT03402165]	Phase 4	1,200 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Drug Interaction Between RDV and SOF in ASC18 Tablets (RDV/SOF Compound Tablets) and the Influence of Food Effect on the Pharmacokinetics of ASC18 Tablets Were Evaluated in Healthy Subjects. Comparison of the Pharmacokinetic Parameters of ASC18 Tablets（Ra [NCT04358523]	Phase 1	50 participants (Actual)	Interventional	2020-03-20	Completed
A Multicenter, Randomized, Parallel Assigned, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection [NCT03458481]	Phase 2	129 participants (Actual)	Interventional	2017-07-31	Completed
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks or Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks in DAA Treatment Naïve HCV Subjects With GT3b, Compensated Cirrhosis in China [NCT05467826]	Phase 4	100 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials [NCT02510300]		461 participants (Actual)	Observational [Patient Registry]	2015-10-21	Terminated(stopped due to The study stopped early because the study objectives were met.)
A Multi-center, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naïve Patie [NCT01188772]	Phase 2	147 participants (Actual)	Interventional	2010-08-31	Completed
A Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Harvoni Treatment Regimen in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea [NCT02951364]		1,081 participants (Actual)	Observational	2016-12-05	Completed
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Daul Therapy in Egyptian Pediatric Patients With Chronic Hepatitis C Infection. A Prospective, Randomized, Multicenter Study [NCT02985281]	Phase 2/Phase 3	41 participants (Anticipated)	Interventional	2016-12-31	Enrolling by invitation
The SIM-SOF Trial: A Randomized Trial Comparing Simeprevir-Sofosbuvir Versus Peginterferon/Ribavirin/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype-1a-infected Patients With Cirrhosis [NCT02168361]	Phase 4	93 participants (Actual)	Interventional	2013-12-31	Completed
A Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in People Who Inject Drugs and People With HIV Coinfection. [NCT02625909]	Phase 3	222 participants (Actual)	Interventional	2017-03-09	Completed
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection [NCT02250807]	Phase 3	40 participants (Actual)	Interventional	2015-01-31	Completed
A Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Standard of Care [NCT01054729]	Phase 2	64 participants (Actual)	Interventional	2010-01-31	Completed
Phase 1 Pharmacokinetic Trial of Sofosbuvir/Velpatasvir in Pregnant Women With Chronic Hepatitis C Virus Infection [NCT04382404]	Phase 1	11 participants (Actual)	Interventional	2020-10-22	Completed
Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and Ribavirin [NCT02596880]	Phase 3	100 participants (Actual)	Interventional	2015-09-30	Completed
SOF/VEL±RBV: Real-World Efficacy and Safety in GT 3 and 6 HCV Patients in China [NCT04948801]		150 participants (Anticipated)	Observational	2018-12-08	Recruiting
A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection [NCT02413593]	Phase 2	111 participants (Actual)	Interventional	2015-04-30	Completed
Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection [NCT02457611]	Phase 2	26 participants (Actual)	Interventional	2015-06-30	Completed
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 [NCT04246723]	Phase 2	85 participants (Actual)	Interventional	2019-05-06	Completed
A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients [NCT01805882]	Phase 2	229 participants (Actual)	Interventional	2013-01-31	Completed
The Safety and Efficacy of Sofosbuvir & Daclatasvir Combined Therapy for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4 [NCT03080415]	Phase 3	40 participants (Actual)	Interventional	2017-03-18	Completed
Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World [NCT02964091]	Phase 4	300 participants (Actual)	Interventional	2016-10-31	Completed
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid [NCT02707601]	Phase 3	150 participants (Actual)	Interventional	2016-04-01	Completed
A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Non-Genotype 1 HCV Infection [NCT02378961]	Phase 2	128 participants (Actual)	Interventional	2015-02-16	Completed
Eliminación de la infección Por el Virus de la Hepatitis C en PWID en Los Estados Del Norte de México [NCT05503979]		1,000 participants (Anticipated)	Observational	2022-11-15	Not yet recruiting
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection [NCT01641640]	Phase 3	328 participants (Actual)	Interventional	2012-06-30	Completed
Sofosbuvir in Combination With Ribavirin or Simeprevir: Real-life Study of Patients With Hepatitis C Genotype 4 [NCT04385407]	Phase 2	203 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3 [NCT02304159]	Phase 4	39 participants (Actual)	Interventional	2015-01-31	Completed
LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients [NCT02631772]	Phase 4	32 participants (Actual)	Interventional	2016-06-01	Completed
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination [NCT03776760]		600 participants (Anticipated)	Observational	2019-05-28	Recruiting
Simeprevir (SMV) + Sofosbuvir (SOF) With or Without Ribavirin (RBV) for Interferon-intolerant or Ineligible (IFN-II) Patients With Chronic Hepatitis C (CHC) [NCT02214420]	Phase 4	24 participants (Actual)	Interventional	2014-10-31	Completed
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia [NCT02825212]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2016-02-29	Completed
Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19) [NCT04535869]	Phase 3	50 participants (Anticipated)	Interventional	2020-12-28	Recruiting
A Non-randomized Trial to Evaluate a TEst and Treat Intervention Integrating Novel Point-of-care Hepatitis C RNA Testing, Linkage to Nursing Care, and Peer-supported Delivery of HCV Testing and Treatment aMong Current People Who Inject Drugs With HCV Atte [NCT03492112]		101 participants (Actual)	Interventional	2019-09-10	Completed
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting [NCT02350569]	Phase 2	17 participants (Actual)	Interventional	2015-05-22	Completed
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy [NCT05717400]	Phase 4	15 participants (Anticipated)	Interventional	2023-02-07	Recruiting
An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment [NCT01497327]	Phase 1	24 participants (Actual)	Interventional	2011-07-31	Completed
A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV [NCT02128542]	Phase 4	66 participants (Actual)	Interventional	2014-06-30	Completed
Efficacy and Safety of Treatment Against Hepatitis C Virus Infection Based on Direct-acting Antivirals in Real-life Conditions: The GEHEP Cohort [NCT02333292]		1,128 participants (Actual)	Observational	2014-12-31	Completed
A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection [NCT02032901]	Phase 3	173 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 Weeks in Genotype 1 or 4 HCV Infected Subjects With Renal Insufficiency [NCT01958281]	Phase 2	38 participants (Actual)	Interventional	2013-10-07	Completed
An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection [NCT01779518]		0 participants	Expanded Access		Approved for marketing
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial. [NCT04497649]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Phase 2, Single-Center, Open-Label Pilot Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfe [NCT02480387]	Phase 2	20 participants (Actual)	Interventional	2015-05-31	Completed
An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Nosocomial Genotype 1 HCV Infection [NCT01924949]	Phase 2	5 participants (Actual)	Interventional	2013-07-31	Completed
An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antivira [NCT02399345]	Phase 3	10 participants (Actual)	Interventional	2015-03-31	Completed
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients [NCT04391985]	Phase 1/Phase 2	113 participants (Actual)	Interventional	2017-03-01	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection [NCT01604850]	Phase 3	202 participants (Actual)	Interventional	2012-06-30	Completed
An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects With Sickle Cell Disease [NCT02301936]	Phase 2	10 participants (Actual)	Interventional	2015-03-02	Completed
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study [NCT02717949]	Phase 4	1 participants (Actual)	Interventional	2016-02-25	Terminated(stopped due to failure to recruit)
A Phase 2, Randomized, Open-label Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 6 or 8 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Subjects With Chronic Hepatitis C Virus Genotype 1 I [NCT02349048]	Phase 2	68 participants (Actual)	Interventional	2015-01-31	Completed
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 2 HCV Infection [NCT01910636]	Phase 3	153 participants (Actual)	Interventional	2013-02-28	Completed
The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs. [NCT02347345]	Phase 4	34 participants (Actual)	Interventional	2016-11-15	Completed
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responder [NCT01466790]	Phase 2	168 participants (Actual)	Interventional	2012-01-31	Completed
A Phase 3b Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection [NCT04211909]	Phase 3	87 participants (Actual)	Interventional	2020-01-03	Completed
An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Stud [NCT01987453]	Phase 2	100 participants (Actual)	Interventional	2014-07-31	Completed
Efficacy of Decentralized Care in the Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model [NCT03488485]		50,000 participants (Anticipated)	Interventional	2016-06-18	Recruiting
Benefits of Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination [NCT03490097]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2017-12-01	Completed
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders [NCT02120300]	Phase 2	122 participants (Actual)	Interventional	2014-04-30	Completed
A Phase 3b, Multicenter, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Genotype 1 and 3 Chronic HCV Infection. [NCT01896193]	Phase 3	127 participants (Actual)	Interventional	2013-06-30	Completed
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant [NCT01687270]	Phase 2	40 participants (Actual)	Interventional	2012-11-30	Completed
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal [NCT02660905]	Phase 3	25 participants (Actual)	Interventional	2016-04-30	Completed
Open-label Study of Efficacy and Safety of Generic Sofosbuvir/Ledipasvir±Ribavirin in Iranian Patients With Hepatitis C Virus Genotype 1 Infection [NCT03061032]	Phase 3	200 participants (Anticipated)	Interventional	2017-03-31	Not yet recruiting
Efficacy and Safety of Sofosbuvir and Daclatasvir in Treating Patients With Hepatitis C and Renal Failure. [NCT03063879]	Phase 4	95 participants (Actual)	Interventional	2017-04-01	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977+Ribavirin for 12 Weeks in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection. [NCT01682720]	Phase 3	421 participants (Actual)	Interventional	2012-09-30	Completed
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters [NCT05616598]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2022-03-01	Completed
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/- Ribavirin for 12 and 24 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection. [NCT01701401]	Phase 3	870 participants (Actual)	Interventional	2012-09-30	Completed
Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study [NCT03949764]	Phase 4	374 participants (Actual)	Interventional	2019-09-23	Active, not recruiting
Efficacy and Safety of 8- Versus 12-week Sofosbuvir-ravidasvir Treatment of Non-cirrhotic Chronic Hepatitis C Patients: An Open-label, Randomized, Multicenter Study in Malaysia [NCT04885855]	Phase 2/Phase 3	316 participants (Anticipated)	Interventional	2021-03-23	Recruiting
Association of Serum Interleukin -6 and Transforming Growth Factor Beta Levels With Response to Antiviral Therapy for Chronic Hepatitis c Patients [NCT03882307]	Early Phase 1	40 participants (Anticipated)	Interventional	2022-10-31	Recruiting
The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC [NCT02959359]	Phase 4	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to The supplies of study drug were halted by Gilead Sciences Ltd.)
The Pulmonary Safety of the New Oral Antihepatitis C Treatment [NCT04122066]		50 participants (Anticipated)	Observational	2020-06-30	Not yet recruiting
Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt (Single Center Study) [NCT04773756]	Phase 4	54 participants (Actual)	Interventional	2020-11-01	Completed
A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection [NCT02081079]	Phase 2	85 participants (Actual)	Interventional	2014-03-31	Completed
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis [NCT02201901]	Phase 3	268 participants (Actual)	Interventional	2014-07-31	Completed
A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Effect of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Subjects With Chr [NCT02219685]	Phase 2	40 participants (Actual)	Interventional	2014-08-31	Completed
A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection [NCT02378935]	Phase 2	205 participants (Actual)	Interventional	2015-02-17	Completed
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS-5816/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen [NCT02536313]	Phase 2	49 participants (Actual)	Interventional	2015-07-29	Completed
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection a [NCT02114151]	Phase 3	103 participants (Actual)	Interventional	2014-04-30	Completed
Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4) [NCT02319031]	Phase 3	53 participants (Actual)	Interventional	2015-02-28	Completed
A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1, 4 [NCT02358044]	Phase 3	257 participants (Actual)	Interventional	2015-02-27	Completed
An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Tre [NCT02356562]	Phase 2	29 participants (Actual)	Interventional	2015-02-03	Completed
A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection [NCT02021643]	Phase 3	687 participants (Actual)	Interventional	2013-12-10	Completed
A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection. [NCT01838590]	Phase 3	103 participants (Actual)	Interventional	2013-03-31	Completed
A Phase 2, Open-Label Study of Sofosbuvir in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3 [NCT01808248]	Phase 2	47 participants (Actual)	Interventional	2013-02-28	Completed
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects [NCT01783678]	Phase 3	275 participants (Actual)	Interventional	2013-01-31	Completed
An Open Label Trial to Assess Safety, Tolerability, and Efficacy of the Fixed Dose Combination of GS-7977 and GS-5885 in HCV Genotype 1 Subjects Coinfected With HIV [NCT01878799]	Phase 2	50 participants (Actual)	Interventional	2013-06-30	Completed
Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1 [NCT01994486]	Phase 2	20 participants (Actual)	Interventional	2013-12-31	Completed
Safety, Tolerability, and Efficacy of Simeprevir 150 mg Daily Plus Sofosbuvir 400 mg Daily for 24 Weeks in Patients With Chronic Hepatitis C Genotype 1 With CPT Score of 6 or Lower Who Are IFN-Intolerant or Unwilling to be Treated With IFN [NCT02485080]	Phase 4	0 participants (Actual)	Interventional	2015-09-30	Withdrawn(stopped due to Withdrawn due to lack of resources)
A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection [NCT03312023]	Phase 2	21 participants (Actual)	Interventional	2018-02-01	Completed
Pilot Therapeutic Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia [NCT05992077]		36,600 participants (Anticipated)	Interventional	2023-08-07	Not yet recruiting
Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C: Multi-center, Prospective, Observational Real-world Study in EASTERN China [NCT04952207]		300 participants (Anticipated)	Observational [Patient Registry]	2019-03-06	Recruiting
A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatmen [NCT02421211]	Phase 2	41 participants (Actual)	Interventional	2015-05-19	Completed
Directly Observed Therapy for the Delivery of HCV Therapy Among HCV-infected Individuals in Chennai, India [NCT02541409]	Phase 2	50 participants (Actual)	Interventional	2015-09-30	Completed
Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens [NCT02605304]	Phase 2	7 participants (Actual)	Interventional	2016-02-17	Terminated(stopped due to The study experienced enrollment difficulties.)
Effect of Ledipasvir and Sofosbuvir on Proteinuria and Estimated Glomerular Filtration Rate in Patients With Early Stage (1-3) Hepatitis C Associated Chronic Kidney Disease [NCT02503735]		14 participants (Actual)	Interventional	2015-07-15	Terminated(stopped due to Unable to meet enrollment goal)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV [NCT02201940]	Phase 3	741 participants (Actual)	Interventional	2014-07-31	Completed
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection [NCT02722837]	Phase 3	119 participants (Actual)	Interventional	2016-04-04	Completed
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant [NCT02781571]	Phase 2	79 participants (Actual)	Interventional	2016-07-27	Completed
An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors [NCT02781649]	Phase 4	10 participants (Actual)	Interventional	2016-07-20	Completed
A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoing Cancer Chemotherapy [NCT02868242]	Phase 2	19 participants (Actual)	Interventional	2016-08-28	Completed
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study) [NCT02175966]	Phase 2	35 participants (Actual)	Interventional	2014-07-28	Completed
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV [NCT02671500]	Phase 3	375 participants (Actual)	Interventional	2016-04-19	Completed
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects [NCT01667731]	Phase 3	224 participants (Actual)	Interventional	2012-07-31	Completed
Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam [NCT03537196]	Phase 4	979 participants (Actual)	Interventional	2018-11-13	Completed
Sofosbuvir Plus Daclatasvir With or Without Ribavirin for Chronic Hepatitis C Infection: Impact of Drug Concentration on Viral Load Decay [NCT03318887]		130 participants (Actual)	Observational	2014-02-01	Completed
Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection [NCT02473211]	Phase 2/Phase 3	106 participants (Actual)	Interventional	2015-01-31	Completed
"To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis - A Randomized Open- Label Study" [NCT02464631]		62 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir and Ledipasvir which have proven better efficacy in the HCV cure)
Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-acting Antiviral Agents [NCT03063723]		25 participants (Actual)	Observational	2016-01-01	Completed
A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HC [NCT02607735]	Phase 3	416 participants (Actual)	Interventional	2015-11-11	Completed
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection [NCT02601573]	Phase 2	101 participants (Actual)	Interventional	2016-01-05	Completed
An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies [NCT01625338]	Phase 3	534 participants (Actual)	Interventional	2012-06-30	Completed
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV) [NCT02032888]	Phase 3	238 participants (Actual)	Interventional	2014-02-28	Completed
deLIVER: Direct Acting Antiviral Effects on the Liver [NCT02938013]	Phase 4	15 participants (Actual)	Interventional	2017-01-31	Completed
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection [NCT02021656]	Phase 3	384 participants (Actual)	Interventional	2013-12-10	Completed
A Phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir & Ribavirin) Versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a Single Dose of Dactavira (EP [NCT03186313]	Phase 3	72 participants (Actual)	Interventional	2016-09-30	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 HCV Infection Who Are Interferon Intolerant, Interferon Ineligib [NCT01542788]	Phase 3	278 participants (Actual)	Interventional	2012-03-31	Completed
Assessment of Haematological and Biochemical Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients in Assiut Province [NCT03163849]	Phase 3	50 participants (Anticipated)	Interventional	2019-09-01	Active, not recruiting
A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a [NCT03105349]	Phase 4	0 participants (Actual)	Interventional	2017-07-01	Withdrawn(stopped due to No availability of investigational medication.)
A Sofosbuvir-based Quadruple Regimen is Highly Effective in HCV Type 4-infected Egyptian Patients With DAA Treatment Failure [NCT04387539]	Phase 1/Phase 2	94 participants (Actual)	Interventional	2017-03-01	Completed
A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection [NCT02613871]	Phase 3	111 participants (Actual)	Interventional	2015-12-22	Completed
A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection [NCT02487030]	Phase 3	255 participants (Actual)	Interventional	2015-09-07	Completed
Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial [NCT03032666]	Phase 4	7 participants (Actual)	Interventional	2017-05-01	Completed
Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or [NCT02455167]	Phase 3	9 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to Study stopped due to low accrual and availability of other treatment options)
Sofosbuvir Based Regimens in Treatment of COVID 19 Patients [NCT04460443]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2020-08-01	Recruiting
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection [NCT02346721]	Phase 3	111 participants (Actual)	Interventional	2015-02-23	Completed
An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study [NCT02300103]	Phase 2	69 participants (Actual)	Interventional	2014-12-01	Completed
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensatio [NCT01687257]	Phase 2	50 participants (Actual)	Interventional	2012-07-31	Completed
A Phase IV Pilot Study to Assess Community-Based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia [NCT02339038]	Phase 4	600 participants (Actual)	Interventional	2015-01-07	Completed
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection: Real-world Effectiveness and Safety in Taiwan [NCT05092074]		100 participants (Anticipated)	Observational	2021-10-01	Recruiting
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection [NCT01713283]	Phase 2	60 participants (Actual)	Interventional	2012-10-31	Completed
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant [NCT01938430]	Phase 2	339 participants (Actual)	Interventional	2013-09-30	Completed
Comparative Open-label,Randomized, Fed, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sci [NCT03062423]	Phase 1	36 participants (Actual)	Interventional	2016-10-31	Completed
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies [NCT02600351]	Phase 3	87 participants (Actual)	Interventional	2015-11-11	Terminated(stopped due to Due to lack of feasibility of enrolling participants, the study was terminated early.)
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3) [NCT02640157]	Phase 3	506 participants (Actual)	Interventional	2015-12-31	Completed
Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Egyptian Patients With HCV [NCT03069001]	Phase 4	90 participants (Actual)	Interventional	2015-06-30	Completed
Treatment of Recent Injection Drug Use With Chronic HCV Infection in U.S. Liver Referral Clinics: A Prospective, Observational Cohort Study And Contemporaneous Therapy Cohort Without Injection Drug Use [NCT05895448]	Phase 4	125 participants (Anticipated)	Interventional	2018-03-01	Active, not recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naive Subjects W [NCT01851330]	Phase 3	647 participants (Actual)	Interventional	2013-05-31	Completed
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection [NCT02480712]	Phase 3	107 participants (Actual)	Interventional	2015-07-01	Completed
Efficacy and Safety of Sofosbuvir Plus Daclatasvir With or Without Ribavirin: Large Real-life Results of Patients With Chronic Hepatitis C Genotype 4 [NCT04387526]	Phase 2/Phase 3	946 participants (Actual)	Interventional	2016-04-01	Completed
A Randomized Controlled Study To Assess Safety, Tolerability And Efficacy Of GS-7977 In Combination With Full or Low Dose RBV In HCV Genotype 1, Monoinfected Treatment Naive Participants [NCT01441180]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2011-09-30	Completed
A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection [NCT01975675]	Phase 3	341 participants (Actual)	Interventional	2013-10-31	Completed
A Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Sovaldi in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea [NCT02907996]		2,033 participants (Actual)	Observational	2016-09-09	Completed
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection [NCT01826981]	Phase 2	359 participants (Actual)	Interventional	2013-04-30	Completed
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting [NCT02728206]	Phase 2	9 participants (Actual)	Interventional	2016-06-12	Completed
Evaluation of Quality of Life, Neurocognitive Performance, Fatigue, and Emotional State in HCV Patients Before, During, and in the (Long-term) Follow-up of an IFN-free Antiviral Therapy [NCT02469012]		30 participants (Anticipated)	Interventional	2014-10-31	Recruiting
HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) [NCT03282474]	Phase 2	10 participants (Actual)	Interventional	2017-12-07	Completed
An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant [NCT01559844]	Phase 2	61 participants (Actual)	Interventional	2012-03-31	Completed
A Clinical and Pharmacokinetic Study of the Effectiveness of Hepatitis C Treatment (Sofosbuvir+Daclatasvir) in HIV Co-infected and Non HIV Co-infected Patients at the Level of Non-hospital Based Management in Myanmar [NCT03158857]		0 participants (Actual)	Observational	2022-01-31	Withdrawn(stopped due to Long local IRB process to meet with the treatment deadline)
A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients With Chronic Genotype 2 or 3 [NCT01497366]	Phase 3	527 participants (Actual)	Interventional	2011-12-31	Completed
A Phase II, Open-label, Single Arm, Multicentre, International Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use [NCT02336139]	Phase 2	103 participants (Actual)	Interventional	2016-03-16	Completed
Investigation of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816 [NCT02468648]	Phase 2	72 participants (Actual)	Interventional	2015-06-09	Completed
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders [NCT02786537]	Phase 4	1,275 participants (Actual)	Interventional	2016-06-30	Completed
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection [NCT02249182]	Phase 2	226 participants (Actual)	Interventional	2014-11-05	Completed
A Phase 3b, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection [NCT02738333]	Phase 3	239 participants (Actual)	Interventional	2016-04-12	Completed
Evaluation of Efficacy and Safety of KW-136 Plus Sofosbuvir for Treatment-naive Adults Chronically Infected With Hepatitis C Virus: a Randomized, Open-label, Multicenter Phase 2 Trial [NCT03416491]	Phase 2	110 participants (Actual)	Interventional	2017-02-15	Completed
Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis [NCT02992457]	Phase 4	10,000 participants (Actual)	Interventional	2015-01-31	Completed
A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection [NCT02074514]	Phase 3	117 participants (Actual)	Interventional	2014-03-31	Completed
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infec [NCT02073656]	Phase 3	335 participants (Actual)	Interventional	2014-02-28	Completed
A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 or GT3 Infection [NCT02133131]	Phase 2	143 participants (Actual)	Interventional	2014-06-13	Completed
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C) [NCT02128217]	Phase 1	44 participants (Actual)	Interventional	2014-05-30	Completed
The Role of Combined Ribavirin and Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment of Chronic Hepatitis C Non-responders; A Randomized Controlled Trial [NCT04695769]	Phase 4	281 participants (Actual)	Interventional	2020-11-21	Completed
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve and -Experienced Subjects With Chronic Genotype 1 Hepatitis C [NCT02114177]	Phase 3	310 participants (Actual)	Interventional	2014-04-30	Completed
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks With Ribavirin or for 24 Weeks Without Ribavirin in Treatment-Experienced Cirrho [NCT01965535]	Phase 2	155 participants (Actual)	Interventional	2013-10-31	Completed
Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT) [NCT02478229]	Phase 3	1 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to difficulty recruiting patients)
Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19 [NCT04443725]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2020-07-31	Not yet recruiting
A Pilot Phase II Study of New Direct-Acting Antiviral Agent, HARVONI® (Ledipasvir/Sofosbuvir), for the Treatment of Genotype 1 or 2 HCV-Associated Indolent B-Cell Non- Hodgkin's Lymphoma [NCT03261349]	Phase 2	21 participants (Anticipated)	Interventional	2017-09-01	Not yet recruiting
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant [NCT02010255]	Phase 2	334 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjec [NCT02639247]	Phase 3	333 participants (Actual)	Interventional	2015-12-23	Completed
A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection [NCT02292706]		1,609 participants (Actual)	Observational [Patient Registry]	2014-12-29	Terminated(stopped due to The study stopped early because the study objectives were met.)
Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir [NCT03247296]		200 participants (Actual)	Observational	2017-02-28	Active, not recruiting
[NCT03200184]	Phase 4	1,448 participants (Actual)	Interventional	2016-09-01	Completed
A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis [NCT02226549]	Phase 2	47 participants (Actual)	Interventional	2014-07-31	Completed
A Phase 3 Evaluation of Daclatasvir, Sofosbuvir, and Ribavirin in Genotype 1-6 Chronic Hepatitis C Infection Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant [NCT02032875]	Phase 3	116 participants (Actual)	Interventional	2014-03-31	Completed
A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection. [NCT01962441]	Phase 3	601 participants (Actual)	Interventional	2013-09-24	Completed
A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection [NCT02251717]	Phase 2	114 participants (Actual)	Interventional	2014-10-14	Completed
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Subjects With Chronic Genotype 3 HCV Infection [NCT02201953]	Phase 3	558 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus [NCT02292719]	Phase 2	70 participants (Actual)	Interventional	2014-12-19	Completed
A Phase 2 Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of 12 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir, Followed by a 5-Year Post-treatment Long-term Follow-up, in Treatment-naïve and Treatment-experienced [NCT02262728]	Phase 2	40 participants (Actual)	Interventional	2014-09-30	Completed
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection [NCT02202980]	Phase 2	273 participants (Actual)	Interventional	2014-08-04	Completed
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection [NCT02220998]	Phase 3	269 participants (Actual)	Interventional	2014-09-30	Completed
A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation [NCT01532908]	Phase 2	11 participants (Actual)	Interventional	2012-11-21	Terminated(stopped due to The study was terminated due to funding constraints)
A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection [NCT02175758]	Phase 2	106 participants (Actual)	Interventional	2014-07-07	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-331007: Cmax at Day 27
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-566500: Cmax at Day 27
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-566500: Cmax at Day 0
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-331007: Cmax at Day 0
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0
NCT01054729 (17) [back to overview]	Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27
NCT01054729 (17) [back to overview]	Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0
NCT01054729 (17) [back to overview]	Percentage of Participants With Rapid Virologic Response at Week 4
NCT01054729 (17) [back to overview]	Percentage of Participants Who Developed Resistance to Sofosbuvir
NCT01054729 (17) [back to overview]	Change in Circulating HCV RNA at Week 4
NCT01054729 (17) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment
NCT01188772 (14) [back to overview]	Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 8)
NCT01188772 (14) [back to overview]	Percentage of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) and 24 (SVR24)
NCT01188772 (14) [back to overview]	Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period
NCT01188772 (14) [back to overview]	Plasma Pharmacokinetics of GS-331007 (Cmax at Day 8)
NCT01188772 (14) [back to overview]	Plasma Pharmacokinetics of GS-331007 (Cmax at Day 29)
NCT01188772 (14) [back to overview]	Percentage of Participants With Virologic Response at the End of Treatment
NCT01188772 (14) [back to overview]	Percentage of Participants With Rapid Virologic Response at Week 4
NCT01188772 (14) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response
NCT01188772 (14) [back to overview]	Percentage of Participants With Complete Early Virologic Response at Week 12
NCT01188772 (14) [back to overview]	Percentage of Participants Who Developed Resistance to Sofosbuvir
NCT01188772 (14) [back to overview]	Change in HCV RNA From Baseline to Week 12
NCT01188772 (14) [back to overview]	Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 29)
NCT01188772 (14) [back to overview]	Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 15)
NCT01188772 (14) [back to overview]	Plasma Pharmacokinetics of GS-331007 (Cmax at Day 15)
NCT01260350 (9) [back to overview]	Percentage of Participants With HCV RNA < LOD at Week 12
NCT01260350 (9) [back to overview]	Percentage of Participants With HCV RNA < LOD at Week 6
NCT01260350 (9) [back to overview]	Percentage of Participants With Virologic Failure
NCT01260350 (9) [back to overview]	Percentage of Participants Who Experienced Adverse Events
NCT01260350 (9) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT01260350 (9) [back to overview]	Change From Baseline in HCV RNA at Week 6
NCT01260350 (9) [back to overview]	Change From Baseline in HCV RNA at Week 12
NCT01260350 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)
NCT01260350 (9) [back to overview]	Percentage of Participants With HCV RNA < LOD at Week 8
NCT01329978 (17) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)
NCT01329978 (17) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)
NCT01329978 (17) [back to overview]	Percentage of Participants With HCV RNA Below < LOD at Week 8
NCT01329978 (17) [back to overview]	Percentage of Participants With HCV RNA Below < LOD at Week 4
NCT01329978 (17) [back to overview]	Percentage of Participants With HCV RNA Below < LOD at Week 24
NCT01329978 (17) [back to overview]	Percentage of Participants With HCV RNA Below < LOD at Week 12
NCT01329978 (17) [back to overview]	Percentage of Participants With HCV RNA < LOD at Week 2
NCT01329978 (17) [back to overview]	Percentage of Participants With ALT Normalization at Week 12
NCT01329978 (17) [back to overview]	Percentage of Participants With ALT Normalization at Post-treatment Week 4
NCT01329978 (17) [back to overview]	Change in HCV RNA at Week 8
NCT01329978 (17) [back to overview]	Change in HCV RNA at Week 4
NCT01329978 (17) [back to overview]	Percentage of Participants With ALT Normalization at Week 24
NCT01329978 (17) [back to overview]	Change in HCV RNA at Week 2
NCT01329978 (17) [back to overview]	Change in HCV RNA at Week 12
NCT01329978 (17) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01329978 (17) [back to overview]	Percentage of Participants Who Experienced Adverse Events
NCT01329978 (17) [back to overview]	Percentage of Participants With Virologic Failure Following Treatment (Viral Relapse).
NCT01359644 (7) [back to overview]	Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Follow-up Week 24
NCT01359644 (7) [back to overview]	Percentage of Participants With Viral Breakthrough During the Treatment Period
NCT01359644 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)
NCT01359644 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12)
NCT01359644 (7) [back to overview]	Number of Participants Who Died and With Serious Adverse Events (SAEs) and Grade 3-4 Adverse Events (AEs), During the Treatment Period Prior to Addition of Rescue Therapy
NCT01359644 (7) [back to overview]	Number of Participants Who Died and With Serious Adverse Events (SAEs), Grade 3-4 Adverse Events (AEs), and Grade 3-4 Abnormalities on Laboratory Test Results During Follow-up Period
NCT01359644 (7) [back to overview]	Percentage of Participants Who Experienced Viral Relapse During Follow-up Period
NCT01441180 (2) [back to overview]	Participants With Adverse Events
NCT01441180 (2) [back to overview]	Sustained Virologic Response
NCT01466790 (7) [back to overview]	Number of Participants With Viral Relapse
NCT01466790 (7) [back to overview]	Number of Participants With Viral Breakthrough
NCT01466790 (7) [back to overview]	Number of Participants With Inadequate Virologic Response
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) at Week 48
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Planned End of Treatment (EOT)
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Planned End of Treatment (EOT)
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Planned End of Treatment (EOT)
NCT01497366 (7) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT01497366 (7) [back to overview]	Change From Baseline in HCV RNA
NCT01497366 (7) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01497366 (7) [back to overview]	Percentage of Participants With Viral Relapse Following Treatment
NCT01497366 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After Stopping All Study Drugs (SVR24)
NCT01497366 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12)
NCT01497366 (7) [back to overview]	Number of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities
NCT01532908 (6) [back to overview]	Number of Subjects With Undetectable HCV RNA at Day 56 Post Liver Transplantation
NCT01532908 (6) [back to overview]	Change in Viral Load Between Baseline Pre-transplant HCV RNA Levels and Study Day 7, 10, 14, 28, 35, 42, 49, 56, 70, 84 and 98 in Liver Transplant Recipients
NCT01532908 (6) [back to overview]	Safety and Tolerability of Study Treatment by Number of Adverse Events Reported
NCT01532908 (6) [back to overview]	Number of Subjects With Undetectable Serum HCV RNA at Study Day 7, 10, 14, 28, 35, 42, 49, 70, 84 and 98 in Liver Transplant Recipients and for Those Subjects Receiving an Additional 4 Weeks of Treatment at Study Day 105, 112 and 126
NCT01532908 (6) [back to overview]	Number of Subjects With Sustained Virologic Response (SVR) at Week 12 and Week 24
NCT01532908 (6) [back to overview]	Number of Participants With HCV Resistance-associated Variants to MBL-HCV1 and Oral Direct-acting Antivirals Before and After Receipt of Study Treatment
NCT01542788 (6) [back to overview]	Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug
NCT01542788 (6) [back to overview]	Percentage of Participants Achieving SVR12
NCT01542788 (6) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01542788 (6) [back to overview]	Percentage of Participants Experiencing Viral Breakthrough
NCT01542788 (6) [back to overview]	Percentage of Participants Achieving SVR4
NCT01542788 (6) [back to overview]	Percentage of Participants Achieving SVR24
NCT01559844 (8) [back to overview]	Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48
NCT01559844 (8) [back to overview]	Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12
NCT01559844 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (ie, 25 mL/IU) During Treatment Through Week 48
NCT01559844 (8) [back to overview]	Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sofosbuvir Prior to Receiving Transplant
NCT01559844 (8) [back to overview]	Percentage of Participants With Graft Loss Following Transplant
NCT01559844 (8) [back to overview]	HCV RNA and Change From Baseline in HCV RNA Through Week 8
NCT01559844 (8) [back to overview]	Number of Participants Who Died
NCT01559844 (8) [back to overview]	Proportion of Participants With Virologic Failure Prior to Transplant
NCT01604850 (6) [back to overview]	Percentage of Participants Achieving SVR24
NCT01604850 (6) [back to overview]	Percentage of Participants Achieving SVR12
NCT01604850 (6) [back to overview]	Adverse Events Leading to Permanent Discontinuation of Study Drug
NCT01604850 (6) [back to overview]	Percentage of Participants Achieving SVR4
NCT01604850 (6) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01604850 (6) [back to overview]	Percentage of Participants With Viral Relapse
NCT01625338 (5) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01625338 (5) [back to overview]	Percentage of Participants With Viral Relapse
NCT01625338 (5) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT01625338 (5) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT01625338 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01641640 (6) [back to overview]	Percentage of Participants Achieving SVR4
NCT01641640 (6) [back to overview]	Percentage of Participants Achieving SVR24
NCT01641640 (6) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response (SVR)12
NCT01641640 (6) [back to overview]	Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug
NCT01641640 (6) [back to overview]	Percentage of Participants With Viral Relapse
NCT01641640 (6) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01667731 (10) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT01667731 (10) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT01667731 (10) [back to overview]	Change From Baseline in HCV RNA at Week 1
NCT01667731 (10) [back to overview]	Change From Baseline in HCV RNA at Week 6
NCT01667731 (10) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT01667731 (10) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01667731 (10) [back to overview]	Percentage of Participants Experiencing On-treatment Virologic Failure
NCT01667731 (10) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01667731 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01667731 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01682720 (4) [back to overview]	Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01682720 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01682720 (4) [back to overview]	Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse
NCT01682720 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01687257 (7) [back to overview]	Percentage of Participants Experiencing On-Treatment Virologic Failure
NCT01687257 (7) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01687257 (7) [back to overview]	Change From Baseline in Child-Pugh-Turcotte (CPT) Score
NCT01687257 (7) [back to overview]	Change From Baseline in Model for End Stage Liver Disease (MELD) Scores
NCT01687257 (7) [back to overview]	Percentage of Participants With SVR at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
NCT01687257 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01687257 (7) [back to overview]	Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at End of Treatment
NCT01687270 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
NCT01687270 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01687270 (6) [back to overview]	HCV RNA and Change From Baseline at Weeks 2, 4, and 8
NCT01687270 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 12 and 24
NCT01687270 (6) [back to overview]	Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event
NCT01687270 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT01701401 (10) [back to overview]	Percentage of Participants With Virologic Failure
NCT01701401 (10) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Study Drug
NCT01701401 (10) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT01701401 (10) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT01701401 (10) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT01701401 (10) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug
NCT01701401 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT01701401 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT01701401 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT01701401 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)
NCT01713283 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01713283 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01713283 (5) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01713283 (5) [back to overview]	Percentage of Participants Experiencing On-treatment Virologic Failure
NCT01713283 (5) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01783678 (9) [back to overview]	HCV RNA Change From Baseline at Week 6
NCT01783678 (9) [back to overview]	HCV RNA Change From Baseline at Week 4
NCT01783678 (9) [back to overview]	HCV RNA Change From Baseline at Week 2
NCT01783678 (9) [back to overview]	HCV RNA Change From Baseline at Week 1
NCT01783678 (9) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01783678 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01783678 (9) [back to overview]	Percentage of Participants Experiencing Virologic Failure
NCT01783678 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01783678 (9) [back to overview]	HCV RNA Change From Baseline at Week 8
NCT01805882 (1) [back to overview]	The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs
NCT01808248 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01808248 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01808248 (5) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01808248 (5) [back to overview]	Percentage of Participants Experiencing On-treatment Virologic Failure
NCT01808248 (5) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01826981 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01826981 (11) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT01826981 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
NCT01826981 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
NCT01826981 (11) [back to overview]	Percentage of Participants With Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01826981 (11) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01826981 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
NCT01826981 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
NCT01826981 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
NCT01826981 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR 24)
NCT01826981 (11) [back to overview]	For Cohort 6, Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 16 and 20 Weeks After Discontinuation of Therapy (SVR16 and SVR 20)
NCT01838590 (5) [back to overview]	Percentage of Participants Experiencing On-treatment Virologic Failure
NCT01838590 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01838590 (5) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT01838590 (5) [back to overview]	Percentage of Participants Experiencing Virologic Relapse
NCT01838590 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01851330 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01851330 (10) [back to overview]	Percentage of Participants Experiencing Virologic Failure
NCT01851330 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01851330 (10) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT01851330 (10) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT01851330 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT01851330 (10) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT01851330 (10) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug
NCT01851330 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT01851330 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT01878799 (1) [back to overview]	Percentage of Participants With Achieved SVR12 (HCV RNA
NCT01896193 (5) [back to overview]	Percentage of Participants Experiencing Virologic Relapse
NCT01896193 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01896193 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01896193 (5) [back to overview]	Percentage of Participants Experiencing On-treatment Virologic Failure
NCT01896193 (5) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01910636 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01910636 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01910636 (5) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01910636 (5) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01910636 (5) [back to overview]	Percentage of Participants Experiencing Viral Breakthrough
NCT01924949 (6) [back to overview]	Percentage of Participants Permanently Discontinuing Study Drug Due to an Adverse Event
NCT01924949 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01924949 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01924949 (6) [back to overview]	HCV RNA Change From Baseline
NCT01924949 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT01924949 (6) [back to overview]	Percentage of Participants Experiencing Virologic Failure
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 24
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 20
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 16
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 12
NCT01938430 (25) [back to overview]	Percentage of Participants With Virologic Failure
NCT01938430 (25) [back to overview]	HCV RNA and Change From Baseline at Week 1
NCT01938430 (25) [back to overview]	HCV RNA and Change From Baseline at Week 8
NCT01938430 (25) [back to overview]	HCV RNA and Change From Baseline at Week 6
NCT01938430 (25) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01938430 (25) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in CPT Score
NCT01938430 (25) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in MELD Score
NCT01938430 (25) [back to overview]	HCV RNA and Change From Baseline at Week 2
NCT01938430 (25) [back to overview]	HCV RNA and Change From Baseline at Week 12
NCT01938430 (25) [back to overview]	Percentage of Participants With SVR 8 Weeks After Discontinuation of Therapy (SVR8)
NCT01938430 (25) [back to overview]	Percentage of Participants With SVR 4 Weeks After Discontinuation of Therapy (SVR4)
NCT01938430 (25) [back to overview]	Percentage of Participants With SVR 24 Weeks After Discontinuation of Therapy (SVR24)
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 1
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT01938430 (25) [back to overview]	HCV RNA and Change From Baseline at Week 4
NCT01938430 (25) [back to overview]	Percentage of Participants With SVR 2 Weeks After Discontinuation of Therapy (SVR2)
NCT01938430 (25) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01938430 (25) [back to overview]	Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT01938430 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 6
NCT01958281 (35) [back to overview]	PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	Pharmacokinetic (PK) Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT01958281 (35) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT01958281 (35) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01958281 (35) [back to overview]	Percentage of Participants With Overall Virologic Failure
NCT01958281 (35) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
NCT01958281 (35) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events Associated With Vital Sign Abnormalities
NCT01958281 (35) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT01958281 (35) [back to overview]	Percentage of Participants Experiencing Clinically Significant 12-lead Electrocardiogram (ECG) Abnormalities
NCT01958281 (35) [back to overview]	PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01958281 (35) [back to overview]	PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)
NCT01958281 (35) [back to overview]	PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)
NCT01962441 (10) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT01962441 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01962441 (10) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01962441 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
NCT01962441 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
NCT01962441 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
NCT01962441 (10) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01962441 (10) [back to overview]	HCV RNA at Weeks 1, 2, 4, 8, and 12
NCT01962441 (10) [back to overview]	Percentage of Participants Experiencing On-Treatment Virologic Failure
NCT01962441 (10) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12
NCT01965535 (5) [back to overview]	Percentage of Participants With Virologic Failure
NCT01965535 (5) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01965535 (5) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (ie, < 25 IU/mL) at Weeks 1, 2, 4, 8, 12, and 24
NCT01965535 (5) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12
NCT01965535 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01975675 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01975675 (5) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT01975675 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12), Treatment-naive, Noncirrhotic Participants
NCT01975675 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01975675 (5) [back to overview]	Percentage of Participants Experiencing Virologic Failure
NCT01987453 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT01987453 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01987453 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT01987453 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01987453 (6) [back to overview]	Change in HCV RNA From Baseline
NCT01987453 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment
NCT01994486 (6) [back to overview]	Characterize Steady State of Sofosbuvir Active SOF Metabolite, GS-331007
NCT01994486 (6) [back to overview]	Number of Subjects With Sustained Virologic Response at 4 Weeks After Completion of Last Dose
NCT01994486 (6) [back to overview]	Proportion of Subjects With Viral Relapse
NCT01994486 (6) [back to overview]	Proportion of Subjects Who Achieve Undetectable Hepatitis C Virus RNA at 12 Weeks After Completing Study Drug Regimen
NCT01994486 (6) [back to overview]	Safety of Telaprevir and Sofosbuvir When Dosed in Combination for 12 Weeks
NCT01994486 (6) [back to overview]	Frequency of Adverse Events Leading to Discontinuation of Both Telaprevir and Sofosbuvir Among Subjects Treated With Telaprevir and Sofosbuvir
NCT02010255 (25) [back to overview]	Percentage of Participants With SVR 8 Weeks After Discontinuation of Therapy (SVR8)
NCT02010255 (25) [back to overview]	Percentage of Participants With SVR 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02010255 (25) [back to overview]	Percentage of Participants With SVR 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 1
NCT02010255 (25) [back to overview]	HCV RNA Levels and Change From Baseline at Week 4
NCT02010255 (25) [back to overview]	HCV RNA Levels and Change From Baseline at Week 6
NCT02010255 (25) [back to overview]	HCV RNA Levels and Change From Baseline at Week 8
NCT02010255 (25) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT02010255 (25) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in CPT Score
NCT02010255 (25) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in MELD Score
NCT02010255 (25) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02010255 (25) [back to overview]	Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT02010255 (25) [back to overview]	Percentage of Participants With SVR 2 Weeks After Discontinuation of Therapy (SVR2)
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 6
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 24
NCT02010255 (25) [back to overview]	HCV RNA Levels and Change From Baseline at Week 2
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 20
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 16
NCT02010255 (25) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 12
NCT02010255 (25) [back to overview]	HCV RNA Levels and Change From Baseline at Week 12
NCT02010255 (25) [back to overview]	HCV RNA Levels and Change From Baseline at Week 1
NCT02010255 (25) [back to overview]	Percentage of Participants With Virologic Failure
NCT02021643 (8) [back to overview]	Percentage of Participants With Viral Relapse
NCT02021643 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02021643 (8) [back to overview]	Percentage of Participants With On-Treatment Virologic Failure
NCT02021643 (8) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02021643 (8) [back to overview]	Change From Baseline in HCV RNA (log10 IU/mL)
NCT02021643 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02021643 (8) [back to overview]	Change From Baseline in HCV RNA (log10 IU/mL)
NCT02021643 (8) [back to overview]	Change From Baseline in HCV RNA (log10 IU/mL)
NCT02021656 (6) [back to overview]	Percentage of Participants Experiencing Viral Breakthrough
NCT02021656 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02021656 (6) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT02021656 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event
NCT02021656 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02021656 (6) [back to overview]	HCV RNA and Change From Baseline in HCV RNA Through Week 12 for China Only
NCT02032875 (8) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), AEs Leading to Interruption, Treatment-related AEs/SAEs, Grade 3 to 4 AEs/SAEs, and Death
NCT02032875 (8) [back to overview]	Percentage of Genotype-1 Infected Cirrhotic Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)
NCT02032875 (8) [back to overview]	Percentage of HCV Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)
NCT02032875 (8) [back to overview]	Percentage of Participants With CC or Non-CC Genotype Who Achieved Sustained Virologic Response at 12 Weeks After the Last Dose of Study Drug (SVR12)
NCT02032875 (8) [back to overview]	Percentage of Participants Who Achieved Sustained Virologic Response at Post-treatment Week 12 (SVR12) for All Genotypes and Genotypes 2, 3, 4, 6
NCT02032875 (8) [back to overview]	Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels Below the Lower Limit of Quantitation Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment
NCT02032875 (8) [back to overview]	Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels Below the Lower Limit of Quantitation Target Detected or Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment; Follow Up Weeks 4, 8, and 24
NCT02032875 (8) [back to overview]	Number of Participants With Treatment Emergent Grade 3-4 Laboratory Abnormalities
NCT02032888 (10) [back to overview]	Percentage of Hepatitis C Virus (HCV)/HIV-coinfected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT02032888 (10) [back to overview]	Percentage of Hepatitis C Virus (HCV)/HIV-coinfected Treatment-experienced Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT02032888 (10) [back to overview]	Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT02032888 (10) [back to overview]	Percentage of Participants Coinfected With Hepatitis C Virus/HIV Who Achieved HCV RNA Levels
NCT02032888 (10) [back to overview]	Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be
NCT02032888 (10) [back to overview]	Percentage of Participants With CC or Non-CC Genotype at the IL28B rs12979860 Single Nucleotide Polymorphisms Who Achieved Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT02032888 (10) [back to overview]	Number of Participants With Treatment-emergent Grade 3-4 Abnormalities on Laboratory Test Results
NCT02032888 (10) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-related AEs/SAEs, Grade 3 to 4 AEs/SAEs, and Who Died During Follow-up Period
NCT02032888 (10) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Interruption or Discontinuation, Treatment-related AEs/SAEs and Grade 3 to 4 AEs/SAEs and Who Died During Treatment Period
NCT02032888 (10) [back to overview]	Percentage of Participants of All Genotypes Coinfected With Hepatitis C Virus (HCV)/HIV Who Achieved Sustained Virologic Response Rate at Follow-up Week 12 (SVR12)
NCT02032901 (10) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs)
NCT02032901 (10) [back to overview]	Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Less Than the Lower Limit of Quantitation (LLOQ) - Target Not Detected (TND)
NCT02032901 (10) [back to overview]	Percentage of Participants With CC or Non-CC Genotype at the IL28B rs12979860 Single Nucleotide Polymorphisms (SNPs) Who Achieved Sustained Virologic Response After 12 Weeks of Follow-up (SVR12)
NCT02032901 (10) [back to overview]	Percentage of Participants With Or Without Cirrhosis at Baseline Who Achieved Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT02032901 (10) [back to overview]	Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND)
NCT02032901 (10) [back to overview]	Percentage of Treatment-Experienced Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND)
NCT02032901 (10) [back to overview]	Percentage of Participants With Rapid Virologic Response at Week 4 (RVR) Target Not Detected (TND)
NCT02032901 (10) [back to overview]	Percentage of Participants With End of Treatment Response (EOTR) Target Not Detected (TND)
NCT02032901 (10) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR) Target Not Detected (TND)
NCT02032901 (10) [back to overview]	Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Less Than the Lower Limit of Quantitation (LLOQ)- Target Detected (TD) or Target Not Detected (TND)
NCT02073656 (12) [back to overview]	Change From Baseline in Serum Creatinine at the End of Treatment (Week 12) and at Posttreatment Weeks 12 and 24
NCT02073656 (12) [back to overview]	For Participants in the Retreatment Substudy, Change From Baseline in HCV RNA at Retreatment Weeks 2, 4, and 8
NCT02073656 (12) [back to overview]	For Participants in the Retreatment Substudy, Percentage of Participants With HCV RNA < LLOQ at Retreatment Weeks 2, 4, 8, 12, 16, 20, and 24
NCT02073656 (12) [back to overview]	For Participants in the Retreatment Substudy, Percentage of Participants With SVR at 4, 12, and 24 Weeks After Discontinuation of Therapy (SVR4, SVR12, and SVR24)
NCT02073656 (12) [back to overview]	For Participants in the Retreatment Substudy, Percentage of Participants With Virologic Failure
NCT02073656 (12) [back to overview]	Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment
NCT02073656 (12) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02073656 (12) [back to overview]	Percentage of Participants With Virologic Failure
NCT02073656 (12) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, and 12
NCT02073656 (12) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02073656 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02073656 (12) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, and 8
NCT02074514 (4) [back to overview]	Percentage of Participants With Virologic Failure and Viral Relapse
NCT02074514 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02074514 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02074514 (4) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02081079 (5) [back to overview]	Percentage of Patients With Virologic Failure
NCT02081079 (5) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02081079 (5) [back to overview]	Change From Baseline in HCV RNA at Weeks 2, 4, 8, and 12
NCT02081079 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02081079 (5) [back to overview]	Percentage of Participants Who Permanently Discontinued LDV/SOF Due to an Adverse Event
NCT02114151 (12) [back to overview]	Percentage of Participants With On-treatment Virologic Response
NCT02114151 (12) [back to overview]	Number of Participants Not Achieving SVR Showing Emerging Mutation at Time of Failure in HCV NS3/4A Sequence and NS5B up to Follow-up Week 24
NCT02114151 (12) [back to overview]	Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Overall Body System Score (OBSS) up to Follow-up Week 12
NCT02114151 (12) [back to overview]	Change From Baseline in Fatigue Severity Score (FSS) up to Follow-up Week 24
NCT02114151 (12) [back to overview]	Change From Baseline in EuroQol 5 Dimension Questionnaire (EQ-5D) up to Follow-up Week 24
NCT02114151 (12) [back to overview]	Percentage of Participants With Viral Relapse
NCT02114151 (12) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02114151 (12) [back to overview]	Percentage of Participants With On-treatment Failure
NCT02114151 (12) [back to overview]	Percentage of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Actual End of Treatment (EOT)
NCT02114151 (12) [back to overview]	Percentage of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Actual End of Treatment (EOT)
NCT02114151 (12) [back to overview]	Percentage of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Actual End of Treatment (EOT)
NCT02114151 (12) [back to overview]	Percentage of Participants With Depression by Using Center for Epidemiologic Studies Depression Scale (CES-D)
NCT02114177 (10) [back to overview]	Percentage of Participants Achieving a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)
NCT02114177 (10) [back to overview]	Percentage of Participants Achieving a Sustained Virologic Response 4 Weeks After the Actual End of Treatment (SVR4)
NCT02114177 (10) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02114177 (10) [back to overview]	Change From Baseline in Fatigue Severity Scale (FSS) Score up to Follow-up Week 24
NCT02114177 (10) [back to overview]	Change From Baseline in EuroQol 5 Dimension (EQ-5D) Visual Analogue Scale
NCT02114177 (10) [back to overview]	Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores
NCT02114177 (10) [back to overview]	Percentage of Participants With Viral Relapse
NCT02114177 (10) [back to overview]	Change From Baseline in Hepatitis C Symptom and Impact Questionnaire 4 (HCV-SIQv4) Overall Body System Score (OBSS)
NCT02114177 (10) [back to overview]	Percentage of Participants Achieving a On-treatment Virologic Response
NCT02114177 (10) [back to overview]	Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)
NCT02120300 (8) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02120300 (8) [back to overview]	Percentage of Participants With Virologic Failure
NCT02120300 (8) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
NCT02120300 (8) [back to overview]	Change From Baseline in Serum Creatinine at the End of Treatment and at Posttreatment Week 12 (HIV-1/HCV Co-infected Participants Only)
NCT02120300 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
NCT02120300 (8) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02120300 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02120300 (8) [back to overview]	Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL at Weeks 4, 8, 12, 16, 20, and 24 (HIV-1/HCV Co-infected Participants Only)
NCT02128217 (19) [back to overview]	Change in CD4+ Cell Count
NCT02128217 (19) [back to overview]	Number of Participants Who Had HCV Virologic Relapse
NCT02128217 (19) [back to overview]	Percentage of HCV Virologic Failure Participants That Developed SOF- or LDV-Associated Resistance Mutations
NCT02128217 (19) [back to overview]	Percentage of Participants With an Occurrence of a Grade ≥ 2 Adverse Event, Serious AE According to ICH Criteria, or Treatment-limiting AE.
NCT02128217 (19) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 (SVR12)
NCT02128217 (19) [back to overview]	Adherence as Measured by LDV/SOF Pill Count
NCT02128217 (19) [back to overview]	Adherence as Measured by RBV Pill Count
NCT02128217 (19) [back to overview]	Adherence as Measured by SOF Pill Count
NCT02128217 (19) [back to overview]	Cellular Concentration of Tenofovir Diphosphate (TFV-DP)
NCT02128217 (19) [back to overview]	Concentration of Tenofovir (TFV) in Plasma
NCT02128217 (19) [back to overview]	Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs)
NCT02128217 (19) [back to overview]	Count and Percentage of Participants With an Adverse Event by Type.
NCT02128217 (19) [back to overview]	Percentage of Participants With HCV RNA Undetectable After End of Study Treatment
NCT02128217 (19) [back to overview]	Percentage of Participants With HCV RNA Undetectable During Study Treatment
NCT02128217 (19) [back to overview]	Ribavirin Concentration in Plasma
NCT02128217 (19) [back to overview]	Self-reported Adherence to LDV/SOF
NCT02128217 (19) [back to overview]	Self-reported Adherence to RBV
NCT02128217 (19) [back to overview]	Self-reported Adherence to SOF
NCT02128217 (19) [back to overview]	Count of Participants With HIV-1 RNA <50 Copies/mL
NCT02128542 (6) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT02128542 (6) [back to overview]	Percentage of Participants Experiencing Viral Breakthrough
NCT02128542 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02128542 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy
NCT02128542 (6) [back to overview]	Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment
NCT02128542 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02133131 (3) [back to overview]	Number of Participants Discontinuing Study Therapy Due to an AE
NCT02133131 (3) [back to overview]	Number of Participants Experiencing at Least 1 Adverse Event (AE)
NCT02133131 (3) [back to overview]	Percentage of Participants With Sustained Viral Response (SVR) 12 Weeks After Completing All Study Therapy (SVR12)
NCT02168361 (2) [back to overview]	Proportion of Participants With Sustained Virologic Response 12 (SVR-12)
NCT02168361 (2) [back to overview]	Serum HCV RNA Level
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Palatability of SOF Granules at Day 1 as Assessed by the Percentage of Participants Able/Unable to Taste the SOF Oral Granules
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02175758 (25) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
NCT02175758 (25) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02175758 (25) [back to overview]	For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02175758 (25) [back to overview]	For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02175966 (8) [back to overview]	Percentage of Participants With End of Treatment Response (EOTR)
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved HCV RNA
NCT02175966 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 (SVR12)
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved HCV RNA < LLOQ TND
NCT02175966 (8) [back to overview]	Number of Participants With Deaths, Serious Adverse Events (SAEs) and AEs Leading to Discontinuation From Treatment
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved SVR12 Associated With HCV Geno Subtype 1a vs 1b
NCT02175966 (8) [back to overview]	Number of Participants With Selected Grade 3/4 Laboratory Abnormalities
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved SVR12 Associated With Interleukin-28B (IL28B) rs12979860 SNP Status (CC Genotype or Non-CC Genotype)
NCT02201901 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02201901 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
NCT02201901 (8) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 24 in MELD Score
NCT02201901 (8) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
NCT02201901 (8) [back to overview]	Percentage of Participants With Virologic Failure
NCT02201901 (8) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 24 in Child-Pugh-Turcotte (CPT) Score
NCT02201901 (8) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02201901 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02201940 (6) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02201940 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, and 12
NCT02201940 (6) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, and 12
NCT02201940 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02201940 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02201940 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02201953 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
NCT02201953 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02201953 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02201953 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02201953 (6) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02201953 (6) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
NCT02202980 (10) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02202980 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment by Study Visit
NCT02202980 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment by Study Visit
NCT02202980 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment by Study Visit
NCT02202980 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment by Study Visit
NCT02202980 (10) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02202980 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment by Study Visit
NCT02202980 (10) [back to overview]	Percentage of Participants With Virologic Failure
NCT02202980 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02202980 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment by Study Visit
NCT02214420 (1) [back to overview]	Sustained Viral Response
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 4 Weeks After Discontinuation of Therapy: Motor
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 4 Weeks After Discontinuation of Therapy: Memory T Score
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 4 Weeks After Discontinuation of Therapy: Executive 2 Conceptual Shift and Initiation
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 4 Weeks After Discontinuation of Therapy: Executive 1 Processing Speed
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 4 Weeks After Discontinuation of Therapy: Attention Scaled Score
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 24 Weeks After Discontinuation of Therapy: Motor
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 24 Weeks After Discontinuation of Therapy: Executive 2 Conceptual Shift and Initiation
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 24 Weeks After Discontinuation of Therapy: Executive 1 Processing Speed
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 24 Weeks After Discontinuation of Therapy: Attention Scaled Score
NCT02219685 (22) [back to overview]	Change From Baseline in Health-Related Quality of Life at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by WPAI: Hepatitis C - Activity Impairment
NCT02219685 (22) [back to overview]	Change From Baseline in Neurocognitive Function at 24 Weeks After Discontinuation of Therapy: Memory T Score
NCT02219685 (22) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 4, 12, and 24 Weeks After Discontinuation of Therapy (SVR4, SVR12, and SVR24)
NCT02219685 (22) [back to overview]	Change From Pre-treatment Assessment in Mood Related Assessment at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by Beck Hopelessness Scale (BHS)
NCT02219685 (22) [back to overview]	Change From Pre-treatment Assessment in Mood Related Assessment at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by Beck Depression Inventory-II (BDI-II)
NCT02219685 (22) [back to overview]	Change From Baseline in MRS Metabolic Ratio at 4 Weeks After Discontinuation of Therapy: Myoinositol
NCT02219685 (22) [back to overview]	Change From Baseline in MRS Metabolic Ratio at 4 Weeks After Discontinuation of Therapy: Choline
NCT02219685 (22) [back to overview]	Change From Baseline in Magnetic Resonance Spectroscopy (MRS) Metabolic Ratio at 4 Weeks After Discontinuation of Therapy: NAA + NAAG
NCT02219685 (22) [back to overview]	Change From Baseline in Health-Related Quality of Life at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by Work Productivity and Activity Impairment Questionnaire, Hepatitis C (WPAI: Hepatitis C) - Overall Work Impairment
NCT02219685 (22) [back to overview]	Change From Baseline in Health-Related Quality of Life at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by Short Form 36 (SF-36) Health Survey Scale - Physical Component Score
NCT02219685 (22) [back to overview]	Change From Baseline in Health-Related Quality of Life at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by SF-36 Health Survey Scale - Mental Component Score
NCT02219685 (22) [back to overview]	Change From Baseline in Health-Related Quality of Life at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
NCT02219685 (22) [back to overview]	Change From Baseline in Health-Related Quality of Life at 4 and 24 Weeks After Discontinuation of Therapy as Assessed by Chronic Liver Disease Questionnaire - HCV (CLDQ-HCV)
NCT02220998 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, and 12
NCT02220998 (6) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, and 12
NCT02220998 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02220998 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02220998 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02220998 (6) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02226549 (3) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02226549 (3) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02226549 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02249182 (26) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02249182 (26) [back to overview]	For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF
NCT02249182 (26) [back to overview]	For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
NCT02249182 (26) [back to overview]	Acceptability of LDV/SOF Tablets as Measured by the Percentage of Participants Able/Unable to Swallow Placebo Tablet at Day 1
NCT02249182 (26) [back to overview]	Acceptability of LDV/SOF Granules as Measured by Palatability at Day 1
NCT02249182 (26) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
NCT02250807 (7) [back to overview]	Percentage of Participants With On-Treatment Failure
NCT02250807 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12)
NCT02250807 (7) [back to overview]	Percentage of Participants With On-treatment Virologic Response of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT02250807 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Therapy (SVR24)
NCT02250807 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After End of Therapy (SVR4)
NCT02250807 (7) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02250807 (7) [back to overview]	Percentage of Participants With Viral Relapse
NCT02251717 (4) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02251717 (4) [back to overview]	Percentage of Participants With Virologic Failure
NCT02251717 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02251717 (4) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02262728 (11) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)
NCT02262728 (11) [back to overview]	Pre-dose (Trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)
NCT02262728 (11) [back to overview]	Percentage of Participants With On-treatment Failure
NCT02262728 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)
NCT02262728 (11) [back to overview]	Percentage of Participants With SVR12 Who Maintained to Have HCV RNA
NCT02262728 (11) [back to overview]	Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)
NCT02262728 (11) [back to overview]	Percentage of Participants With On-Treatment Virologic Response
NCT02262728 (11) [back to overview]	Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)
NCT02262728 (11) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)
NCT02262728 (11) [back to overview]	Absolute Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels at Follow-up Week 24 (Week 36)
NCT02262728 (11) [back to overview]	Percentage of Participants With SVR 4 Weeks After End of Study Drug Treatment (SVR4) and SVR 24 Weeks After End of Study Drug Treatment (SVR24)
NCT02292706 (6) [back to overview]	Number of Participants With Detectable HCV RNA Due to Re-emergence of Pre-existing Virus Through Week 240
NCT02292706 (6) [back to overview]	Number of Participants With Detectable HCV Resistance Mutations Through Week 240
NCT02292706 (6) [back to overview]	Percentage of Participants Who Developed Hepatocellular Carcinoma (HCC) Through Week 240
NCT02292706 (6) [back to overview]	Percentage of Participants Maintaining Sustained Virologic Response (SVR) at Week 240
NCT02292706 (6) [back to overview]	Percentage of Participants With Any Liver-Associated Events
NCT02292706 (6) [back to overview]	Number of Participants With Detectable HCV RNA Due to Re-infection Through Week 240
NCT02292719 (3) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02292719 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02292719 (3) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02300103 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02300103 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02300103 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02300103 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On-treatment
NCT02300103 (6) [back to overview]	HCV RNA Change From Baseline
NCT02300103 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02301936 (14) [back to overview]	Change From Pretreatment Assessment in Health-related Quality of Life as Evaluated by Short Form (SF-36) Health Survey Scale- Mental Component Score
NCT02301936 (14) [back to overview]	Change From Pretreatment Assessment in Health-related Quality of Life as Evaluated by Short Form (SF-36) Health Survey Scale- Physical Component Score
NCT02301936 (14) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02301936 (14) [back to overview]	HCV RNA Change From Baseline
NCT02301936 (14) [back to overview]	HCV RNA Change From Baseline
NCT02301936 (14) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02301936 (14) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02301936 (14) [back to overview]	Change From Pretreatment Assessment in Health-related Quality of Life as Evaluated by Short Form (SF-36) Health Survey Scale- Physical Component Score
NCT02301936 (14) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02301936 (14) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02301936 (14) [back to overview]	Percentage of Participants With Virologic Failure
NCT02301936 (14) [back to overview]	Change From Pretreatment Assessment in Health-related Quality of Life as Evaluated by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
NCT02301936 (14) [back to overview]	Change From Pretreatment Assessment in Health-related Quality of Life as Evaluated by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
NCT02301936 (14) [back to overview]	Change From Pretreatment Assessment in Health-related Quality of Life as Evaluated by Short Form (SF-36) Health Survey Scale- Mental Component Score
NCT02304159 (3) [back to overview]	Number of Participants With Abnormal Safety Laboratory Tests (ALT and/or Total Bilirubin) That Required Discontinuing Study Drugs
NCT02304159 (3) [back to overview]	Number of Participants With Adverse Events
NCT02304159 (3) [back to overview]	Number of Participants With Undetectable HCV Virus 12 Weeks After Stopping Study Drugs
NCT02319031 (3) [back to overview]	Number of Participants With Death, Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), Grade 3 or Grade 4 (Grade 3/4) AEs, and Grade 3/4 Laboratory Abnormalities
NCT02319031 (3) [back to overview]	Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 4 (SVR4) and Follow-up Week 24 (SVR24)
NCT02319031 (3) [back to overview]	Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)
NCT02339038 (1) [back to overview]	Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs
NCT02346721 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02346721 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02346721 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02346721 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02346721 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment
NCT02346721 (6) [back to overview]	HCV RNA Change From Baseline
NCT02347345 (5) [back to overview]	Gene Expression Profiles
NCT02347345 (5) [back to overview]	sCD14 (ng/mL)
NCT02347345 (5) [back to overview]	Virologic Response to Therapy as Measured by HCV RNA
NCT02347345 (5) [back to overview]	Gene Expression Profiles
NCT02347345 (5) [back to overview]	sCD14 (ng/mL)
NCT02349048 (8) [back to overview]	Percentage of Participants With On-treatment Virologic Response
NCT02349048 (8) [back to overview]	Percentage of Participants With On-Treatment Failure
NCT02349048 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 Weeks (SVR4) and 24 Weeks (SVR24) After End of Study Drug Treatment
NCT02349048 (8) [back to overview]	Number of Participants With Late Viral Relapse
NCT02349048 (8) [back to overview]	Percentage of Participants With or Without an NS3 Q80K Polymorphism at Baseline Achieving SVR
NCT02349048 (8) [back to overview]	Number of Participants With Viral Relapse
NCT02349048 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After End of Study Drug Treatment (SVR12)
NCT02349048 (8) [back to overview]	Number of Participants With HCV Nonstructural Protein 3/4A (NS3/4A), NS5A and NS5B Sequence in Participants Not Achieving SVR
NCT02350569 (5) [back to overview]	Percentage of Participants With Virologic Failure
NCT02350569 (5) [back to overview]	Percentage of Participants Who Prematurely Discontinued Study Drug Due to an Adverse Event
NCT02350569 (5) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment at Days 1, 3, 5, 7, 14, 21, and 28
NCT02350569 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02350569 (5) [back to overview]	Percentage of Participants With SVR 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02356562 (4) [back to overview]	Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment
NCT02356562 (4) [back to overview]	Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment
NCT02356562 (4) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02356562 (4) [back to overview]	Percentage of Participants With Post-Treatment Relapse
NCT02358044 (6) [back to overview]	Percentage of Participants Discontinuing Study Treatment Due to an AE
NCT02358044 (6) [back to overview]	Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period Plus First 14 Follow-up Days
NCT02358044 (6) [back to overview]	Percentage of Participants Experiencing at Least One Tier 1 Safety Event (Key Safety Parameter) During the Treatment Period and First 14 Follow-up Days
NCT02358044 (6) [back to overview]	Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of All Treatment (SVR12)
NCT02358044 (6) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)
NCT02358044 (6) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 4 Weeks After Ending Study Treatment (SVR4)
NCT02378935 (10) [back to overview]	HCV RNA Change From Baseline
NCT02378935 (10) [back to overview]	HCV RNA Change From Baseline
NCT02378935 (10) [back to overview]	Percentage of Participants With Virologic Failure
NCT02378935 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02378935 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02378935 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02378935 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02378935 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02378935 (10) [back to overview]	HCV RNA Change From Baseline
NCT02378935 (10) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02378961 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02378961 (10) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02378961 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02378961 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02378961 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02378961 (10) [back to overview]	HCV RNA Change From Baseline
NCT02378961 (10) [back to overview]	HCV RNA Change From Baseline
NCT02378961 (10) [back to overview]	HCV RNA Change From Baseline
NCT02378961 (10) [back to overview]	Percentage of Participants With Virologic Failure
NCT02378961 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02399345 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment
NCT02399345 (3) [back to overview]	Percentage of Subjects With On-treatment Virologic Failure
NCT02399345 (3) [back to overview]	Percentage of Subjects With Post-treatment Relapse
NCT02413593 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02413593 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02413593 (6) [back to overview]	Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12
NCT02413593 (6) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02413593 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02413593 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8 and 12
NCT02421211 (19) [back to overview]	Percentage of Participants With Viral Relapse
NCT02421211 (19) [back to overview]	Percentage of Participants With On-treatment Failure
NCT02421211 (19) [back to overview]	Minimum Plasma Concentration (Cmin) of Simeprevir (SMV)
NCT02421211 (19) [back to overview]	Minimum Plasma Concentration (Cmin) of Ledipasvir (LDV)
NCT02421211 (19) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02421211 (19) [back to overview]	Maximum Plasma Concentration (Cmax) of Simeprevir
NCT02421211 (19) [back to overview]	Maximum Plasma Concentration (Cmax) of Ledipasvir
NCT02421211 (19) [back to overview]	Fluctuation Index (FI) of Simeprevir
NCT02421211 (19) [back to overview]	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Ledipasvir
NCT02421211 (19) [back to overview]	Percentage of Participants With On-treatment Virologic Response
NCT02421211 (19) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 4 Weeks After the Actual EOT (SVR4) and 12 Weeks After the Actual EOT (SVR12)
NCT02421211 (19) [back to overview]	Fluctuation Index (FI) of Ledipasvir
NCT02421211 (19) [back to overview]	Average Plasma Concentration at Steady State (Cavg,ss) of Simeprevir
NCT02421211 (19) [back to overview]	Average Plasma Concentration at Steady State (Cavg,ss) of Ledipasvir
NCT02421211 (19) [back to overview]	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Simeprevir
NCT02421211 (19) [back to overview]	Trough Plasma Concentration (Ctrough) of Simeprevir
NCT02421211 (19) [back to overview]	Trough Plasma Concentration (Ctrough) of Ledipasvir
NCT02421211 (19) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir
NCT02421211 (19) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Ledipasvir
NCT02455167 (3) [back to overview]	Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: 12 Weeks
NCT02455167 (3) [back to overview]	Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: Baseline
NCT02455167 (3) [back to overview]	The Sustained Virologic Response (SVR) in Patients Infected With HCV Genotype 1, Cirrhosis, and Early Clinical Decompensation
NCT02457611 (9) [back to overview]	Percentage of Participants With Virologic Failure
NCT02457611 (9) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02457611 (9) [back to overview]	Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4
NCT02457611 (9) [back to overview]	Change From Baseline in HCV RNA at Weeks 2, 4, and 6
NCT02457611 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Study Treatment (SVR4)
NCT02457611 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Completion of Treatment (SVR12)
NCT02457611 (9) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02457611 (9) [back to overview]	Change in HIV RNA From Day 1 to End of Treatment as Assessed by Proportion of Participants Who Had Confirmed HIV Virologic Rebound During the Study.
NCT02457611 (9) [back to overview]	Percent Change From Baseline in CD4 T-cell Count at the End of Treatment and at Posttreatment Week 4
NCT02468648 (4) [back to overview]	Number of Participants Who Sustained Virologic Response
NCT02468648 (4) [back to overview]	Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)
NCT02468648 (4) [back to overview]	Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)
NCT02468648 (4) [back to overview]	Number of Participants With Sustained Virologic Response
NCT02472886 (8) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE)
NCT02472886 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02472886 (8) [back to overview]	Percentage of HIV/HCV- Coinfected Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4
NCT02472886 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02472886 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02472886 (8) [back to overview]	Percentage of Participants With Virologic Failure
NCT02472886 (8) [back to overview]	For HIV/HCV- Coinfected Participants, Change From Baseline in CD4 T-cell Count at the End of Treatment and Posttreatment Week 4
NCT02472886 (8) [back to overview]	HCV RNA Change From Day 1
NCT02480712 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02480712 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02480712 (8) [back to overview]	Percentage of Participants That Maintained HIV-1 RNA < 50 Copies/mL While On HCV Treatment
NCT02480712 (8) [back to overview]	HCV RNA Change From Baseline/Day 1
NCT02480712 (8) [back to overview]	Percentage of Participants With Virologic Failure
NCT02480712 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02480712 (8) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02480712 (8) [back to overview]	Serum Creatinine Change From Baseline At the End of Treatment and At Posttreatment Week 12
NCT02487030 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02487030 (4) [back to overview]	Percentage of Participants With Overall Virologic Failure
NCT02487030 (4) [back to overview]	Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)
NCT02487030 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02503735 (6) [back to overview]	The Percent Change in Proteinuria
NCT02503735 (6) [back to overview]	Change in Urinary β-2microglobulin Levels After Therapy
NCT02503735 (6) [back to overview]	Number of Participants With ≥25% Reduction in Proteinuria
NCT02503735 (6) [back to overview]	Median Change in eGFR From Baseline to Timepoint Week 52
NCT02503735 (6) [back to overview]	Median Change in eGFR From Baseline to Timepoint Week 24
NCT02503735 (6) [back to overview]	Mean Time in Weeks to Maximum Reduction in Proteinuria
NCT02536313 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT02536313 (6) [back to overview]	HCV RNA Change From Baseline/Day 1 Through Week 12
NCT02536313 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02536313 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Treatment (SVR12)
NCT02536313 (6) [back to overview]	Percentage of Participants Who Permanently Discontinued SOF/VEL/VOX Due to an Adverse Event
NCT02536313 (6) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02541409 (4) [back to overview]	HCV Treatment Completion
NCT02541409 (4) [back to overview]	Sustained Virologic Response (SVR)
NCT02541409 (4) [back to overview]	Serious Adverse Events
NCT02541409 (4) [back to overview]	Change in Insulin Resistance
NCT02600351 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Cessation of Therapy (SVR12)
NCT02600351 (6) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02600351 (6) [back to overview]	Percentage of Participants With HCV RNA < the Lower Limit of Quantitation (LLOQ) at 4 and 24 Weeks Posttreatment
NCT02600351 (6) [back to overview]	Percentage of Participants With Viral Relapse
NCT02600351 (6) [back to overview]	Percentage of Participants Who Discontinued From Study Treatment for an Adverse Event
NCT02600351 (6) [back to overview]	Number of Participants With Emerging Resistance
NCT02601573 (4) [back to overview]	Percentage of Participants Experiencing an Adverse Event (AE)
NCT02601573 (4) [back to overview]	Percentage of Participants Discontinuing From Study Therapy Due to an AE
NCT02601573 (4) [back to overview]	Percentage of Participants Achieving SVR12 (Sustained Virologic Response 12 Weeks After the End of All Study Therapy)
NCT02601573 (4) [back to overview]	Percentage of Participants Achieving SVR24 (Sustained Virologic Response 24 Weeks After the End of All Study Therapy)
NCT02605304 (11) [back to overview]	Number of Participants With HIV-1 RNA >50 Copies/mL
NCT02605304 (11) [back to overview]	Number of Participants With Unquantifiable HCV RNA
NCT02605304 (11) [back to overview]	Number of Participants With Unquantifiable HCV RNA
NCT02605304 (11) [back to overview]	Percentage of Participants With Protocol-specified Renal Events
NCT02605304 (11) [back to overview]	CD4+ T-cell (CD4) Count Change From Baseline
NCT02605304 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 Weeks After Treatment Discontinuation (SVR4)
NCT02605304 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12)
NCT02605304 (11) [back to overview]	CD4+ T-cell (CD4) Count Change From Baseline
NCT02605304 (11) [back to overview]	Number of Participants With HIV-1 RNA >50 Copies/mL
NCT02605304 (11) [back to overview]	Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment
NCT02605304 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)
NCT02607735 (11) [back to overview]	Change From Baseline in HCV RNA (Primary Study)
NCT02607735 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) (Primary Study)
NCT02607735 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment (Primary Study)
NCT02607735 (11) [back to overview]	Change From Baseline in HCV RNA (Deferred Treatment Substudy)
NCT02607735 (11) [back to overview]	Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event (Primary Study)
NCT02607735 (11) [back to overview]	Percentage of Participants With SVR at 4, 12, and 24 Weeks After Discontinuation of Therapy (Deferred Treatment Substudy)
NCT02607735 (11) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24) (Primary Study)
NCT02607735 (11) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4) (Primary Study)
NCT02607735 (11) [back to overview]	Percentage of Participants With Virologic Failure (Deferred Treatment Substudy)
NCT02607735 (11) [back to overview]	Percentage of Participants With Virologic Failure (Primary Study)
NCT02607735 (11) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment (Deferred Treatment Substudy)
NCT02607800 (8) [back to overview]	Change From Baseline in HCV RNA
NCT02607800 (8) [back to overview]	Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event
NCT02607800 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT02607800 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT02607800 (8) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02607800 (8) [back to overview]	Percentage of Participants With Virologic Failure
NCT02607800 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02607800 (8) [back to overview]	Change From Baseline in HCV RNA
NCT02613871 (16) [back to overview]	Percentage of Participants With Virologic Failure
NCT02613871 (16) [back to overview]	HCV RNA Change From Baseline While on Treatment
NCT02613871 (16) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Posttreatment Weeks 24, 36, 48, 60, 72, 84, 96, and 108
NCT02613871 (16) [back to overview]	Plasma HBV DNA Change From Baseline While on Treatment
NCT02613871 (16) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment
NCT02613871 (16) [back to overview]	Serum LOXL-2 Level Change From Baseline While on Treatment
NCT02613871 (16) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02613871 (16) [back to overview]	Percentage of Participants With Any Adverse Event Leading to Permanent Discontinuation of Study Drug
NCT02613871 (16) [back to overview]	Percentage of Participants That Required HBV Therapy During the Study
NCT02613871 (16) [back to overview]	Plasma HBV DNA Change From Baseline at Posttreatment Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, and 108
NCT02613871 (16) [back to overview]	Percentage of Participants That Develop Hepatocellular Carcinoma (HCC) During the Study
NCT02613871 (16) [back to overview]	Serum LOXL-2 Level Change From Baseline at Posttreatment Weeks 4, 12, and 36
NCT02613871 (16) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02613871 (16) [back to overview]	HBsAg Level Change From Baseline at Posttreatment Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, and 108
NCT02613871 (16) [back to overview]	HBsAg Level Change From Baseline While on Treatment
NCT02613871 (16) [back to overview]	Fibrosis Status as Assessed by Fibroscan Score at Posttreatment Weeks 12, 60, and 108
NCT02625909 (4) [back to overview]	Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Intention-to-treat (ITT) Population
NCT02625909 (4) [back to overview]	Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Modified Intention-to-treat (ITT) Population
NCT02625909 (4) [back to overview]	Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Per Protocol (PP) Population
NCT02625909 (4) [back to overview]	Number of Participants With Undetectable HCV RNA at End of Treatment (ETR) of SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent HCV Infection- Among Intention-to-treat (ITT) Population
NCT02631772 (3) [back to overview]	Number of Participants With Virologic Failure
NCT02631772 (3) [back to overview]	Treatment Efficacy
NCT02631772 (3) [back to overview]	Hemoglobin Levels
NCT02639247 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT02639247 (6) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02639247 (6) [back to overview]	Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event
NCT02639247 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02639247 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT02639247 (6) [back to overview]	Change From Baseline in HCV RNA
NCT02639338 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT02639338 (8) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02639338 (8) [back to overview]	Change From Baseline in HCV RNA
NCT02639338 (8) [back to overview]	Change From Baseline in HCV RNA
NCT02639338 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT02639338 (8) [back to overview]	Percentage of Participants With Virologic Failure
NCT02639338 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02639338 (8) [back to overview]	Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event
NCT02640157 (5) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02640157 (5) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02640157 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Noninferiority of Arm A to Arm B
NCT02640157 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Noninferiority of Arm C to Arm A
NCT02640157 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Superiority of Arm A to Arm B
NCT02671500 (7) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02671500 (7) [back to overview]	Change From Baseline in HCV RNA
NCT02671500 (7) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT02671500 (7) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02671500 (7) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02671500 (7) [back to overview]	Percentage of Participants With Overall Virologic Failure
NCT02671500 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02707601 (4) [back to overview]	Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm
NCT02707601 (4) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)
NCT02707601 (4) [back to overview]	Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment
NCT02707601 (4) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)
NCT02722837 (15) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT02722837 (15) [back to overview]	Change From Baseline in HCV RNA at Week 12
NCT02722837 (15) [back to overview]	Change From Baseline in HCV RNA at Week 1
NCT02722837 (15) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT02722837 (15) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT02722837 (15) [back to overview]	Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event
NCT02722837 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02722837 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02722837 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment at Week 12
NCT02722837 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment at Week 2
NCT02722837 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment at Week 4
NCT02722837 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment at Week 8
NCT02722837 (15) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02722837 (15) [back to overview]	Percentage of Participants With Virologic Failure
NCT02722837 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment at Week 1
NCT02723084 (4) [back to overview]	Percentage of Participants With With On-treatment Virologic Failure
NCT02723084 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Non-inferiority of Arm A to Arm B
NCT02723084 (4) [back to overview]	Percentage of Participants With Post-Treatment Relapse
NCT02723084 (4) [back to overview]	Percentage of Participants in Arm A With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02728206 (5) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02728206 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02728206 (5) [back to overview]	Percentage of Participants With Overall Virologic Failure
NCT02728206 (5) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02728206 (5) [back to overview]	Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 10
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 1
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 12
NCT02738333 (23) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02738333 (23) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02738333 (23) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02738333 (23) [back to overview]	Percentage of Participants With Overall Virologic Failure
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 6
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 5
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 3
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 12
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 10
NCT02738333 (23) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 1
NCT02738333 (23) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 6
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 5
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 3
NCT02738333 (23) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT02745535 (5) [back to overview]	Number of Participants Who Achieve End of Treatment Virologic Response (ETR) at Completion of Therapy.
NCT02745535 (5) [back to overview]	Number of Participants Who Achieve Sustained Virologic Response (SVR) 12 Weeks After Completion of Therapy (SVR12)
NCT02745535 (5) [back to overview]	Number of Participants Who Achieve Sustained Virologic Response (SVR) 24 Weeks After Completion of Therapy.
NCT02745535 (5) [back to overview]	Number of Participants Who Achieve Sustained Virologic Response (SVR) 4 Weeks After Completion of Therapy.
NCT02745535 (5) [back to overview]	Number of Participants With Grade 3 and 4 Adverse Events
NCT02759861 (2) [back to overview]	Number of Subjects With Advanced Fibrosis Score of F3/F4 Who Achieve SVR
NCT02759861 (2) [back to overview]	The Number of Subjects Who Achieve Negative RNA in Alcoholics
NCT02781558 (16) [back to overview]	HCV RNA at Week 2
NCT02781558 (16) [back to overview]	HCV RNA at Week 12
NCT02781558 (16) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT02781558 (16) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT02781558 (16) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT02781558 (16) [back to overview]	Change From Baseline in HCV RNA at Week 12
NCT02781558 (16) [back to overview]	Percentage of Participants With Virologic Failure
NCT02781558 (16) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)
NCT02781558 (16) [back to overview]	HCV RNA at Week 4
NCT02781558 (16) [back to overview]	Percentage of Participants Who Have HCV RNA < LLOQ at Week 8
NCT02781558 (16) [back to overview]	Percentage of Participants Who Have HCV RNA < LLOQ at Week 4
NCT02781558 (16) [back to overview]	Percentage of Participants Who Have HCV RNA < LLOQ at Week 2
NCT02781558 (16) [back to overview]	Percentage of Participants Who Have HCV RNA < LLOQ at Week 12
NCT02781558 (16) [back to overview]	Percentage of Participants Who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4)
NCT02781558 (16) [back to overview]	HCV RNA at Week 8
NCT02781558 (16) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug (Which Included SOF/VEL and RBV) Due to Any Adverse Event
NCT02781571 (16) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT02781571 (16) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT02781571 (16) [back to overview]	Change From Baseline in HCV RNA at Week 12
NCT02781571 (16) [back to overview]	Percentage of Participants With Virologic Failure
NCT02781571 (16) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After Cessation of Therapy (SVR4)
NCT02781571 (16) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)
NCT02781571 (16) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT02781571 (16) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT02781571 (16) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT02781571 (16) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 12
NCT02781571 (16) [back to overview]	Percentage of Participants Who Prematurely Discontinued Study Drug Due to Any Adverse Event
NCT02781571 (16) [back to overview]	HCV RNA at Week 8
NCT02781571 (16) [back to overview]	HCV RNA at Week 4
NCT02781571 (16) [back to overview]	HCV RNA at Week 2
NCT02781571 (16) [back to overview]	HCV RNA at Week 12
NCT02781571 (16) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT02781649 (6) [back to overview]	Number of Participants With Grade 3 or Higher Treatment-related Adverse Events as US Department of Health and Human Services Common Terminology of Adverse Events (CTCAE) Version 4
NCT02781649 (6) [back to overview]	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Mutations in the HCV Population From the Deceased Donors
NCT02781649 (6) [back to overview]	Viral Response
NCT02781649 (6) [back to overview]	Kidney Function at 12 Months
NCT02781649 (6) [back to overview]	Kidney Function at 6 Months
NCT02781649 (6) [back to overview]	Antibody Development
NCT02786537 (28) [back to overview]	HCV SVR Durability -No Cirrhosis
NCT02786537 (28) [back to overview]	HCV SVR Durability-Patients With Cirrhosis
NCT02786537 (28) [back to overview]	Median Change in Fatigue-Phase 2
NCT02786537 (28) [back to overview]	Median Change in Fatigue -Phase 1
NCT02786537 (28) [back to overview]	Mean Change in Nausea/Vomiting PROMIS Score -EBR/GZR vs. LDV/SOF
NCT02786537 (28) [back to overview]	Number of Participants With Adverse Events That Caused Treatment Discontinuation-EBR/GZR vs. LDV/SOF
NCT02786537 (28) [back to overview]	Mean Change in Nausea/Vomiting PRO Score -Phase 1
NCT02786537 (28) [back to overview]	Impact of Baseline NS5A RASs on Treatment Outcomes-Phase 2
NCT02786537 (28) [back to overview]	Change in HCV-associated Symptoms (PROMIS Measures) After HCV Treatment Initiation
NCT02786537 (28) [back to overview]	Change in Functional Status (HCV-PRO) Within Treatment
NCT02786537 (28) [back to overview]	Treatment Non-Adherence Probability Estimates
NCT02786537 (28) [back to overview]	Sustained Virologic Response (SVR12) mITT With Imputation-Phase 1 and 2 EBR/GZR, SOF/LDV
NCT02786537 (28) [back to overview]	Post-treatment Progression/Regression of Liver Disease-Fib-4
NCT02786537 (28) [back to overview]	Phase 1/2 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)
NCT02786537 (28) [back to overview]	Phase 1-Sustained Virologic Response (SVR12) mITT With Imputation
NCT02786537 (28) [back to overview]	Phase 1 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)
NCT02786537 (28) [back to overview]	Mean Change in Headache-PRO Scores -Phase 1
NCT02786537 (28) [back to overview]	Median Change in Nausea PROMIS Score-EBR/GZR SOF/LDV
NCT02786537 (28) [back to overview]	Median Change in Nausea PRO Score -Phase 1
NCT02786537 (28) [back to overview]	Mean Change in Headache-EBR/GZR and SOF/LDV
NCT02786537 (28) [back to overview]	Median Change in Headache -Phase 1
NCT02786537 (28) [back to overview]	Median Change in HCV-PRO (Overall Well Being) -Phase 1
NCT02786537 (28) [back to overview]	Mean Change in HCV-PRO (Functional Well-being) EBR/GZR vs. SOF/LDV Score-Phase 2
NCT02786537 (28) [back to overview]	Mean Change in HCV- PRO- Phase 1
NCT02786537 (28) [back to overview]	Median Change in Headache-Phase 2
NCT02786537 (28) [back to overview]	Mean Change in Fatigue PRO Score -Phase 1
NCT02786537 (28) [back to overview]	Mean Change in Fatigue PRO -EBR/GZR vs SOF/LDV
NCT02786537 (28) [back to overview]	16 Wk EBR/GZR With RBV Efficacy on Patients With HCV RASs
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 12
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 16
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 20
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 24
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 3
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 5
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 6
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT02822794 (29) [back to overview]	Percentage of Participants With Overall Virologic Failure
NCT02822794 (29) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02822794 (29) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02822794 (29) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 1
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 10
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 12
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 16
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 20
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 24
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 3
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 5
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 6
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT02822794 (29) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 1
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 10
NCT02825212 (2) [back to overview]	Response in Patients With Mixed Cryoglobulinemia (MC)
NCT02825212 (2) [back to overview]	Sustained Virologic Response (SVR)
NCT02858180 (4) [back to overview]	Number of Subjects With Sustained Virologic Response (SVR) 4
NCT02858180 (4) [back to overview]	Number of Subjects With Sustained Virologic Response (SVR) 12
NCT02858180 (4) [back to overview]	Number of Subjects Who Completed 24 Weeks of Therapy
NCT02858180 (4) [back to overview]	Discontinuation for Adverse Events and Serious Adverse Events
NCT02868242 (7) [back to overview]	Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event
NCT02868242 (7) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02868242 (7) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02868242 (7) [back to overview]	Percentage of Participants With Virologic Failure
NCT02868242 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02868242 (7) [back to overview]	HCV RNA Change From Baseline/Day 1
NCT02868242 (7) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Treatment
NCT02938013 (4) [back to overview]	Amount of HCV RNA Per Infected Hepatocyte Using Single Cell Laser Micro Dissection (scLCM) on Liver Biopsy Specimens, Obtained Just Prior to Treatment Initiation (Pre-treatment), and After the First Week of DAA Therapy.
NCT02938013 (4) [back to overview]	Reduction Over the First Week in Plasma HCV RNA
NCT02938013 (4) [back to overview]	Total Number of HCV-infected Hepatocytes Measured in Liver Tissue Obtained by Liver Biopsy at Day 0 (Pre-treatment) and at Day 7 of Antiviral Therapy
NCT02938013 (4) [back to overview]	Total Number of HCV-infected Hepatocytes That Express Interferon-stimulated Genes (ISGs) Within the First Week of DAA Therapy Using Single Cell Laser Micro Dissection (scLCM).
NCT02939989 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02939989 (3) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02939989 (3) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02994056 (10) [back to overview]	Percentage of Participants With HCV RNA < LLOQ While on Study Treatment
NCT02994056 (10) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score
NCT02994056 (10) [back to overview]	Percentage of Participants Who Permanently Discontinued Study Drug (SOF/VEL or RBV) Due to an Adverse Event
NCT02994056 (10) [back to overview]	Absolute HCV RNA Level Through Week 12
NCT02994056 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02994056 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02994056 (10) [back to overview]	Number of Participants With Virologic Failure
NCT02994056 (10) [back to overview]	Change From Baseline in HCV RNA
NCT02994056 (10) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02994056 (10) [back to overview]	Percentage of Participants With No Change, Improved, and Worsened Child-Pugh-Turcotte (CPT) Class
NCT03022981 (22) [back to overview]	Treatment Phase: Percentage of Participants With Virologic Failure
NCT03022981 (22) [back to overview]	Treatment Phase: Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT03022981 (22) [back to overview]	Treatment Phase: Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT03022981 (22) [back to overview]	Treatment Phase: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT03022981 (22) [back to overview]	Treatment Phase: Percentage of Participants Who Discontinued Study Drug Due to Any Treatment-Emergent Adverse Event (TEAE)
NCT03022981 (22) [back to overview]	Treatment Phase: Growth and Development as Measured by Parental Height
NCT03022981 (22) [back to overview]	PK Lead-in Phase: Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event (AE)
NCT03022981 (22) [back to overview]	PK Lead-in Phase: AUCtau: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval of Velpatasvir (VEL)
NCT03022981 (22) [back to overview]	PK Lead-in Phase: AUCtau: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval of Sofosbuvir (SOF)
NCT03022981 (22) [back to overview]	PK Lead-in Phase: AUCtau: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval of GS-331007 (Metabolite of SOF)
NCT03022981 (22) [back to overview]	Treatment Phase: Percentage of Participants With HCV RNA < LLOQ On Treatment
NCT03022981 (22) [back to overview]	Treatment Phase: Swallowability of SOF/VEL as Assessed by the Participant's Ability to Swallow SOF/VEL Placebo Tablets at Baseline
NCT03022981 (22) [back to overview]	Treatment Phase: Quality of Life (QoL) and Neuropsychiatric Assessments as Measured by PedsQL™ Pediatric QoL Survey
NCT03022981 (22) [back to overview]	Treatment Phase: Percentage of Participants Who Develop Viral Resistance to SOF and/or VEL During Treatment and After Discontinuation of Treatment
NCT03022981 (22) [back to overview]	Treatment Phase: Number of Participants With Acceptability of SOF/VEL as Measured by a Questionnaire to Assess Acceptability, Including Palatability at Week 12
NCT03022981 (22) [back to overview]	Treatment Phase: Number of Participants With Acceptability of SOF/VEL as Measured by a Questionnaire to Assess Acceptability, Including Palatability at Day 1
NCT03022981 (22) [back to overview]	Treatment Phase: Changes in Growth and Development as Measured by Tanner Stage Assessment From Baseline
NCT03022981 (22) [back to overview]	Treatment Phase: Change From Baseline in HCV RNA at Weeks 1, 4, 8, and 12
NCT03022981 (22) [back to overview]	Treatment Phase: Change From Baseline in Growth and Development as Measured by Weight Percentiles
NCT03022981 (22) [back to overview]	Treatment Phase: Change From Baseline in Growth and Development as Measured by Height Percentiles
NCT03022981 (22) [back to overview]	Treatment Phase: Change From Baseline in Growth and Development as Measured by Bone Age
NCT03022981 (22) [back to overview]	PK Lead-in Phase: Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 7
NCT03036839 (20) [back to overview]	PK Parameter: AUCtau of SOF
NCT03036839 (20) [back to overview]	PK Parameter: Cmax of SOF
NCT03036839 (20) [back to overview]	HCV RNA
NCT03036839 (20) [back to overview]	HCV RNA
NCT03036839 (20) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT03036839 (20) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT03036839 (20) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT03036839 (20) [back to overview]	Change From Baseline in HCV RNA
NCT03036839 (20) [back to overview]	Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event
NCT03036839 (20) [back to overview]	Change From Baseline in HCV RNA
NCT03036839 (20) [back to overview]	Change From Baseline in HCV RNA
NCT03036839 (20) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT03036839 (20) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT03036839 (20) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT03036839 (20) [back to overview]	Percentage of Participants With Virologic Failure
NCT03036839 (20) [back to overview]	Pharmacokinetics (PK) Parameter: AUCtau of LDV
NCT03036839 (20) [back to overview]	PK Parameter: AUCtau of GS-331007 (Metabolite of SOF)
NCT03036839 (20) [back to overview]	HCV RNA
NCT03036839 (20) [back to overview]	PK Parameter: Cmax of GS-331007 (Metabolite of SOF)
NCT03036839 (20) [back to overview]	PK Parameter: Cmax of LDV
NCT03036852 (15) [back to overview]	Number of Participants Who Develop Viral Resistance (as Assessed by Presence of HCV NS5A and NS5B Genes) to SOF and VEL During Treatment and After Discontinuation of Treatment
NCT03036852 (15) [back to overview]	Percentage of Participants With Virologic Failure
NCT03036852 (15) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)
NCT03036852 (15) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)
NCT03036852 (15) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT03036852 (15) [back to overview]	PK Parameter: Cmax of SOF
NCT03036852 (15) [back to overview]	PK Parameter: Cmax of VEL
NCT03036852 (15) [back to overview]	PK Parameter: Ctau of VEL
NCT03036852 (15) [back to overview]	Change From Baseline in HCV RNA
NCT03036852 (15) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT03036852 (15) [back to overview]	Pharmacokinetic (PK) Parameter: AUCtau of SOF
NCT03036852 (15) [back to overview]	PK Parameter: AUCtau of VEL
NCT03036852 (15) [back to overview]	PK Parameter: Cmax of GS-331007 (Metabolite of SOF)
NCT03036852 (15) [back to overview]	Percentage of Participants Who Permanently Discontinued the Study Drug Due to an Adverse Event
NCT03036852 (15) [back to overview]	PK Parameter: AUCtau of GS-331007 (Metabolite of SOF)
NCT03057847 (6) [back to overview]	Number of Participants Achieving Sustained Virologic Response (SVR)
NCT03057847 (6) [back to overview]	Number of Missed Treatment Doses
NCT03057847 (6) [back to overview]	Number of Participants Reporting Treatment Side Effects
NCT03057847 (6) [back to overview]	Intravenous Drug Use Recidivism
NCT03057847 (6) [back to overview]	Number of Participants Initiating in Hepatitis C Virus (HCV) Treatment
NCT03057847 (6) [back to overview]	HCV Reinfection
NCT03074331 (3) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT03074331 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT03074331 (3) [back to overview]	Percentage of Participants With Virologic Failure
NCT03118674 (4) [back to overview]	Number of Participants With Resolution of Active PCT by 7 Months After Start of Therapy
NCT03118674 (4) [back to overview]	Number of Participants With Complete Biochemical Remission of PCT
NCT03118674 (4) [back to overview]	Number of Participants With Cure of CHC
NCT03118674 (4) [back to overview]	Time to Resolution of Active PCT
NCT03235154 (3) [back to overview]	Adherence to Study Treatment
NCT03235154 (3) [back to overview]	Health-Related Quality of Life
NCT03235154 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment (SVR-12)
NCT03236506 (1) [back to overview]	Adherence as Assessed by the Total Percentage of Tablets Taken (Out of Those Dispensed) During the Treatment Period
NCT03312023 (3) [back to overview]	Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects With Chronic Hepatitis B From Baseline to End of 12 Weeks Treatment.
NCT03312023 (3) [back to overview]	Changes in Serum Hepatitis B Virus DNA Levels (HBV DNA as Measured in IU/mL) With Treatment of Ledipasvir and/or Sofosbuvir From Baseline to End of 12 Weeks of Treatment in Subjects With Chronic Hepatitis B Infection.
NCT03312023 (3) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Ledipasvir and/or Sofosbuvir Treatment in Subjects With Chronic Hepatitis B Infection.
NCT03480932 (3) [back to overview]	Medication Adherence
NCT03480932 (3) [back to overview]	Serious Adverse Events
NCT03480932 (3) [back to overview]	SVR12
NCT03487848 (9) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels Below the Lower Limit of Quantitation (LLOQ) at Post-Treatment Follow-Up Week 12
NCT03487848 (9) [back to overview]	Apparent Total Body Clearance (CLT/F) for Daclatasvir
NCT03487848 (9) [back to overview]	Area Under the Concentration-Time Curve (AUC(TAU)) for Daclatasvir
NCT03487848 (9) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Daclatasvir
NCT03487848 (9) [back to overview]	Number of Participants Experiencing Laboratory Abnormalities - Follow-up Analysis
NCT03487848 (9) [back to overview]	Time of Maximum Observed Plasma Concentration (Tmax) for Daclatasvir
NCT03487848 (9) [back to overview]	Number of Participants Experiencing Laboratory Abnormalities - On-treatment Analysis
NCT03487848 (9) [back to overview]	Number of Participants Experiencing Adverse Events
NCT03487848 (9) [back to overview]	Minimum (Trough) Observed Plasma Concentration (Cmin) for Daclatasvir
NCT03512210 (5) [back to overview]	Percentage of Participants Who Prematurely Discontinued HCV Study Medications
NCT03512210 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 (SVR12)
NCT03512210 (5) [back to overview]	Percentage of Participants With at Least One Unplanned Clinic Visit Prior to SVR12 Evaluation
NCT03512210 (5) [back to overview]	Percentage of Participants With an Occurrence of Serious Adverse Events According to International Council for Harmonization (ICH) Criteria
NCT03512210 (5) [back to overview]	Percentage of Participants With an Occurrence of One or More Non-serious, Grade >= 3 Adverse Event (AE), or Treatment Limiting AE.
NCT03619837 (3) [back to overview]	Proportion of Participants With HCV RNA Level Below Limits of Quantification (LOQ)
NCT03619837 (3) [back to overview]	Survival Rate of Patients and Their Allografts 6 Months Post Transplant
NCT03619837 (3) [back to overview]	Safety as Measured by the Proportion of Participants Who Prematurely Discontinue Antiviral Therapy Before the Planned End of Treatment
NCT03801707 (4) [back to overview]	Estimated Glomerular Filtration Rate (eGFR) at 6 and 12 Months Post-transplant
NCT03801707 (4) [back to overview]	Graft Survival at 6 and 12 Months
NCT03801707 (4) [back to overview]	Patient's Survival at 6 and 12 Months
NCT03801707 (4) [back to overview]	Proportion of Patients With Undetectable Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR) at 12 Weeks After Completion of HCV Treatment
NCT03823911 (1) [back to overview]	Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein
NCT04112303 (5) [back to overview]	Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Study Drug
NCT04112303 (5) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 24 Weeks After Discontinuation of Treatment (SVR24)
NCT04112303 (5) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of Treatment (SVR4)
NCT04112303 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Treatment (SVR12)
NCT04112303 (5) [back to overview]	Percentage of Participants With Virologic Failure
NCT04211909 (7) [back to overview]	Number of Participants With Alanine Aminotransferase (ALT) Normalization
NCT04211909 (7) [back to overview]	Change From Baseline in HCV RNA
NCT04211909 (7) [back to overview]	Percentage of Participants With Virologic Failure
NCT04211909 (7) [back to overview]	Percentage of Participants With SVR < LLOQ 4 Weeks After Discontinuation of Study Treatment
NCT04211909 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Study Treatment
NCT04211909 (7) [back to overview]	Percentage of Participants With HCV RNA < LLOQ on Treatment
NCT04211909 (7) [back to overview]	Percentage of Participants Who Permanently Discontinued the Study Drug Due to an Adverse Event

Plasma Pharmacokinetics of GS-331007: Cmax at Day 27

The Cmax of GS-331007 was measured at Day 27 following continuous dosing of sofosbuvir. (NCT01054729)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)

Intervention	ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	233.79
Sofosbuvir 200 mg+PEG+RBV	357.38
Sofosbuvir 400 mg+PEG+RBV	717.23

Intervention	ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	218.08
Sofosbuvir 200 mg+PEG+RBV	332.26
Sofosbuvir 400 mg+PEG+RBV	1257.50

Intervention	h*ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	375.70
Sofosbuvir 200 mg+PEG+RBV	732.27
Sofosbuvir 400 mg+PEG+RBV	2011.23

Intervention	h*ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	280.19
Sofosbuvir 200 mg+PEG+RBV	585.56
Sofosbuvir 400 mg+PEG+RBV	1867.24

Intervention	ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	64.75
Sofosbuvir 200 mg+PEG+RBV	132.72
Sofosbuvir 400 mg+PEG+RBV	237.46

Intervention	ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	69.99
Sofosbuvir 200 mg+PEG+RBV	145.51
Sofosbuvir 400 mg+PEG+RBV	293.35

Intervention	ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	197.32
Sofosbuvir 200 mg+PEG+RBV	357.33
Sofosbuvir 400 mg+PEG+RBV	662.13

Intervention	ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	253.54
Sofosbuvir 200 mg+PEG+RBV	475.14
Sofosbuvir 400 mg+PEG+RBV	1355.65

Intervention	h*ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	262.00
Sofosbuvir 200 mg+PEG+RBV	571.95
Sofosbuvir 400 mg+PEG+RBV	1072.91

Intervention	h*ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	266.22
Sofosbuvir 200 mg+PEG+RBV	645.95
Sofosbuvir 400 mg+PEG+RBV	1315.94

Intervention	percentage of participants (Number)
	Any AE	Drug-related AE	Grade 3 or higher AE	AE leading to drug discontinuation/interruption	Serious AE
Placebo+PEG+RBV	85.7	42.9	0.0	0.0	0.0
Sofosbuvir 100 mg+PEG+RBV	87.5	12.5	0.0	0.0	0.0
Sofosbuvir 200 mg+PEG+RBV	83.3	27.8	0.0	0.0	0.0
Sofosbuvir 400 mg+PEG+RBV	86.7	33.3	0.0	0.0	0.0

Intervention	h*ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	2256.81
Sofosbuvir 200 mg+PEG+RBV	3389.23
Sofosbuvir 400 mg+PEG+RBV	7398.99

Intervention	h*ng/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	2173.18
Sofosbuvir 200 mg+PEG+RBV	3984.88
Sofosbuvir 400 mg+PEG+RBV	7559.91

Intervention	log10 IU/mL (Mean)
Sofosbuvir 100 mg+PEG+RBV	-5.323
Sofosbuvir 200 mg+PEG+RBV	-5.081
Sofosbuvir 400 mg+PEG+RBV	-5.346
Placebo+PEG+RBV	-2.8

Intervention	percentage of participants (Number)
	SVR12	SVR24
Placebo+PEG+RBV	50.0	42.9
Sofosbuvir 100 mg+PEG+RBV	56.3	56.3
Sofosbuvir 200 mg+PEG+RBV	72.2	83.3
Sofosbuvir 400 mg+PEG+RBV	86.7	80.0

Intervention	ng•h/mL (Mean)
Sofosbuvir 200 mg (Genotype 1)	3020.30
Sofosbuvir 400 mg (Genotype 1)	8620.07
Sofosbuvir 400 mg (Genotype 2/3)	5738.61

Intervention	percentage of participants (Number)
	SVR12	SVR24
Placebo (Genotype 1)	57.7	57.7
Sofosbuvir 200 mg (Genotype 1)	89.6	89.6
Sofosbuvir 400 mg (Genotype 1)	91.5	91.5
Sofosbuvir 400 mg (Genotype 2/3)	92.0	92.0

Intervention	ng/mL (Mean)
Sofosbuvir 200 mg (Genotype 1)	331.48
Sofosbuvir 400 mg (Genotype 1)	750.78
Sofosbuvir 400 mg (Genotype 2/3)	518.18

Intervention	ng/mL (Mean)
Sofosbuvir 200 mg (Genotype 1)	285.77
Sofosbuvir 400 mg (Genotype 1)	897.41
Sofosbuvir 400 mg (Genotype 2/3)	574.13

Intervention	percentage of participants (Number)
Sofosbuvir 200 mg (Genotype 1)	93.8
Sofosbuvir 400 mg (Genotype 1)	100.0
Placebo (Genotype 1)	61.5
Sofosbuvir 400 mg (Genotype 2/3)	100.0

Intervention	percentage of participants (Number)
Sofosbuvir 200 mg (Genotype 1)	97.9
Sofosbuvir 400 mg (Genotype 1)	97.9
Placebo (Genotype 1)	19.2
Sofosbuvir 400 mg (Genotype 2/3)	96.0

sofosbuvir

Description

Cross-References

Synonyms (141)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (9)

Pathways (3)

Protein Targets (8)

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (48)

Molecular Functions (35)

Ceullar Components (11)

Bioassays (331)

Research

Studies (2,186)

Market Indicators

Research Demand Index: 79.73

Study Types

Clinical Trials (322)

Trial Overview

Trial Outcomes

Plasma Pharmacokinetics of GS-331007: Cmax at Day 27

Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0

Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27

Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0

Plasma Pharmacokinetics of GS-566500: Cmax at Day 27

Plasma Pharmacokinetics of GS-566500: Cmax at Day 0

Plasma Pharmacokinetics of GS-331007: Cmax at Day 0

Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27

Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27

Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0

Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period

Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27

Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0

Percentage of Participants With Rapid Virologic Response at Week 4

Percentage of Participants Who Developed Resistance to Sofosbuvir

Change in Circulating HCV RNA at Week 4

Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment

Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 8)

Percentage of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) and 24 (SVR24)

Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period

Plasma Pharmacokinetics of GS-331007 (Cmax at Day 8)

Plasma Pharmacokinetics of GS-331007 (Cmax at Day 29)

Percentage of Participants With Virologic Response at the End of Treatment

Percentage of Participants With Rapid Virologic Response at Week 4

Percentage of Participants With Extended Rapid Virologic Response

Percentage of Participants With Complete Early Virologic Response at Week 12

Percentage of Participants Who Developed Resistance to Sofosbuvir

Change in HCV RNA From Baseline to Week 12

Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 29)

Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 15)

Plasma Pharmacokinetics of GS-331007 (Cmax at Day 15)

Percentage of Participants With HCV RNA < LOD at Week 12

Percentage of Participants With HCV RNA < LOD at Week 6

Percentage of Participants With Virologic Failure

Percentage of Participants Who Experienced Adverse Events

Change From Baseline in HCV RNA at Week 8

Change From Baseline in HCV RNA at Week 6

Change From Baseline in HCV RNA at Week 12

Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)

Percentage of Participants With HCV RNA < LOD at Week 8

Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)

Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)

Percentage of Participants With HCV RNA Below < LOD at Week 8

Percentage of Participants With HCV RNA Below < LOD at Week 4

Percentage of Participants With HCV RNA Below < LOD at Week 24

Percentage of Participants With HCV RNA Below < LOD at Week 12

Percentage of Participants With HCV RNA < LOD at Week 2

Percentage of Participants With ALT Normalization at Week 12

Percentage of Participants With ALT Normalization at Post-treatment Week 4

Change in HCV RNA at Week 8

Change in HCV RNA at Week 4

Intervention	log10 IU/mL (Mean)
Sofosbuvir 200 mg (Genotype 1)	-5.39
Sofosbuvir 400 mg (Genotype 1)	-5.20
Placebo (Genotype 1)	-4.16
Sofosbuvir 400 mg (Genotype 2/3)	-4.95

Intervention	ng•h/mL (Mean)
Sofosbuvir 200 mg (Genotype 1)	2789.62
Sofosbuvir 400 mg (Genotype 1)	9191.86
Sofosbuvir 400 mg (Genotype 2/3)	5874.52

Intervention	ng•h/mL (Mean)
Sofosbuvir 200 mg (Genotype 1)	3178.53
Sofosbuvir 400 mg (Genotype 1)	11245.43
Sofosbuvir 400 mg (Genotype 2/3)	5465.41

Intervention	ng/mL (Mean)
Sofosbuvir 200 mg (Genotype 1)	269.93
Sofosbuvir 400 mg (Genotype 1)	1087.21
Sofosbuvir 400 mg (Genotype 2/3)	515.13

Intervention	percentage of participants (Number)
Group 1: SOF+RBV 12 wk: GT 2 or 3, TN	100.0
Group 2: SOF+RBV 12 wk +PEG 4 wk: GT 2 or 3, TN	100.0
Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN	100.0
Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN	100.0
Group 5: SOF 12 wk: GT 2 or 3, TN	100.0
Group 7: SOF+RBV 12 wk: GT 1, TE	100.0
Group 8: SOF+RBV 12 wk: GT 1, TN	100.0
Group 9: SOF+RBV 12 wk: GT 2 or 3, TE	100.0
Group 11: SOF+RBV 12 wk: GT 2 or 3, TN	100.0
Group 12: SOF+RBV+LDV 12 wk: GT 1, TE	100.0
Group 13: SOF+RBV+LDV 12 wk: GT 1, TN	100.0
Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE	100.0
Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN	100.0
Group 16: LDV/SOF FDC 12 wk: GT 1, Fibrosis	100.0
Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, Fibrosis	100.0
Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN	100.0
Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, Hemophiliac	100.0

Intervention	percentage of participants (Number)
	On-treatment virologic failure	Viral relapse
Group 1: SOF+RBV 12 wk: GT 2 or 3, TN	0.0	0.0
Group 10: SOF+RBV 8 wk: GT 2 or 3, TN	0.0	36.0
Group 11: SOF+RBV 12 wk: GT 2 or 3, TN	0.0	40.0
Group 12: SOF+RBV+LDV 12 wk: GT 1, TE	0.0	0.0
Group 13: SOF+RBV+LDV 12 wk: GT 1, TN	0.0	0.0
Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE	0.0	0.0
Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN	0.0	8.0
Group 16: LDV/SOF FDC 12 wk: GT 1, Fibrosis	0.0	30.0
Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, Fibrosis	0.0	0.0
Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN	0.0	20.0
Group 2: SOF+RBV 12 wk +PEG 4 wk: GT 2 or 3, TN	0.0	0.0
Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, Hemophiliac	0.0	0.0
Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN	0.0	32.0
Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN	0.0	0.0
Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN	0.0	0.0
Group 5: SOF 12 wk: GT 2 or 3, TN	0.0	40.0
Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN	0.0	0.0
Group 7: SOF+RBV 12 wk: GT 1, TE	0.0	90.0
Group 8: SOF+RBV 12 wk: GT 1, TN	0.0	16.0
Group 9: SOF+RBV 12 wk: GT 2 or 3, TE	0.0	32.0

Intervention	log10 IU/mL (Mean)
Group 1: SOF+RBV 12 wk: GT 2 or 3, TN	-5.52
Group 2: SOF+RBV 12 wk +PEG 4 wk: GT 2 or 3, TN	-5.44
Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN	-5.23
Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN	-5.20
Group 5: SOF 12 wk: GT 2 or 3, TN	-4.59
Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN	-4.94
Group 7: SOF+RBV 12 wk: GT 1, TE	-5.70
Group 8: SOF+RBV 12 wk: GT 1, TN	-4.95
Group 9: SOF+RBV 12 wk: GT 2 or 3, TE	-5.38
Group 10: SOF+RBV 8 wk: GT 2 or 3, TN	-4.92
Group 11: SOF+RBV 12 wk: GT 2 or 3, TN	-5.01
Group 12: SOF+RBV+LDV 12 wk: GT 1, TE	-5.74
Group 13: SOF+RBV+LDV 12 wk: GT 1, TN	-4.80
Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE	-5.84
Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN	-5.19
Group 16: LDV/SOF FDC 12 wk: GT 1, Fibrosis	-5.36
Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, Fibrosis	-5.18
Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN	-4.93
Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, Hemophiliac	-5.35

Intervention	percentage of participants (Number)
SOF+PEG+RBV 12 Weeks	90.4
SOF+PEG+RBV 24 Weeks	92.7
SOF+PEG+RBV 12 Week/Rerandomization Group	91.0
SOF Rerandomization Group	93.3
SOF+RBV Rerandomization Group	94.7

Intervention	percentage of participants (Number)
SOF+PEG+RBV 12 Weeks	98.0
SOF+PEG+RBV 24 Weeks	100.0
SOF+PEG+RBV 12 Week/Rerandomization Group	98.7

Intervention	percentage of participants (Number)
SOF+PEG+RBV 12 Weeks	68.6
SOF+PEG+RBV 24 Weeks	85.5
SOF+PEG+RBV 12 Week/Rerandomization Group	77.1